









  Copyright 
  by 
    Kevin Wade Tiller 
            2004
    
   "The views expressed 
 in this document are those
 of the author and do not 
necessarily reflect the official
 policy or position of the 
 Air Force, the Department
   of Defence of the U.S.




The Dissertation Committee for Kevin Wade Tiller 
certifies that this is the approved version of the following dissertation: 
 
 
Alendronate and Hormone Replacement Therapy in the Prevention of 
Osteoporotic Fracture: A Pharmacoeconomic Analysis Employing a 








Karen L. Rascati, Co-Supervisor 
James P. Wilson, Co-Supervisor 
David M. Bennett, Jr. 
Michael T. Johnsrud  
Kenneth A. Lawson  
Chandler W. Stolp  
Alendronate and Hormone Replacement Therapy in the Prevention of 
Osteoporotic Fracture: A Pharmacoeconomic Analysis Employing a 









Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 




The University of Texas at Austin 
August, 2004 
                                                                 iv
Alendronate and Hormone Replacement Therapy in the Prevention of 
Osteoporotic Fracture: A Pharmacoeconomic Analysis Employing a 





Kevin Wade Tiller, Ph.D. 
The University of Texas at Austin, 2004 
 
Supervisors:  Karen L. Rascati and James P. Wilson 
 
Osteoporosis is a common chronic condition which poses a substantial clinical, 
economic, and health-related quality-of-life (HRQOL) burden to the individual, the U.S. 
health care system, and society in general.  The overall objective of this study was to 
evaluate the economic, clinical and humanistic outcomes of current osteoporosis 
interventions employed in the prevention of osteoporotic fractures in the Department of 
Defense (DoD) population.  The overall objective encompassed four primary objectives: 
to assess the epidemiology of osteoporotic fracture in women ≥ age 50; to determine the 
effectiveness of current osteoporosis interventions; to identify significant risk factors and 
other covariates in the prediction of osteoporotic fracture; and to determine the cost-
effectiveness of current osteoporosis interventions.  A three-year sample-based 
retrospective cohort study was conducted using DoD health care and prescription claims 
from fiscal years 2000 to 2003.  Using an intent-to-treat study design, a total of 49,851 
women ≥ age 50 were followed for osteoporotic fracture.  The effectiveness of the 
vinterventions was determined by performing a series of both logistic and direct Cox 
proportional hazard regressions.  The net-benefit regression method of cost-effectiveness 
was employed to determine the cost-effectiveness of the treatment interventions and to 
determine the importance of covariates on the marginal cost-effectiveness of an 
intervention, while statistically controlling for the presence of risk factors and other 
covariates.  The epidemiologic study results showed that the three-year cumulative 
incidence of an osteoporotic fracture was 2.5 % for the cohort (0.4% in patients without a 
diagnosis of osteoporosis; 6.1% in patients with a diagnosis of osteoporosis).  The 
intervention effectiveness results obtained from the logistic regression model and the 
direct Cox proportional-hazards model were consistent and suggested that women treated 
with the combination of alendronate and HRT are at a lower risk for any fracture, hip 
fracture, and vertebral fracture when compared to no treatment.  In contrast, treatment 
with alendronate or HRT alone was not found to provide a statistically significant 
decreased risk of any fracture, hip fracture, vertebral fracture, or wrist fracture when 
compared to no treatment.  The results of this study revealed that the risk of osteoporotic 
fracture increased: 4-fold with a prior fracture, 4% with each year over 50, and between 
38 and 55% with oral corticosteroid use > 1-year (in a three-year period).  The findings 
also suggest that statin use was associated with a decreased risk of osteoporotic fracture.  
The results from the net-benefit regression method of CEA showed that the current use of 
DoD’s osteoporosis treatment interventions is not cost-effective in the short-term when 
compared to no treatment.  However, this study provided evidence that the current 
treatment interventions become more cost-effective when targeted at high risk 
populations, such as patients with a prior osteoporotic fracture or patients ≥ age 65.  The 
results of this study were potentially influenced by the presence of selection bias. 
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Chapter 1  
Literature Review 
INTRODUCTION 
 Osteoporosis is a common chronic condition with a substantial clinical, economic, 
and health-related quality-of-life (HRQOL) burden to the individual, the U.S. health care 
system, and society in general.  Osteoporosis and osteopenia (low bone mass) pose a 
major public health threat to an estimated 44 million Americans ≥ 50 years of age.  In the 
U.S., an estimated 10 million (8 million women, 2 million men) individuals already have 
osteoporosis and 34 million have osteopenia.1  Osteoporosis is a systemic disease 
characterized by low bone mass and structural deterioration of the bone tissue, which 
leads to bone fragility and increased susceptibility to fractures.2  Approximately, 1.5 
million osteoporotic fractures occur annually, of which there are approximately 300,000 
hip fractures, 700,000 vertebral fractures, 250,000 wrist fractures, and 300,000 fractures 
at other sites.1  In 1995, osteoporotic fractures were responsible for 3.4 million office and 
emergency room visits, 180,000 nursing home admissions, and over 400,000 
hospitalizations.  In the same year, the direct economic cost was estimated to be $14 
billion.3  A more recent estimate places the direct annual medical costs associated with 
osteoporotic fractures to the U.S. healthcare system at $17 billion (2001 dollars).3  The 
economic burden of osteoporosis is projected to potentially triple by the year 2040, given 
the aging U.S. population.2    
 Osteoporosis is a chronic asymptomatic disease for many women, with some not 
even aware of their low bone mineral density (BMD).  However, as the disease 
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progresses and the severity of osteoporosis increases, patients become more likely to 
experience the physiologic impact of osteoporosis: skeletal fractures, height loss, and 
kyphosis resulting from vertebral fractures.  Although mortality has been associated with 
hip and more recently vertebral fracture4, the primary impact of osteoporotic fractures is 
not on the individual’s quantity of life but instead on the individual’s health-related 
quality-of-life (HRQOL).  The impact of osteoporosis affects not only the individual’s 
physical but also the psychological and social dimensions of HRQOL.  It is most often 
the physical manifestations of osteoporosis (i.e., diminished functional status and pain) 
that subsequently lead to the deterioration of the psychological (i.e., anxiety, depression, 
and low self-esteem) and the social (social support and roles function) dimensions of 
HRQOL.  However, some studies indicate that even the diagnosis of osteoporosis has led 
to an altered self-perception and illness behavior.5  
 The remainder of Chapter 1 is divided into eight sections.  The next section 
provides the generally recognized definition, diagnosis criteria, and treatment threshold 
for osteoporosis.  Also included in this section is a discussion of the epidemiology of 
osteoporosis and osteoporotic fractures.  Sections II and III provide a comprehensive 
literature review of the clinical trial evidence supporting the efficacy, safety, and 
tolerability (section II) and an economic assessment (section III) of the Department of 
Defense’s formulary agents for the prevention of osteoporotic fractures (alendronate, 
hormone replacement therapy (HRT), and the combination of alendronate and HRT).  
The following section provides an overview of the methodology literature pertinent to the 
proposed study.  Section V discusses the literature to date regarding the association 
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between statins and fracture and provides justification for the inclusion of statins in any 
economic assessment of treatment interventions for osteoporotic fracture prevention due 
to statins potential to act as confounder.  Section VI provides a brief overview of the use 
of retrospective databases in outcomes research.  Finally, sections VII and VIII provide 
the rationale and objectives of the study and the list of null hypotheses, respectively.  
OSTEOPOROSIS & OSTEOPOROTIC FRACTURE 
Definition 
 Osteoporosis is defined as a systemic skeletal disease characterized by low bone 
mass and microarchitectural deterioration of bone tissue, with a consequent increase in 
bone fragility and susceptibility to fracture.6   
Diagnosis of Osteoporosis 
      Since as much as 80% of bone strength is dependent upon bone mineral density 
(BMD),7,8 four diagnostic categories have been proposed by the World Health 
Organization (WHO) and modified by the International Osteoporosis Foundation based 
on assessment of BMD by dual energy X-ray absorptiometry (DXA) for Caucasian 
women.9-11  
• Normal: hip BMD ≥ 1 SD below the young adult reference mean (T score ≥ -1) 
• Osteopenia: hip BMD ≤ 1 SD below the young adult reference mean, but > than 
2.5 SD below the young adult reference mean (T score < -1 and > -2.5) 
• Osteoporosis: hip BMD ≤ 2.5 SD or more below the young adult reference mean 
(T score ≤ -2.5) 
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• Established osteoporosis: hip BMD ≤ 2.5 SD or more below the young adult 
reference mean (T score ≤ -2.5) in the presence of one or more fragility fractures. 
 Dual energy X-ray absorptiometry (DXA)11 and BMD measurement at the hip12 
are the gold standards for measurement of BMD in the diagnosis of osteoporosis.  The 
WHO and International Osteoporosis Foundation recommend the use of the National 
Health and Nutrition Examination Survey (NHANES III) reference database in women 
aged 20-29 years as the BMD reference range.11 
Treatment Threshold 
 The National Osteoporosis Foundation (NOF) recommends treatment for all 
postmenopausal women who present with vertebral or hip fracture, women who have 
BMD T-scores below -2 and women who have T-scores below -1.5 as well as additional 
risk factors, especially prior fracture.13  
Epidemiology of Osteoporosis and Osteoporotic Fractures 
      Osteoporosis primarily affects postmenopausal women.  Using criteria established 
by the WHO, approximately 13% to 18% of  U.S. women ≥ 50 years of age have 
osteoporosis and another 37% to 50% have osteopenia.14 The NOF currently estimates 
that approximately eight million U.S. women have osteoporosis and an additional 22 
million women have osteopenia.15    As the U.S. population ages, the prevalence of 
osteoporosis and osteopenia will increase.  The NOF estimates that by 2020, 14 million 
men and women will have osteoporosis and another 48 million will have osteopenia.2 
Osteoporotic fractures, along with their associated morbidity and mortality, provide the 
clinical significance of osteoporosis. 
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      The NOF estimates that osteoporotic fractures will occur in one in two women 
and one in eight men after age 50.1 North American women ≥ 50 years of age have an 
estimated life-time risk of 18% for hip fracture, 16% for clinically diagnosed vertebral 
fracture, and 16% for Colles’ (wrist) fracture.16, 17 The estimated annual incidence of 
osteoporotic fractures in the U.S. is >1.5 million, of which there will be approximately 
700,000 vertebral fractures, 300,000 hip fractures, 250,000 wrist fractures, and 300,000 
fractures at other sites.1 The one-in-six lifetime risk of hip fracture is greater than the 
reported one-in-nine risk of developing breast cancer.17, 18 Of the one million hip and 
spine fractures, 90% will be due to the underlying condition of osteoporosis.19 The actual 
prevalence of vertebral fractures in U.S. women could vary by up to three-fold, 
dependent  on the criteria used to define vertebral fracture.20-22 Moreover, only about one-
third of all vertebral deformities noted on radiographs come to medical attention with less 
than 10% necessitating hospital admission.23  
Risk Factors for Osteoporosis and Osteoporotic Fracture 
      The pathogenesis of osteoporotic fracture is multi-factorial with many risk factors 
having been identified.  Table 1.1 below provides a list of clinically important risk 
factors.  Low BMD and past or current history of fracture are the strongest predictors of 
osteoporotic fractures among elderly women.24, 25 
Bone Mineral Density (BMD) 
      Given that BMD explains 60% to 85% of bone strength variance,26 research has 
demonstrated that the ability to predict hip fracture from measurement of BMD is at least 
as good as the measurement of blood pressure in predicting stroke, and considerably 
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better than the measurement of serum cholesterol in predicting coronary artery 
disease.10,27  Research has shown that: each standard deviation (SD) decrease in lumbar 
spine BMD is associated with about a 2-fold increase in spine fracture risk;12 a 1 SD 
decrease in femoral neck BMD28 is associated with a 2- to 3-fold increase in hip fracture 
risk (among women ≥ 65 years); and a 2.5 SD decrease in trochanteric hip BMD is 


















Table 1.1 Risk factors for osteoporosis and osteoporotic fracture7, 13, 24, 29-31 
Demographic Factors 
• Advanced Age* 
• White or Asian ethnicity 
• Female Sex 
Skeletal Factors 
• Low BMD 
• High bone turnover with excessive bone resorption* 
• Prevalent vertebral deformities/fractures 
• Hip axis length 
• Presence of an existing fracture 
• History of maternal fracture 
• Personal or family history of osteoporosis and/or osteoporotic fracture* 
Behavioral Factors 
• Smoking* or excessive alcohol intake 
• Low level of physical activity 
• Low calcium and vitamin D intake 
Clinical/Medical Factors 
• History of recurrent falls 
• Estrogen deficiency (women) - primary or secondary amenorrhea, premature 
menopause 
• Hypogonadism (men) 
• Long-term immobilization 
• Low body weight and body mass index* 
• Impaired neuromuscular function* (slow gait, decreased quadriceps strength) 
[inability to rise from a chair, reduced grip strength] 
• Impaired vision* (decreased acuity or depth perception) 
• Impaired cognition 
• Environmental hazards (e.g., throw rugs, slippery floors) 
• Disease (e.g., congestive heart failure, renal failure, cystic fibrosis, chronic 
pulmonary disease, hepatic disease, hyperthyroidism, malabsorptive disorders, 
myeloma, local neoplasm, parathyroid disease,  
• Solid organ transplantation 
• Certain medications: anticonvulsants, antipsychotics, long-acting 
benzodiazepines, corticosteroids*, sedatives, and tricyclic antidepressants  
* Denotes risk factors that increase fracture risk over and above that provided by BMD 
Personal History of Fracture 
      Apart from BMD, a personal history of fracture is one of the strongest clinical 
predictors of subsequent fractures.32 It has been shown that a past history of 
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postmenopausal fracture confers a 4-fold increase in the risk of hip fracture relative to a 
negative fracture history.25 A past history and/or current presence of a symptomatic or 
asymptomatic vertebral fracture(s) and/or deformities is a strong predictor of the 
subsequent risk osteoporotic fractures.   
• Vertebral fracture increases the risk of additional fractures by at least 4-fold 
(independent of BMD).33    
• One in five women with an existing vertebral fracture will experience another 
vertebral fracture within the following year, with risk increasing as numbers of 
baseline vertebral fractures increases.24  
• Baseline vertebral deformities increase the risk of hip fracture 3-fold and non-
vertebral fractures 2-fold.34 
• Vertebral deformity increases the risk of sustaining another vertebral fracture 
more than 12-fold during a 10-year period.35  
• Vertebral fracture increases the risk of subsequent hip fracture 2.3-fold and 
Colles’ fracture (wrist) 1.6-fold during a 10 year period.35 
• The presence of two or more prevalent vertebral fractures increases fracture risk 
for any specific BMD12-fold.36 
 The most devastating osteoporotic fracture is fracture of the hip.  The risk of hip 
fracture is increased after previous fracture at the hip > 2.0-fold, the spine > 2.0-fold, and 
the forearm and proximal humerous 2.0-fold.  Risk of vertebral fracture is similarly 
increased after a previous fracture at the hip 2.5-fold, the spine 4.4-fold, the forearm 1.7-
fold, or the proximal humerous 1.9-fold.32 
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Age 
      NHANES III data captured in the 1990s provided evidence that the prevalence of 
osteoporosis among Caucasian women increased with age.  The proportion of women 
with osteoporosis increased sharply from less than 1% of women aged ≤ 30, to 4% of 
women aged 50-59, to 20 % of women aged 60-69, to 34% of women aged 70-79, and to 
52% of women aged 80-89.37 
 The risk of osteoporotic fractures also increases with age.  The lifetime 
probabilities and 5-year probabilities of various types of fractures at various ages for 
average-risk Caucasian women have been calculated by the NOF based on the Study of 
Osteoporotic Fractures (SOF)38 (Table 1.2).  The NOF calculated the probabilities based 
on two competing factors: 1) the probability of having a fracture at any age, which 
increases with age; and 2) the probability of reaching a given age, which decreases with 
age. 
Table 1.2 The lifetime and 5-year probabilities of various types of fractures at various 
ages for average-risk Caucasian women2 
Fracture 
Type 
Current Age, Years 
 50 55 60 65 70 75 80 85 90 
Probability during remainder of life      
Hip 0.1429 0.1413 0.1394 0.1380 0.1360 0.1332 0.1228 0.1016 0.0694
Wrist 0.1438 0.1314 0.1146 0.0926 0.0762 0.0550 0.0420 0.0311 0.0191
Spine 0.1496 0.1467 0.1420 0.1347 0.1251 0.111 0.0916 0.0660 0.0397
Other 0.3123 0.2988 0.2794 0.2590 0.2217 0.1911 0.1564 0.0794 0.0289
Probability in subsequent five-years      
Hip 0.0023 0.0044 0.0055 0.0101 0.0158 0.330 0.0525 0.0719 0.0694
Wrist 0.0158 0.0219 0.0281 0.0232 0.0284 0.0211 0.0202 0.0225 0.0191
Spine 0.0057 0.0098 0.0148 0.0208 0.0291 0.0389 0.0469 0.0489 0.0397
Other 0.0691 0.0882 0.0955 0.1183 0.1089 0.1098 0.1349 0.0765 0.0289
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 Hip fracture incidence rates increase exponentially with age in postmenopausal 
women.39  The increased fracture risk can be partly attributed to the age-related decrease 
in BMD at the proximal femur,14 but can also be attributed to an age-related increase in 
falls,40 which are responsible for at least 90% of hip fractures.41 The risk of falls is 2-fold 
higher in women than men, and this risk increases 2-fold between 60 and 80 years of 
age.29 In general, for every 10-year increase in age, there is a 70% increase in the risk of a 
fall.42  
Race/ethnicity 
      Race/ethnicity is an indirect risk factor for osteoporotic fracture due to its 
association with the prevalence of osteoporosis and osteopenia.  Established diagnostic 
and therapeutic guidelines are based on the BMD of Caucasian women, however women 
of other racial and ethnic backgrounds are also at risk.  According to the same NHANES 
III data set, 19% of non-Hispanic white women, 17% of Mexican American women, and 
11% of non-Hispanic black women aged 50 years or older have osteoporosis.37 Asian 
American43-46 and Native American47, 48 women have been reported to have BMDs even 
lower than Caucasian women. 
Gender  
 Women are at higher risk of osteoporotic fractures then men.  Similar to age, the 
increased osteoporotic fracture risk of women compared to men is due to a gender-related 
decrease in BMD and gender-related increase in falls. Due primarily to these reasons, the 
incidence of hip fracture in women is about twice that seen in men at any age in the U.S., 
with more than three-quarters of all hip fractures occurring in women.  The lifetime risk 
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of hip facture from age 50 for Caucasian women is 17% compared to 6% for Caucasian 
men and the lifetime risk of a clinically diagnosed vertebral fracture is about 16% in 
Caucasian women compared to 5% in Caucasian men in the U.S..18  
Corticosteroid Use 
 Corticosteroid therapy is the most common cause of drug-related osteoporosis, 
with an estimated 30-50% of patients receiving chronic corticosteroid therapy 
experiencing fractures.49  Corticosteroids increase bone loss, reduce new bone formation, 
and accelerate osteocyte death, all of which weaken bone.  Bone loss is believed to be 
most rapid in the first few months of treatment and affects both axial and appendicular 
skeleton, but is most pronounced at the spine.  Bone loss is observed even with the use of 
low doses of corticosteroids, but is most rapid and extensive at doses ≥ 5mg/day of 
prednisone or its equivalent.50-53 
Other Established Risk Factors for Fracture 
 The significance of some risk factors is age dependent.  Risk factors for falling 
(impaired neuromuscular function, vision, and cognition, environmental hazards, certain 
medications, and disease states) are stronger predictors of fracture among the elderly than 
the young.  Hypogonadism is an important risk factor in both males and females.  
Smoking, alcohol, and poor calcium nutrition have been characterized as weak risks; 
however, smoking has been found to be a statistically significant risk factor independent 
of BMD.  Complete immobilization leads to rapid bone loss at the affected sites and is an 
important risk factor; however, there is less evidence to suggest that low levels physical 
activity increases the risk of osteoporotic fracture.  A low body-mass index is an 
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important risk factor for osteoporotic fracture, given its association with bone size.  
Finally, a maternal history of hip fracture is an independent risk factor for fracture.  For 
any specific BMD, a maternal history of hip fracture is associated with an approximate 2-
fold increased risk of hip fracture.54  
Morbidity 
      Although mortality has been associated with hip and vertebral fracture, the 
primary impact of osteoporotic fractures is the reported reduction of the individual’s 
health-related quality-of-life (HRQOL)30, 55 and related functional impairments.  It is 
most often the physical manifestations of osteoporosis resulting from hip or multiple 
vertebral fractures, diminished functional status and pain, that subsequently lead to the 
deterioration of the psychological (anxiety, depression, and low self-esteem) and the 
social (social support and roles function) dimensions of HRQOL.  Several studies have 
examined the impact of hip and vertebral osteoporotic fractures on psychosocial 
outcomes.     Mossey et al.56 examined depression in 200 women recovering from hip 
fractures and concluded that women experiencing high levels of depression after hip 
fracture surgery were more likely to experience poorer recovery of function.  A study 
conducted by Cook et al.57  examined the anxiety, fear, and other emotional reactions in 
100 women with osteoporotic vertebral fractures.  In this study, the investigators found a 
high proportion of women with osteoporotic vertebral fractures reported experiencing a 
fear of falling (82%), fear of new fractures (74%), frustration (66%), anger (53%), and 
feeling overwhelmed (49%).  Paier58 conducted a qualitative study in women with 
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symptomatic vertebral fractures and found that the women experienced a loss of self-
esteem, isolation, vulnerability, and embarrassment related to physical appearance. 
      A further concern is the functional impairment associated with osteoporotic 
fractures.  In general, after allowing for expected functional impairment in old people, 
fractures of the hip, spine, and distal forearm cause approximately 7% of women to 
become dependent upon others to help them accomplish the basic activities of daily 
living and precipitate nursing home care  in a further 8%.59  As expected, hip fractures 
contribute the most to this burden.18  Post hip fracture, the most important long-term 
impairment is the ability to walk.  Approximately 20% of patients who experience a hip 
fracture are non-ambulatory to begin with, but of those who are ambulatory prior to a 
fracture, half cannot walk independently afterwards.60 The discharge status post hip 
fracture is age dependent and the likelihood of discharge to a nursing home increases 
with age.  Approximately 1 in 6 patients age 50 to 55 are discharged from the hospital to 
the nursing home compared to more than half of those older than 90 years.61 A critical 
assessment point is one-year post hip fracture.  At one-year post hip fracture, only 40% of 
surviving patients regain their previous level of mobility, and only 25% regain their 
former functional status.62 Of those who lived independently before hip fracture, 50% 
remain in long-term care or need help with the activities of daily living the year after the 
event,63 and one-third of patients are admitted to nursing homes.30 Ultimately, up to one-
third of individuals who have a hip fracture can become totally dependent.64, 65  When 
elderly women were surveyed, 80% preferred death over admission to a nursing home 
after a hip fracture.66  
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      The morbidity associated with single compression vertebral fractures is primarily 
limited to  acute symptoms and acute pain, which typically resolve over weeks or 
months.67 However, vertebral fractures are often multiple and consequently produce 
cumulative physical effects, such as dorsal kyphosis (dowager’s hump), height loss, 
chronic pain, loss of pulmonary capacity, impaired gait and balance, digestive problems, 
and psychological effects such as low self esteem, body image, and mood.55, 68-72   
      Morbidity is also associated with wrist fractures.  Women who sustain wrist 
fractures often experience long-term sequelae, which includes pain, deformity, and 
functional impairment.73  At a three-year follow-up post wrist fracture, approximately 
75% of patients reported regaining almost full function and 25% of patients reported a 
variable loss of wrist strength.55 
Mortality 
      The mortality associated with hip fractures is the most serious.  Approximately 
10-20% more women die than expected for age within the first year.  This risk is greatest  
immediately after the fracture and decreases over time.74  A few of these deaths can be 
attributed directly to the hip fracture, but most are attributed to the chronic illnesses that 
led to both fracture and patient’s ultimate demise.75, 76 It has been estimated that in the 
U.S., hip fractures result in 31,000 excess deaths within 6 months of the event.77 
Vertebral fractures have a raised mortality rate that extends well beyond the first year 
after the fracture.77 The 5-year survival rate is reduced by 16% in women with vertebral 
fractures.55 
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 CLINICAL TRIAL EVIDENCE OF EFFICACY, SAFETY AND TOLERABILITY 
      A systematic review of the literature was undertaken to compare the efficacy, 
safety, and tolerability of alendronate, hormone replacement therapy (HRT), and the 
combination of alendronate and hormone replacement therapy (AHRT) in the prevention 
of osteoporotic fractures in patients with osteopenia, osteoporosis, or established 
osteoporosis.  The criteria for trials to be included in the review consisted of: 1) 
randomized placebo-controlled trials (RCTs) of at least one-year’s duration (calcium 
and/or vitamin D controlled trials were accepted as placebo controlled); 2) participants 
had a diagnosis of osteopenia, osteoporosis, or established osteoporosis; 3) reported 
vertebral and/or non-vertebral fractures; and 4) were published in English.  The results 
included in this review will focus on fracture outcomes, safety, and tolerability only, 
thereby excluding commonly reported results pertaining to percent change in bone 
mineral density (BMD) from baseline, biochemical indices of bone turnover, and percent 
change in height from baseline.  The following literature review will discuss findings 
from RCTs in the following order - alendronate, HRT, and AHRT. 
Alendronate 
      In all, eight trials42, 78-84 were identified that met the inclusion criteria, two42, 82 of 
which were different arms of the Fracture Intervention Trial, the first “mega-trial” of an 
antiosteoporosis agent.  All of the trials were similar in that each recruited primarily 
Caucasian postmenopausal women with primary osteoporosis or osteopenia and each trial 
provided participants elemental calcium and/or vitamin D in comparable doses.  The 
studies differed in study duration, sample size, prevalence of previous fractures, mean 
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age, doses of alendronate, and measurement of vertebral and non-vertebral fractures.  The 
duration of trials ranged from one-year80, 83, 84 to 4.2 years.82 The sample size of the trials 
ranged from 18878 to 4,43282 participants.  Several of the trials78, 80, 82 excluded 
participants with a previous history of osteoporotic fractures, one trial42 had previous 
osteoporotic fractures as an inclusion criterion, and another did not measure the risk 
factor.84  The mean age of participants ranged from 5979 to 70.842 years of age.  The study 
doses of alendronate ranged from 1mg81 to 40mg.78  Vertebral fractures were reported as 
a primary outcome in one trial,42 and as a secondary outcome in 3 trials.78, 80, 81 One study 
reported clinical (symptomatic) vertebral fractures as a primary outcome and 
morphometrically diagnosed vertebral fractures as a secondary outcome.82 One study 
reported non-vertebral fractures as a primary outcome42 and four trials reported such 
fractures as secondary outcomes.42, 78, 80, 81, 84 In two studies,79, 83 clinical fractures were 
only noted as part of the safety monitoring, of which one study79 reported only 
aggregated figures of vertebral and non-vertebral fractures. 
     The Fracture Intervention Trial (FIT)42, 82 is considered to be the hallmark RCT of 
alendronate.  It was the first mega-trial of an antiosteoporosis agent, which by definition 
of a mega-trial had the population size and trial duration to provide sufficient statistical 
power to examine fracture outcomes and their consequences.  The FIT enrolled 6,459 
postmenopausal women with a hip BMD T-score < -1.6 (2,027 women with prior 
vertebral fractures42; 4,432 without prior vertebral fractures82).  In the FIT (in women 
with prior vertebral fracture), alendronate reduced the incidence of morphometrically 
diagnosed vertebral fractures by 47% (RR (relative risk), 0.53; 95% CI, 0.41 to 0.68), 
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clinical vertebral fractures by 55% (RH (relative hazard), 0.45; 95% CI, 0.27 to 0.72), 
and all clinical fractures by 28% (RH, 0.72; 95% CI, 0.58 to 0.90) compared to placebo.  
In the FIT (in women without prior vertebral fractures), alendronate reduced the 
incidence of morphometrically diagnosed fractures by 44% (RR, 0.56; 95% CI, 0.39 to 
0.80), and significantly reduced the incidence of clinical fractures in women with an 
initial T-score of -2.5 or less (RH, 0.64; 95% CI, 0.50 to 0.82).   In the three trials78-80 
prior to the FIT, only one trial80 demonstrated a reduced incidence in vertebral fractures 
(RR, 0.52; 95% CI, 0.28 to 0.95) and a trend towards reduction in incidence of fractures 
at non-vertebral sites (estimated risk 0.79; 95% CI, 0.52 to 1.22).  In the three trials81, 83, 84 
post FIT, two trials81, 84 demonstrated a significantly reduced incidence in non-vertebral 
fractures (RR, 0.53; 95% CI, 0.30 to 0.90;84 RR not reported81).   
      Kanis et al.85 performed a meta-analysis on the clinical trials of alendronate that 
morphometrically defined a vertebral fracture as a 20% reduction in vertebral height42, 80-
82 to assess efficacy of alendronate (Table 1.3). 
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Table 1.3 Efficacy of alendronate: relative risk of fracture85 
SITE OF FRACTURE RR (95% CI) 
All patients  
• Vertebral 0.544 (0.448 to 0.659) 
• Hip 0.611 (0.392 to 0.951) 
• Wrist 0.866 (0.672 to 1.115) 
• Other 0.862 (0.740 to 1.003) 
• All non-vertebral 0.825 (0.736 to 0.926) 
Patients with prior fracture  
• Vertebral 0.529 (0.408 to 0.687) 
• Hip 0.497 (0.244 to 1.013) 
• Wrist 0.528 (0.317 to 0.879) 
• Other 0.993 (0.763 to 1.293) 
• All non-vertebral 0.811 (0.648 to 1.013) 
Patients without prior fracture  
• Vertebral 0.558 (0.387 to 0.805) 
• Hip 0.795 (0.438 to 1.443) 
• Wrist 1.188 (0.869 to 1.624) 
• Other 0.803 (0.662 to 0.967) 
• All non-vertebral 0.889 (0.761 to 1.039) 
       
 In general, the relative risk reduction of alendronate for vertebral fractures was 
greater than that for non-vertebral fractures.  Significant relative risk reductions were 
found for vertebral, wrist, and hip fractures, whereas the effects at other sites were not 
statistically significant.  Alendronate had higher relative risk reductions for vertebral 
(morphometrically or clinically diagnosed) and non-vertebral fractures in patients with a 
previous vertebral fracture42 and in patients with osteoporosis (BMD ≥ 2.5 SD below the 
mean).82    
     Alendronate was well tolerated in the trials.  The most frequent adverse event 
experienced by participants taking alendronate was upper gastrointestinal (GI) events.  
However, there was not a statistically significant difference in the rate of adverse events 
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between alendronate and placebo, including upper gastrointestinal events.  It should be 
noted that the trials excluded participants with a history of gastrointestinal disease.  Brief 
reviews of the clinical trials are provided below. 
      Chestnut et al.78 conducted a two-year, multi-center, double-blind, placebo-
controlled RCT to examine a potential “dose-response” effect of alendronate on BMD in 
postmenopausal women with osteoporosis.  A total of 188 postmenopausal (98% 
Caucasian) women, between 42-75 years of age, with lumbar spine BMD > 2 SD below 
the mean for young premenopausal women, were assigned by a randomized block 
allocation schedule to one of six treatment groups: placebo or 5 or 10mg alendronate for 
2 years; alendronate 20 or 40mg for one year followed by placebo for one year; or 
alendronate 40mg for 3 months followed by 2.5mg for 21 months.  Evidence of previous 
spine or hip fracture attributable to osteoporosis was an exclusion criterion.  All 
participants received elemental calcium 500mg/day.  The primary outcome measure was 
BMD of the lumbar spine, proximal femur, forearm, and total body.  Secondary outcome 
measures included the effect on calcium metabolism, biochemical indices of bone 
turnover, safety and tolerability, vertebral fractures, and non-vertebral fractures.  No new 
vertebral fractures were identified during the study.  There were 13 non-vertebral 
fractures in 12 patients, which were evenly distributed across all treatment groups.  
Alendronate therapy was well tolerated overall; upper GI intolerance was the most 
common complaint, which was primarily experienced with the 40mg dose (seven of the 
nine who withdrew from study medication were taking the 40mg dosage).   
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      Adami et al.79 conducted a two-year, double-blind, placebo-controlled RCT, with 
open-label calcitonin arm to examine the effect of alendronate on bone mass in 
postmenopausal women affected by osteoporosis.  A total of 286 postmenopausal women 
(Caucasian), between 48-76 years of age, with lumbar spine BMD > 2 SD below the 
mean for young premenopausal women were randomized to one of four treatment groups: 
placebo; alendronate 10 or 20mg/day; or intranasal salmon calcitonin 100IU/day.  
Evidence of previous vertebral fractures was not an entry criterion (only 5% of subjects 
had prevalent fractures).  All participants received elemental calcium 500mg/day.  The 
primary outcome measure was percent change in lumbar spine BMD.  Secondary 
outcome measures included percent change in femoral neck and trochanter BMD and 
biochemical indices of bone turnover.  Fracture outcomes were monitored as part of 
adverse event monitoring.  No significant differences in fracture outcomes were noted 
between treatment groups (3 in the placebo and 1 in each of the other treatment groups).  
All treatment groups were similar to placebo with regard to both the overall safety profile 
and upper gastrointestinal adverse events.  The incidence of upper GI adverse events was 
12.9% for alendronate and 14.1% for placebo.    
      Liberman et al.80 conducted a three-year, multi-national, double-blind, placebo-
controlled RCT to determine the efficacy of alendronate on bone mass and fracture 
outcomes in postmenopausal women affected by osteoporosis.  A total of 994 
postmenopausal women (87.4% Caucasian, 0.4% Black, and12.2% other), between 45-80 
years of age, with lumbar spine BMD ≥ 2.5 SD below the mean value in premenopausal  
Caucasian women were randomized to one of four treatment groups: placebo or 
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alendronate 5, 10 or 20mg/day (20mg/day group switched at year 2 to 5mg/day).  
Evidence of previous vertebral fractures was not an entry criterion (approximately 20% 
of each treatment group had a previous vertebral fracture).  All of the participants 
received elemental calcium 500mg/day.  The primary outcome measures included the 
percent change in BMD at the spine, femoral neck, trochanter, forearm, and total body, 
the effect on calcium-regulating hormones, the effect on biochemical indices of bone 
turnover, and the safety and tolerability of alendronate.  Secondary outcome measures 
included incidence of vertebral fractures, progression of vertebral deformities, height 
loss, and symptomatic non-vertebral fractures.  The definition of an incident of vertebral 
fracture was a reduction of at least 20%, with absolute decrease of at least 4 mm, in 
height of any vertebral body between baseline and follow-up.  There was a significant 
difference (p = 0.03) in new vertebral fractures (RR, 0.52; 95% CI, 0.28 to 0.95) for the 
combined alendronate groups.  This decreased risk was apparent when stratified by age 
(under or over 65 years) or the presence or absence of previous vertebral fracture.  There 
was a trend towards, but not a statistically significant difference in, reduced non-vertebral 
fractures in the alendronate group (estimated risk, 0.79; 95% CI, 0.52 to 1.22).  All 
treatment groups were similar to placebo with regard to both the overall safety profile and 
upper gastrointestinal adverse events.  Of those in the placebo group, 6.0% withdrew 
owing to adverse clinical adverse events, compared to 5.4% of those taking alendronate.  
Rates of upper GI adverse events leading to withdrawal were similar to placebo 
(alendronate 3.5%, placebo 2.0%).  
 22
      Black et al.42 conducted the Fracture Intervention Trial (FIT) in women with pre-
existing vertebral fractures, a 2.9-year, multicenter, double-blind, placebo-controlled 
RCT, to evaluate the effect of alendronate on the risk of morphometric as well as 
clinically evident fractures in postmenopausal women with low bone mass.  A total of 
2,027 postmenopausal women (97% Caucasian, 1% Asian, and 1% African-American), 
between 55-81 years of age, with femoral neck BMD > 2.1 SD below peak bone mass 
and a previous vertebral fracture, were randomized to either placebo (n=1,005) or 
alendronate 5mg [(n=1,022);.dose increased to 10mg at third year)].  All patients with 
estimated calcium intake at baseline less than 1,000mg daily (82%) received daily 
elemental calcium 500mg + 250IU vitamin D.  The primary outcome was the incidence 
of new vertebral fractures.  Secondary outcomes included clinical fractures (non-vertebral 
and symptomatic vertebral fractures), changes in height, BMD of the hip, spine, and total 
body, and changes in biochemical markers of bone turnover.  The definition of an 
incident of vertebral fracture was a reduction of at least 20%, with an absolute decrease 
of at least 4 mm in height of any vertebral body between baseline and follow-up. 
 The results of the study revealed a significant difference (p < 0.001) in 
morphometric vertebral fractures with alendronate (RR, 0.53; 95% CI, 0.41 to 0.68).  
This difference was consistent regardless of age, BMD, number of pre-existing fractures, 
or history of postmenopausal fracture.  The RH of clinically apparent vertebral fractures 
was 0.45 (95% CI, 0.27 to 0.72).  The RH of any clinical fracture was 0.72 (95% CI, 0.58 
to 0.90).  The RR of any non-vertebral fracture was 0.80 (95% CI, 0.63 to 1.01), hip 0.49 
(95% CI, 0.23 to 0.99), wrist 0.52 (95% CI, 0.31 to 0.87), and other 0.99 (95% CI, 0.75 to 
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1.31).  No difference was observed in the rate of adverse events between the alendronate 
and placebo groups.  The overall percentage of women who discontinued treatment due 
to an adverse event was 7.6% in the alendronate group and 9.6% in the placebo group.  
Upper gastrointestinal events were experienced by 41.3% in the alendronate group and 
40.0% in the placebo group.  
      Bone et al.81 conducted a two-year, multicenter, double-blind, placebo controlled, 
RCT to evaluate dose-response relationships for alendronate in osteoporotic elderly 
women.  A total of 359 postmenopausal women between 60-85 years of age (two thirds 
70-85), with lumbar spine BMD ≥ 2.0 SD below mean peak levels, were randomized to 
one of four treatment groups: placebo; alendronate 1mg/day; alendronate 2.5mg/day; or 
alendronate 5mg/day.  Evidence of more than one lumbar crush fracture was an exclusion 
criterion.  All patients received elemental calcium 500mg/day.  The primary outcome 
measure was lumbar spine BMD.  Secondary outcome measures included biochemical 
indices of bone turnover and mineral metabolism, bone histomorphometry, and vertebral 
and non-vertebral fractures.  The definition of an incident of vertebral fracture was a 
reduction of at least 20% in height of any vertebral body between baseline and follow-up.  
Alendronate did not achieve a statistically significant reduction in new vertebral 
fractures, but did for non-vertebral fractures at doses of 2.5 and 5mg.  Alendronate for all 
doses was well tolerated at all doses.  There was no significant difference between 
treatment and placebo groups in terms of adverse effects which were suspected to be drug 
related (19.8% in the alendronate group, 23.1% in the placebo group).   
 24
      Cummings et al.82 conducted the 4.2-year, multicenter, double-blind, placebo-
controlled RCT,  Fracture Intervention Trial (FIT) in women without pre-existing 
vertebral fracture to determine whether alendronate reduced the risk of clinical fractures 
in postmenopausal women who have low BMD but no vertebral fracture.  A total of 
4,432 postmenopausal women (97% Caucasian), between 55-80 years of age, with 
femoral neck BMD of 0.68 g/cm2 were randomized to either placebo (n=2,218) or 
alendronate 5mg [(n=2,214); dose increased to 10mg at the third year because other trials 
suggested that 10mg/day had greater effects on BMD without increasing adverse events].  
A femoral neck BMD of 0.68 g/cm2 was originally thought to correspond to a BMD 
value of at least 2 SD below mean of normal young adult Caucasian women; however, it 
was later determined to correspond to only 1.6 SD.  Consequently, about one-third of the 
population had higher BMD than expected.  All patients with estimated calcium intake at 
baseline less than 1,000mg daily (82%) received daily elemental calcium 500mg + 250IU 
vitamin D.  The primary outcome measure was the incidence of clinical fractures (both 
vertebral and non-vertebral).  Secondary outcomes included: new vertebral fractures 
(morphometrically diagnosed); changes in height; changes in BMD of hip, spine, radius, 
and total body; and changes in biochemical indices of bone metabolism.  The definition 
of an incident of vertebral fracture was a reduction of at least 20%, with absolute 
decrease of at least 4 mm, in height of any vertebral body between baseline and follow-
up.   
 The results of the study revealed that alendronate only significantly reduced the 
risk of clinical vertebral fractures in women with initial T-scores of -2.5 or less (RR, 
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0.50; 95% CI, 0.31 to 0.82) but not in those with T-score greater than -2.5.  Alendronate 
significantly reduced the risk of morphometric vertebral fractures (RR, 0.56; 95% CI, 
0.39 to 0.80).  The RH of any clinical fracture (RH, 0.86; 95% CI, 0.73 to 1.10), non-
vertebral fracture (RH, 0.88; 95% CI, 0.74 to 1.04), hip (RH, 0.79, 95% CI, 0.43 to 1.44), 
wrist (RH, 1.19, 95% CI, 0.87 to 1.64), was not statistically significant; other (RH, 0.79, 
95% CI 0.65 to 0.96) was statistically significant.  However, when results were stratified 
by BMD at entry, alendronate significantly reduced the risk of clinical fractures in 
women with an initial T-score of -2.5 or less (RH, 0.64; 95% CI 0.50 to 0.82).  There 
were no significant differences between groups in regards to adverse events; 9.9% of 
women in the alendronate group and 10.2% of women in the placebo group discontinued 
study medication because of adverse events.  Likewise, 47.5% of women in the 
alendronate group and 47.2% in the placebo group experienced upper gastrointestinal 
problems.  
      Lindsay et al.83 conducted a one-year, multicenter, double-blind, placebo-
controlled RCT in postmenopausal women to evaluate the effect on BMD of adding 
alendronate to ongoing HRT.  A total of 428 postmenopausal women, at least 40 years of 
age (25 years of age if surgically postmenopausal), receiving HRT for at least one year 
before study entry, with a BMD measurement at the lumbar spine or femoral neck at least 
2 SDs below the mean for a reference population of young women (BMD at the other site 
had to be at least 1.5 SD below the mean), were randomized to receive either 10mg of 
alendronate/day or placebo along with previously prescribed HRT.  All patients with 
estimated calcium intake at baseline less than 1,000mg daily received daily elemental 
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calcium sufficient to meet the 1,000mg/day requirement.  All patients received vitamin D 
400IU/day.  The primary outcome measure was the mean percent change in lumbar spine 
BMD.  Secondary endpoints included mean percent change in BMD of the hip trochanter 
and femoral neck.  Data on symptomatic fractures were recorded as adverse events.  No 
symptomatic vertebral fractures were identified in either group.  Non-vertebral fractures 
were more common in the alendronate group, but the difference was not statistically 
significant.  The overall incidence of any clinical adverse event was similar in each 
group.  Approximately 4% of patients in the alendronate group and 7% of patients in the 
placebo group discontinued study drug due to adverse events.  The incidence of 
gastrointestinal events was identical in both groups (10.7%). 
      Pols et al.84 conducted a one-year, multicenter, double-blind, placebo-controlled 
RCT in postmenopausal women (94% Caucasian) to evaluate the efficacy and tolerability 
of alendronate in a population of women with low bone mass.  A total of 1,908 
postmenopausal women, ≤ 85 years of age, with a BMD of the lumbar spine at least 2 SD 
below the mean for mature, premenopausal women were randomized to receive either 
alendronate 10mg/day (n = 950) or placebo (n = 958).  All patients received elemental 
calcium 500mg/day.  The primary outcome measure was lumbar spine BMD.  Secondary 
outcomes included biochemical markers of bone turnover and clinical non-vertebral 
fracture.  The incidence of clinical non-vertebral fractures was significantly lower in the 
alendronate group (p = 0.021), with a RH of 0.53 (95% CI, 0.30 to 0.90).  Alendronate 
was generally well tolerated.  No statistically significant differences between treatment 
groups were found in the overall incidence of adverse events.  The incidence of adverse 
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events resulting in discontinuation of study medication was similar (alendronate 6.4%; 
placebo 5.6%).  There were no significant differences between treatment groups in the 
overall incidence of upper gastrointestinal adverse events (alendronate 21.3%; placebo 
19.3%). 
Hormone Replacement Therapy 
      In all, only three trials86-88 met the inclusion criteria but another recently 
published trial, the Women’s Health Initiative (WHI),89 was included in the review given 
its significant contribution to HRT research.  Prior to the WHI,89 the methodological rigor 
that had been applied to clinical trials of fracture prevention of bisphosphonates had not 
been equally applied to estrogens, which is evident by size and duration of trial.  The 
three trials included in this review were similar in that in each of the studies: Caucasian 
postmenopausal women with a primary osteoporosis or osteopenia with at least one 
previous vertebral fracture were enrolled; the trial populations were small (< 130 
participants); the mean age was similar (range 58 – 64.9); and the participants were 
provided elemental calcium and/or vitamin D in comparable doses.  The studies differed 
in the duration of the HRT intervention and doses used.  The duration of trials ranged 
from one-year87 to four-years.88 The study doses of HRT were different in each study 
(Transdermal 17β estradiol, 0.1mg on days 1-21 + oral medroxyprogesterone acetate, 
10mg, on days 11-21 of 28-day cycle;87 conjugated estrogens, 0.625mg/day, for 25 
days/month + medroxyprogesterone, 10mg/day, on days 15-25;86 conjugated estrogen, 
0.625 mg/day + Norgestrel® 150 µg/day, for 12 days/month88).  Vertebral fractures were 
reported as a secondary outcome in two trials, 86, 88 and in one study no differentiation 
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was made between primary and secondary outcomes.87 Only one study reported non-
vertebral fractures as a secondary outcome.88  The criterion used to define incident of 
vertebral fracture varied between the three studies.    
      The number of patients with vertebral fractures was reported in one study87 and 
the number of patients with non-vertebral fractures was reported in another study.88  The 
results from these two studies only provide evidence of a trend for a reduction in the 
relative risk of vertebral fracture (RR, 0.583, 95% CI, 0.262 to 1.301) but no evidence of 
a reduction in the relative risk of non-vertebral fracture (RR, 1.00; 95% CI (0.068 to 
14.795). 
      Only two trials86, 87 provided information regarding the safety and tolerability of 
HRT.  Reported HRT adverse events, which differed significantly from placebo, 
included: pelvic congestion, cyclic bleeding, and breast tenderness.  Brief reviews of the 
three clinical trials are provided below, followed by a discussion of the WHI89 trial. 
      Pacifici et al.86 conducted a 2-year, open label RCT in postmenopausal women to 
evaluate the effects of phosphate and etidronate versus sequential HRT on axial and 
appendicular bone mass in osteoporotic women.  A total of 128 Caucasian osteoporotic 
women, between 26-80 years of age with at least one non-traumatic vertebral fracture 
and/or spinal demineralization were randomized to one of three treatment groups: 
cyclical K-phosphate and etidronate, cyclical estrogen + progesterone, or placebo.  All 
participants received elemental calcium 1,000mg/day.  The primary outcome measure 
was bone mineral content.  Secondary outcome measures included vertebral fractures, 
biochemical indices of bone turnover, and height loss.  The definition of an incident of a 
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compression vertebral fracture was a reduction of at least 15% in posterior height of any 
vertebral body compared with mean of the posterior height of the nearest intact vertebrae.  
Wedging and biconcave fractures were defined by a loss of anterior and central height 
greater than 20% compared with the posterior height of the same vertebrae.  The number 
of new vertebral fractures was almost identical in all three treatment groups; however, the 
HRT group had significantly less height loss than the other two groups (p < 0.05).  
Significant side effects (pelvic congestion and cyclic bleeding) occurred only in the HRT 
group.   
      Lufkin et al.87 conducted a 1-year, double-blind, placebo-controlled RCT in 
postmenopausal women to evaluate the efficacy of transdermal estradiol therapy in 
postmenopausal women with vertebral fractures.  A total of 75 postmenopausal women, 
between 47-75 years of age, with BMD of the lumbar spine and proximal femur below 
the 10th percentile of premenopausal women and one or more vertebral fractures (≥15% 
reduction in vertebral height) were randomized to either estrogen plus 
medroxyprogesterone (n = 36) or placebo (n = 39).  Outcome measures included BMD, 
biochemical indices of bone turnover, bone histomorphic values, and fracture occurrence. 
The definition of an incident of vertebral fracture was a reduction of at least 15% in 
height of any vertebral body between baseline and follow-up.  After one year, the 
estrogen group had significantly fewer new morphometrically diagnosed vertebral 
fractures (RR = 0.39; p = 0.04).  No report was offered regarding the incidence of non-
vertebral fractures.  Adverse events experienced by participants in the estrogen arm 
which differed significantly from placebo included breast tenderness (estrogen 56%; 
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placebo 5%), endometrial hyperplasia (estrogen 8%; placebo 0%), and all women with 
intact uteri experienced menstrual bleeding associated with estrogen and progestin.  
           Wimalawansa et al.88 conducted a four-year, open-label RCT in Caucasian 
postmenopausal women to evaluate whether there is an added beneficial effect on BMD 
when HRT is combined with cyclical etidronate in women with established osteoporosis.  
A total of 72 postmenopausal women, 58-72 years of age, with a BMD of the lumbar 
spine at least 2 SD below the mean of a 35-year old premenopausal women, with at least 
one morphometrically diagnosed (but no more than four) atraumatic thoracic vertebral 
crush fractures were randomized to one of four treatment groups: placebo, HRT, 
etidronate, or the combination of HRT and etidronate.  All participants received 
elemental calcium 1,000mg and 400 IU of vitamin D.  The primary outcome measure was 
BMD.  Secondary outcome measures included biochemical indices of bone turnover, 
vertebral and non-vertebral fractures, and height loss.  A new vertebral fracture was 
defined as a reduction of 20% or more in vertebral height plus a reduction of 15% or 
more in area in previously unaffected vertebrae.  Further deterioration in height or area of 
previously affected vertebrae was not considered a new fracture.  There was no statistical 
difference in vertebral or non-vertebral fractures, which was primarily thought to be due 
to the low power of the study.  Five of the study participants withdrew from the study due 
to HRT related side effects. 
      The WHI89 estrogen-plus-progestin trial was the first randomized clinical trial to 
demonstrate that HRT reduces the risk of hip, wrist, and vertebral osteoporotic fractures.  
However, the trial was stopped after a mean of 5.2 years (three-years early) because the 
 31
test statistic for invasive breast cancer exceeded the stopping boundary and a global index 
statistic (a nominally significant 15% increase) supported the notion that risks exceeded 
benefits.90  For this reason, investigators determined that HRT should not be used for the 
prevention of osteoporotic fractures in women without vasomotor symptoms.  The WHI 
estrogen-only trial is ongoing, with completion anticipated in 2005.  A brief review of the 
WHI is provided below. 
      The WHI89 was a 5.6-year (average follow-up), multicenter, double-blind, 
placebo controlled, RCT to evaluate the effect of estrogen plus progestin on multiple 
chronic diseases in older women.  Cauley et al.89 report on the final analysis of fracture 
endpoints and tested hypotheses that relative risk reductions differed by risk factors for 
fracture and that the risk-benefit profile of treatment differed across tertiles of fracture 
risk.  A total of 16,608 postmenopausal women (with intact uterus), 50-79 years of age 
were randomized to one of two treatment groups: placebo (n = 8,102) or conjugated 
estrogen (0.625mg) plus medroxyprogesterone acetate (2.5mg), in a single tablet, (n = 
8,506).  BMD measurements were collected in only three of the 40 U.S. clinical centers, 
where only 4% of the women in the estrogen plus progestin arm and 6% in the placebo 
arm were considered to have osteoporosis at the total hip using World Health 
Organization (WHO) criteria.91  The outcome measures included clinical osteoporotic 
fractures, BMD [for a subset of women (n = 1,024)], and global index of risk-benefit 
profile.  Estrogen plus progestin significantly reduced clinical vertebral fractures by 34% 
and hip fractures by 33% (RH, 0.67; 95% CI, 0.47 to 0.96) and total osteoporotic 
fractures by 24% (RH, 0.76; 95% CI, 0.69 to 0.83).  The effect did not differ by risk 
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factors for fracture.  The HR for the global index did not differ across tertiles of fracture 
risk.  Given the unfavorable risk-benefit profile and the availability of safer alternatives 
for the prevention and treatment of osteoporosis related fractures, researchers concluded 
that HRT should not be recommended for the prevention and treatment of osteoporosis in 
women without vasomotor symptoms.  The specific HRT related adverse events were not 
reported. 
Combination of Alendronate and Hormone Replacement Therapy 
      In all, only two trials83, 92 met the inclusion criteria.  In both clinical trials, the 
primary outcome measured was the percent change in BMD of the spine and/or hip.  
Compared with HRT alone, as with earlier trials of HRT, neither of the two clinical trials 
had sufficient power to establish whether combination therapy has greater anti-fracture 
efficacy. 
     Bone et al.92 conducted a two-year, multicenter, double-blind, placebo-controlled 
RCT in postmenopausal osteoporotic women to evaluate the efficacy, safety, and 
tolerability of combined alendronate and HRT.  A total of 425 postmenopausal women 
(92% Caucasian), 42-82 years of age, with a prior hysterectomy and a mean BMD of the 
lumbar spine 2.5 SD below the normal reference young adult were randomized to one of 
four treatment groups: placebo/placebo, alendronate/placebo, conjugated equine estrogen 
(CEE)/placebo, alendronate/CEE.  All participants received elemental calcium 
500mg/day.  Primary outcome measures were: BMD of the spine, femoral neck, femoral 
trochanter and total hip; biochemical indices of bone turnover; bone histomorphometry; 
and safety and tolerability.  Secondary outcome measures included fractures, which were 
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reported as part of adverse event reporting.  There was no significant difference in the 
rate of fracture among the groups.  In fact, reported fractures, for the most part, were non-
vertebral, due to trauma, and occurred at sites which are not typically considered to be 
osteoporotic fractures.   The tolerability of the alendronate and CEE combination was 
consistent with those of the individual treatments.  Upper gastrointestinal events resulting 
in discontinuation of study drug occurred with similar frequency among the four 
treatment groups (alendronate (1%), placebo (0%), CEE (2%), combination (1%)).  The 
CEE treatment was frequently associated with complaints of breast pain and weight gain. 
 ECONOMIC ASSESSMENT OF HORMONE REPLACEMENT THERAPY AND ALENDRONATE IN 
THE PREVENTION OF OSTEOPOROTIC FRACTURES 
 The following is a review of literature regarding the economic evaluation of 
hormone replacement therapy and alendronate in the prevention of osteoporotic fractures.  
This literature review includes articles published from 1980 to present.  The first section 
is a review of the literature regarding the economic evaluation of hormone replacement 
therapy.  A review of the literature regarding the economic evaluation of alendronate in 
the prevention of osteoporotic fractures is provided in the following section.  The last 
section provides a review of three studies that examined the cost-effectiveness of both 
HRT and alendronate along with other osteoporosis agents.   
Pharmacoeconomic Analyses of Hormone Replacement Therapy 
 A total of 18 economic evaluations of hormone replacement therapy (HRT) were 
found, ten93-102 were cost-utility analyses (CUAs), six103-108 were cost-effectiveness 
analyses (CEAs), one109 was a cost-minimization analysis (CMA), and one was a cost-
benefit analysis (CBA).110 The conclusions from these studies suggest that in most 
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instances HRT was cost-effective and compared favorably with other widely accepted 
clinical practices determined to be cost-effective, such as treatment of hypertension.  
More specifically, the studies provided evidence that HRT was more cost-effective in 
symptomatic women;93, 98, 99, 102 in women with a hysterectomy;93, 97, 99, 102 in the 
secondary prevention of fracture, in older women, in women with low BMD, or 
otherwise at increased risk of an osteoporotic fracture;93, 101, 105 and when used for longer 
durations of therapy.95, 98, 99, 103, 105  
  Bone density screening followed by HRT was assessed in six studies.96, 105, 107-110  
Three96, 107, 109 of the six studies concluded that targeting HRT treatment at high-risk 
patients via BMD screening was more cost-effective than not screening.  However, these 
studies did not incorporate any of the non-skeletal effects of HRT.  One study105 found 
unfavorable cost-effectiveness ratios for BMD screening followed by HRT.  Another 
study110 concluded that BMD screening did not meet the pre-established cost-benefit ratio 
of one.  Another study108 concluded that BMD screening was a cost-effective strategy of 
targeting patients at a high risk of osteoporotic fracture when annual treatment costs did 
not exceed $91 (1995$). 
 The cost-effectiveness of HRT in these economic evaluations was influenced by 
many factors such as age, bone mass, uterus status, presence of menopausal symptoms, 
duration of intervention, and methods of costing.  However, the most significant 
differences between the economic evaluations can be attributed to the economic model 
employed to capture the skeletal and non-skeletal health effects of HRT, along with their 
associated quality-of-life adjustments. 
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 Each economic evaluation employed a slightly different economic model using 
different estimates of the risk of fracture in the population, HRT’s anti-fracture efficacy 
and relative risk of non-skeletal health effects.  For the most part, the incidence of 
fracture in the population of interest was obtained from epidemiological surveys specific 
to that population.  Since the time when these studies were performed, no RCT of HRTs 
anti-osteoporotic fracture efficacy had been conducted, each economic evaluation’s 
estimate of HRT’s efficacy was based upon the best epidemiological information 
available at the time.  The estimates of HRT’s efficacy used in the economic evaluations 
differed in both magnitude and duration of effect.  Each economic model also attempted 
to account for the significant non-skeletal effects of HRT (increased risk of endometrial 
cancer, breast cancer and potential cardiovascular benefits, etc.), which were also based 
upon the best available epidemiological evidence at the time.  As a result, there were 
significant differences between the economic evaluations in regards to which non-skeletal 
health effects were included in the economic model, the magnitude of the risk estimate 
for each non-skeletal health effect, and the duration of the non-skeletal health effect risk.  
The selective inclusion/exclusion of certain non-skeletal health effects associated with 
HRT significantly impacted the overall cost-effectiveness of HRT in the prevention of 
osteoporotic fractures.  Table 1.4 provides a list of the health effects included in each 
study, the magnitude of health effect risk estimates, and the duration of health effect risks 
for 15 of the 18 economic evaluations.  The economic evaluations by van der Loos et 
al.,103 Clark and Shuttinga,109 and Francis et al.104 were not included due to either 
limitations in information available or study design. 
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Table 1.4 Health effect assumptions for HRT 




Weinstein93 NI NI 
Weinstein/Schiff94 1.25; applies 5yrs after 
initiation of tx, continues 
5yrs post tx 
NI 
Weinstein/Tosteson95 1.25 NI 
Tosteson et al.96  NI NI 
Tosteson/Weinstein97 ERT: 1.36 after 2yrs of tx + 
2yrs post tx cessation; 
PERT: 1.0 
ERT: 0.5; PERT: 1.0 
Cheung/Wren98 NS Varied from 0.5 to 1.0 
Daly et al.99  ERT & PERT: 1.3 after 
10yrs of use; after tx 
cessation, risk remains 
elevated for period equal to 
tx period 
ERT: 0.75 after 5yrs, 0.5 
after 10yrs, after tx 
cessation protective effect 
remains for period equal to 
tx period; effect is halved 
for PERT 
Tosteson100 ERT: 1.30; 
PERT: 1.0-2.0 
ERT: 0.64; PERT: 0.64 – 
0.8 
Geelhoed/Harris101 Risk rate: 1.02n, so RR at 
15yrs was 1.30 
ERT: 0.5 
OTA105 ERT: 1.35 after 10yrs of tx 
and remains elevated post 
cessation of tx; PERT: 1.0 
ERT: 0.5 for the duration of 
tx, returns to 1.0 after 
cessation of tx; PERT: 0.8 
Torgerson et al.106  NI NI 
Ankjaer-Jensen/Johnell107 1.30; two assumptions: 1) 
linear increased risk, 2) no 
increased risk until after 
10yrs of tx; effect persists 
10yrs post cessation of tx 
Optimistic assumption: 0.5; 
Pessimistic assumption: 
0.65 
Norlund110 NI NI 
Daly et al.102  ERT & PERT: 1.3 after 
10yrs of use; after tx 
cessation, risk remains 
elevated for period equal to 
tx period 
ERT: 0.75 after 5yrs, 0.5 
after 10yrs, after tx 
cessation protective effect 
remains for period equal to 
tx period; effect is halved 
for PERT 
Visentin et al.108  NI NI 
* Abbreviations: ERT: estrogen replacement therapy; PERT: progesterone and estrogen 
replacement therapy; NI: not included; NS: not specified; tx: treatment; yrs: years 
 37








Weinstein93 2.5 applies 5yrs 
after initiation of 
tx to 5yrs post tx 
cessation 
ERT: 0.0 for first 5yrs of 
tx, then 8.0 until tx 
cessation + 5yrs 
NI 
Weinstein/Schiff94 2.5 applies 5yrs 
after initiation of 
tx to 5yrs post tx 
cessation 
ERT: 4.0 for first 5yrs of 
tx, then 8.0 until tx 
cessation, then 4.0 5yrs 
post tx cessation; PERT: 
1.0 
ERT: 9%; 
PERT: 1.5% for 
first 5yrs of tx 
Weinstein/Tosteson95 NI ERT: 4.0 for first 5yrs of 
tx, then 8.0 until tx 
cessation, then 4.0 5yrs 
post tx cessation; PERT: 
1.0 
ERT: 6.0 for 
first two years 
of tx; PERT: 
1.0 
Tosteson et al.96 NI NI NI 
Tosteson/Weinstein97 NI NI NI 
Cheung/Wren98 NI ERT: 8.0; PERT: 2.0 ERT: 9.0%; 
PERT: 1.5% 
Daly et al.99  NI Non-hysterectomized 
women/ERT: 6.0 after 
5yrs, normal 5yrs after tx 
cessation; PERT: 1.0 
NI 
Tosteson100 NI NS NI 
Geelhoed/Harris101 NI 8.0 NI 
OTA105 ERT & PERT: 2.5 ERT: > 10yrs 3.5, < 10yrs 
7.0, returns to 1.0 after tx 
cessation 
NI 
Torgerson et al.106  NI NI NI 
Ankjaer-
Jensen/Johnell107 
NI NI NI 
Norlund110 NI NI NI 
Daly et al.102  NI Non-hysterectomized 
women/ERT: 6.0 after 
5yrs, normal 5yrs after tx 
cessation; PERT: 1.0 
NI 
Visentin et al.108  NI NI NI 
* Abbreviations: ERT: estrogen replacement therapy; PERT: progesterone and estrogen 
replacement therapy; NI: not included; NS: not specified; tx: treatment; yrs: years 
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Weinstein93 Untreated vs. treated: 3.0 during tx, 2.0 
post tx for period equal to tx, then 1.0 
NI 
Weinstein/Schiff94 ERT &PERT: 0.8 for 5yrs, then 0.4 
after tx cessation, protective effect 
remains for period equal to tx period 
NI 
Weinstein/Tosteson95 Determined by Melton’s39 logistic 
regression model; no bone loss during 
tx, then returned to rate at age 50 
Age specific 
probabilities of 
discharge post fracture 
Tosteson et al.96 Determined by Melton’s39 logistic 
regression model; no bone loss during 
tx, then returned to rate at age 50 
Age specific 
probabilities of 
discharge post fracture 
Tosteson/Weinstein97 Determined by Melton’s39 logistic 
regression model; no bone loss during 
tx, then returned to rate at age 50 
Age specific 
probabilities of 
discharge post fracture 
Cheung/Wren98 ERT & PERT: 0.8 for the first 5yrs of 
treatment, and 0.4 thereafter 
NI 
Daly et al.99  ERT &PERT: 0.8 for 5yrs, then 0.4 
after tx cessation protective effect 
remains for period equal to tx period 
NI 
Tosteson100 Melton’s logistic regression model39: 
assumed no bone loss during tx, then 
returned to rate at age 50 
Age specific 
probabilities of 
discharge post fracture 
Geelhoed/Harris101 Melton’s logistic regression model39: 
assumed no bone loss with ERT tx; 
50% of normal rate with lifestyle 
intervention 
Age specific: 10% at 
age 75 to 40% over 85 
years of age 
OTA105 Simulation model based on Study of 
Osteoporotic Fractures on age-specific 
bone mass and hip fracture rates 
NS 
Torgerson et al.106 0.7 NI 
Ankjaer-
Jensen/Johnell107 
Optimistic assumption: 0.5 Pessimistic 
assumption: 0.75 
NI 
Norlund110 0.5 NS 
Daly et al.102  ERT &PERT: 0.8 for 5yrs, then 0.4 
after tx cessation, protective effect 
remains for period equal to tx period 
NI 
Visentin et al.108  0.7 NS 
* Abbreviations: ERT: estrogen replacement therapy; PERT: progesterone and estrogen 
replacement therapy; NI: not included; NS: not specified; tx: treatment; yrs: years 
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Weinstein93 NI 0.036 
Weinstein/Schiff94 NI ERT: 5%; PERT: 2.5% 
Weinstein/Tosteson95 NI NS 
Tosteson et al.96 NI NI 
Tosteson/Weinstein97 NI NI 
Cheung/Wren98 NI ERT: 9% with hyperplasia 
and 23% without; PERT: 
2% with hyperplasia and 
12% without 
Daly et al.99  ERT: 0.75; PERT: 0.875 NI 
Tosteson100 NI NI 
Geelhoed/Harris101 NI 25% the first year, 12.5% 
the second year 
OTA105 NI NI 
Torgerson et al.106 NI NI 
Ankjaer-Jensen/Johnell107 NI NI 
Norlund110 NI NI 
Daly et al.102  ERT: 0.75; PERT: 0.875 NI 
Visentin et al.108  NI NI 
* Abbreviations: ERT: estrogen replacement therapy; PERT: progesterone and estrogen 
replacement therapy; NI: not included; NS: not specified; tx: treatment; yrs: years 
 
 Another important factor for determining the cost-effectiveness HRT and an area 
of significant difference between studies was the quality-of-life (QOL) adjustments 
employed for HRT and HRT-related health effects.  For instance, most studies found 
HRT to be cost-effective in symptomatic postmenopausal women age ≥ 50 but not in 
asymptomatic women of the same age.  The reason for this is that every woman is 
affected by a QOL adjustment for HRT and that the consequences occur in the near 
future; therefore, the effect of discounting is minimal compared to a QOL adjustment for 
hip fracture, which may occur 30 years into the future.  The QOL adjustments for HRT 
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and HRT-hrelated health effects in each of the CUA economic evaluations were based on 
expert opinion rather than empirical evidence; therefore, there were also significant 
differences in QOL adjustments between studies.  Table 1.5 provides a list of the QOL 
























Weinstein93 0.8 for 5yrs 0.05 0.99 
Weinstein/Schiff94 0.8 for 5yrs 0.9 for life ERT: 0.99; PERT: 
0.995 
Weinstein/Tosteson95 0.8 for 5yrs Nursing home 0.4, 
disabled but independent 
0.8, acute uncomplicated 
0.95, post-fracture 
recovered 1.0 
ERT: range 0-2; 
PERT: range -2 to 2 
Tosteson et al.96 NI Nursing home 0.4, 
disabled but independent 




Tosteson/Weinstein97 NI Nursing home 0.4, long-
term disability 0.8, acute 
uncomplicated 0.95, 
disabling hip fracture 
0.76, hip fracture 




Cheung/Wren98 0.8 for 5yrs 0.9 ERT: 0.99; PERT: 
0.995 
Daly et al.99  NI NS 0.95 for severe 
symptoms; 0.99 for 
mild symptoms 
Tosteson100 NI NS Considered relief 
from menopausal 
symptoms and side 
effects from PERT 
Geelhoed/Harris101 NI Nursing home 0.67, acute 
uncomplicated 0.90 
NI 
Daly et al.102  NI NI NS, but assumed 
that symptomatic 
women obtain 5yrs 
of symptom relief 
* Abbreviations: ERT: estrogen replacement therapy; PERT: progesterone and estrogen 
replacement therapy; NI: not included; NS: not specified; tx: treatment; yrs: years 
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 The following provides a brief review of each individual HRT economic 
evaluation.  Weinstein93 conducted the first pharmacoeconomic analysis of estrogen 
replacement therapy (ERT).  The objective of the study was to determine the cost-
effectiveness and cost-utility of ERT in postmenopausal women, particularly for women 
with an intact uterus and thus at risk for endometrial cancer.  A cost-utility analysis was 
performed from a societal perspective.  Weinstein employed a mathematical model in a 
hypothetical population of postmenopausal women, which was subdivided into three 
treatment populations: 1) symptomatic menopausal women aged 50 to 60, 2) women with 
established osteoporosis aged 55 to 70, and 3) asymptomatic postmenopausal women 
aged 50 to 65.  Each treatment population received ERT for either 10 or 15 years.  










Net resource cost (C) was the sum of the component costs: direct cost of treatment – 
drugs, physician visits, and routine tests (∆CRX), costs induced by side effects and 
complications of treatment (∆CSE), savings associated with prevention of morbid events – 
fractures of the hip and wrist (∆CMORB).  Net health benefit (E), measured in life-years-
gained or quality-adjusted-life-years, was the sum of the components: the net change in 
life expectancy (∆Y), the negative quality adjustment associated with side effects and 
complications of treatment (∆YSE), the positive quality adjustment associated with 
prevention of morbid events (∆YMORB), the positive quality adjustment associated with 
the relief from menopausal symptoms (∆YSYMP).  The health effects considered in this 
model included: endometrial cancer, hip and wrist fracture, cholecystectomy, and uterine 
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bleeding.  The assumed relative risks for included health effects are provided in Table 
1.4.  Risks were based on epidemiological and medical literature and national statistics.  
Health resource costs were measured in dollars and health benefits were measured in life-
years-gained and quality-adjusted-life-years.  Quality adjustments were made for 
illustrative purposes and were specified for the relief of menopausal symptoms, 
endometrial cancer, and hip fracture.  The assumed quality-of-life (QOL) adjustments are 
provided in Table 1.5.  A 5% annual discount rate was applied to all costs and health 
benefits were calculated both with and without discounting.  Weinstein concluded that 
estrogen treatment was cost-effective in women who have had a hysterectomy and in 
women with an intact uterus who are at high risk of osteoporosis.  The cost-effectiveness 
in symptomatic women without a prior hysterectomy and at average risk of osteoporosis 
was dependent upon the subjective importance attached to relief of symptoms.    
      Weinstein and Schiff94 conducted a follow-up to the original study conducted by 
Weinstein.93  The two primary objectives in this study were: 1) to examine the available 
evidence in comparing the costs, risks, and benefits of estrogen-progestin (PERT) therapy 
with ERT, and 2) to update the previous study to account for new epidemiologic evidence 
on the risks and benefits of ERT (particularly those relating to fractures and breast 
cancer) and to reflect current economic costs.  The principal advantage of PERT was the 
decreased risk of endometrial hyperplasia and cancer, along with its associated costs of 
treatment and monitoring.  The principal disadvantage of PERT was the subjective 
inconvenience and discomfort associated with progestin-induced periodic menstrual 
bleeding.  This study adopted the same type of pharmacoeconomic analysis, perspective, 
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measures of costs and outcomes, discount rate, mathematical model, and methodology 
used by Weinstein93 in the previous study.  In this study, a hypothetical population of 
postmenopausal women at age 50, with an intact uterus, was subdivided by treatment 
(ERT or PERT) and treatment duration (5, 10, or 15 years) into six different treatment 
populations.  The health effects considered in this model included: endometrial 
hyperplasia, uterine bleeding, endometrial cancer, breast cancer, hip and wrist fracture, 
and cholecystectomy.  The assumed relative risks for included health effects are provided 
in Table 1.4.    Risks were based on epidemiological and medical literature.  QOL 
adjustments were made this time to reflect reality (Weinstein’s expert opinion) and were 
specified for the relief of menopausal symptoms, endometrial cancer, and hip fractures.  
The assumed QOL adjustments are provided in Table 1.5.  Weinstein and Schiff 
concluded that the cost-effectiveness of PERT was comparable to ERT.  If no loss of well 
being is attached to periodic bleeding, then the cost-effectiveness ratios compared 
favorably with corresponding cost-effectiveness ratios for treatment of moderate diastolic 
hypertension. 
      Van der Loos et al.103 conducted a pharmacoeconomic analysis of HRT in the 
prevention of hip fractures.  The objective of the study was to determine HRT’s cost-
effectiveness in hip fracture prevention.  They employed a computer simulation model on 
a hypothetical population of post-menopausal women, which incorporated the relative 
risks of endometrial cancer, breast cancer, hip fracture, disability requiring nursing home 
or home care, and death.  They assumed that HRT prevents: 55.5% of hip fractures if 
administered for life or 15.5% if administered for 15 years, 22.6% of home care if 
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administered for life or 10% if administered for 15 years, and 4.4% of nursing home care 
if administered for life or 2.2% if administered for 15 years.  They estimated a slight gain 
in life for both 15-year and lifelong treatment durations and a cost/benefit ratio of 1.25 
for lifelong administration and a cost/benefit ratio of 1.42 if administered for 15 years.  
(Abstract, original in French). 
      Weinstein and Tosteson95 conducted a follow-up study of Weinstein and Schiff.94  
The objective of this study was to update the previous risk-benefit and cost-effectiveness 
analyses to reflect new epidemiologic and economic evidence.  This study followed the 
same type of pharmacoeconomic analysis, assumptions, and similar data sources of the 
previous study.  The primary piece of new epidemiologic evidence provided was the age-
specific incidence rates for hip fracture and its sequelae, which were estimated from a 
multiple logistic regression model developed by Melton et al.39  Weinstein and Shiff’s94 
mathematical model was applied to a hypothetical population of both symptomatic and 
asymptomatic postmenopausal women aged 50.  Two treatment options were considered, 
ERT and PERT, for treatment durations of five and 15 years.  The health effects 
considered in this model included: hip fracture, endometrial cancer, endometrial 
hyperplasia, uterine bleeding, and breast cancer.  The assumed relative risks for included 
health effects are provided in Table 1.4.  Risks were based on epidemiologic and medical 
literature and national statistics.  The assumed QOL adjustments are provided in Table 
1.5.  This study confirmed findings of Weinstein and Schiff94 that HRT is cost-effective 
and has comparable cost-effectiveness to other widely accepted clinical practices.  In 
addition, Weinstein and Tosteson concluded that the cost-effectiveness of PERT relative 
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to ERT is contingent upon the subjective quality adjustments made for relief of 
menopausal symptoms and that long-term HRT is more cost-effective than short-term 
HRT, due to improved prophylaxis against hip fracture.   
      In 1990, Tosteson et al.96 conducted a pharmacoeconomic analysis of bone 
mineral density (BMD) screening to target hormone replacement therapy (HRT) at 
women at highest risk of hip fracture.  The objective of the study was to determine the 
costs and benefits of BMD screening for osteoporosis.  A cost-utility analysis from a 
societal perspective was performed.  Tosteson et al. employed a Markov state-transition 
model on a hypothetical population of asymptomatic, perimenopausal, Caucasian women 
with intact uterus, which were followed from age 50 to 100.  The population was 
subdivided into three treatment populations: 1) no intervention; 2) bone mass 
measurement at the menopause followed by selective, long-term PERT in women with 
bone mineral density below a specific threshold; and 3) universal PERT at the 
menopause.  Tosteson evaluated four screening strategies, defined by the bone mineral 
density threshold (ranging from < 0.8g/cm2 to < 1.1 g/cm2) for instituting a 15 year 
course of (PERT).  Tosteson et al. used the following cost-effectiveness equation in the 








Net resource cost (C) was the sum of the component costs: direct cost of HRT (CRX), the 
cost of BMD screening (CDPA), and the economic savings associated with the prevention 
of hip fracture (∆CSAVE).  The net health benefit (E) was the net change in health 
outcomes, measured in life-years-gained (∆LY) or quality-adjusted-life-years (∆QALY).  
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Health effects considered in the model only included hip fracture.  The assumed relative 
risks for included health effects are provided in Table 1.4.  Risks were based on 
epidemiologic and medical literature and national statistics.  QOL adjustments were made 
for hip fracture sequelae, which are located in Table 1.5.  A 5% annual discount rate was 
applied to all costs and health benefits.  Tosteson et al. concluded that cost-effectiveness 
ratios for bone density screening with treatment thresholds of < 0.9g/cm2 and < 1.0g/cm2 
were cost-effective in comparison with those reported for generally accepted medical 
practices, whereas the cost-effectiveness ratio obtained for universal hormone 
replacement therapy was not cost-effective.     
      Tosteson and Weinstein97 conducted an updated pharmacoeconomic analysis to 
reflect current medical practice and understanding of the risks and benefits of HRT.  The 
objective of the study was to determine the additional costs and benefits achieved for 
different management strategies.  A cost-effectiveness analysis was performed from a 
societal perspective.  Tosteson and Weinstein employed a Markov state-transition model 
to a hypothetical population of perimenopausal women.  The population was subdivided 
into two different treatment populations: 1) women with a previous hysterectomy, and 2) 
women with an intact uterus.  Women with a prior hysterectomy received either a 10 or 
15 year course of ERT, whereas women with an intact uterus received either a 10 or 15 
year course of PERT.  The following cost-effectiveness equation was used for the 













Net resource costs (∆C) are the sum of the component costs: costs of hormone treatment 
(∆CHRT), costs of long-term nursing home stays (∆CNH), costs of breast cancer (∆CBRCA), 
and the costs of acute hip fracture (∆CHFX).  The components of net health benefit 
represent changes in life-expectancy or quality-adjusted-life-expectancy due to changes 
in hip fracture incidence (∆LEHFX), breast cancer incidence (∆LEBRCA), ischemic heart 
disease death (∆LEIHD), disability and nursing home residency due to hip fracture 
(∆QHFX), and symptomatic relief from menopausal symptoms or discomfort resulting 
from hormone replacement therapy (∆QSYMPT).  The health effects considered in the 
model included: hip fracture, ischemic heart disease, and breast cancer.  The assumed 
relative risks for included health effects are provided in Table 1.4.  Risks were obtained 
from epidemiologic and medical literature.  QOL adjustments were made for hip fracture 
sequelae and relief of menopausal symptoms.  The assumed QOL adjustments are 
provided in Table 1.5.  A 5% annual discount rate was applied to all costs and health 
benefits.  Under base-case model assumptions, Tosteson and Weinstein concluded that 
the cost-effectiveness ratio for ERT in women with a prior hysterectomy was cost-
effective in comparison with those reported for other generally accepted medical 
practices.  In contrast, the cost-effectiveness ratios obtained for PERT in women with an 
intact uterus was not as cost-effective.  The difference in cost-effectiveness ratios 
between ERT and PERT was primarily attributed to the assumed 50% relative risk 
reduction in ischemic heart disease with ERT and not with PERT.     
     Cheung and Wren98 conducted a pharmacoeconomic analysis of HRT in an 
Australian context.  The objectives of the study were to determine: 1) the cost-
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effectiveness of HRT in comparison to other health care interventions; 2) whether ERT or 
PERT is more cost-effective;  3) what duration of treatment optimizes cost-effectiveness; 
and 4) whether it is cost-effective to treat asymptomatic women (with or without prior 
hysterectomy).  A cost-utility analysis was performed from a societal perspective.  
Cheung and Wren employed a mathematical model, similar to the model used by 
Weinstein and Schiff,94 on a cohort of all New South Wales women age 50 (n=27,021).  
The treatment alternatives considered were: 1) no intervention, 2) ERT, and 3) PERT for 
5, 10, or 15-year durations of therapy.  The model examined the effects of three different 
relative risks (RRs) of dying from myocardial infarction following HRT [1.0 (no 
cardioprotection), 0.75 (assumed halved cardioprotection with progestin), and 0.5 
(assumed cardioprotection offered from ERT)] on treatment, duration of therapy, 
presence or absence of menopausal symptoms or progestin side effects, and hysterectomy 
status.  The health effects considered in the model included: breast cancer, hip and wrist 
fracture, myocardial infarction, uterine bleeding, endometrial hyperplasia, and 
endometrial cancer.  The assumed relative risks for included health effects are provided 
in Table 1.4.  Risks were based on epidemiologic and medical literature and national 
statistics.  Health resource costs were measured in Australian dollars and health benefits 
were measured in life-years-gained and quality-adjusted-life-years.  QOL adjustments 
were the same used by Weinstein and Schiff94 except for myocardial infarction which 
was assigned the same value for hip fracture.  The assumed QOL adjustments are 
provided in Table 1.5.  A 5% annual discount rate was applied to all costs and health 
benefits.  Cheung and Wren concluded, under base-case assumptions and a RR of 0.5 of 
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death from myocardial infarction, that HRT was cost-effective for symptomatic women 
when compared to other generally accepted medical practices.  The cost-effectiveness of 
HRT in asymptomatic women was contingent upon the cardioprotection associated with 
HRT.  Treatment duration of 15 years was determined to be more cost-effective than 
treatment durations of 5 and 10 years.     
      Clark and Schuttinga109 conducted a pharmacoeconomic analysis of the cost of 
illness for osteoporotic fractures.  The study’s objective was to estimate the reduction in 
cost of illness achieved through BMD screening at the time of menopause and long-term 
HRT for those most at risk for developing fractures.  A cost analysis was performed from 
the societal perspective.  Clark and Schuttinga employed a model in a hypothetical cohort 
of 100,000 American white women who are BMD screened at age 50 and subsequently 
stratified into three risk groups: High-risk, Mid-risk, and Low-Risk, with 90% of the 
High-risk, 70% of the Mid-Risk, and 0% of Low-Risk receiving HRT for 15 years.  
Health resource costs were measured in dollars, which included not only direct costs but 
indirect costs (lost productivity).  Indirect costs were calculated using the human capital 
approach.  A 6% annual discount rate was applied to all costs.  From their model, Clark 
and Schuttinga estimated a present value reduction in the cost of illness of $5.1 million 
(1988$) for a cohort of 100,000 American Caucasian women, which were followed over 
a 40-year period beginning in 1988.        
      In 1992, Daly et al.99 performed a pharmacoeconomic analysis of HRT in the 
British context.  The study’s objective was to determine the relative benefits of different 
treatment strategies and what factors most influence cost-effectiveness.  They performed 
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a cost-utility analysis from the perspective of the National Health Service (NHS).  Daly et 
al. employed a computer simulation model in a hypothetical population of 
postmenopausal women at age 50.  The hypothetical population was subdivided into 
three intervention populations: 1) treatment of hysterectomized women with ERT, 2) 
treatment of non-hysterectomized women with PERT, and 3) treatment of non-
hysterectomized women with ERT.  In the standard analysis, each treatment intervention 
was initiated at 50 years of age and continued for 10 years.  The health effects considered 
in this model included: endometrial cancer, breast cancer, hip fracture, wrist fracture, 
vertebral fracture, ischemic heart disease, cerebrovascular disease, hysterectomy, and 
dilatation and curettage.  The assumed relative risks for included health effects are 
provided in Table 1.4.  Risks were based on epidemiologic and medical literature and 
national statistics.  Health resource costs were measured in pounds sterling and health 
benefits were measured in life-years-gained and quality-adjusted life-years. In this study, 
costs incurred by the NHS of providing health care during extended lifetime were 
included.  QOL adjustments were made for severe menopausal symptoms and for 
moderate menopausal symptoms.  The assumed QOL adjustments are provided in Table 
1.5.  A 6% annual discount rate was applied to all costs and health benefits were 
calculated both with and without discounting. 
 Daly et al. concluded, under model assumptions, that ERT use in symptomatic 
and asymptomatic women with a prior hysterectomy was more cost-effective than the 
treatment of hypertension.  However, the cost per QALY of PERT for women with mild 
menopausal symptoms was three times higher than the cost per QALY of ERT in 
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hysterectomized women with mild menopausal symptoms.  Other significant findings by 
Daly et al. under model assumptions include the life-saving potential of a lasting 50% 
reduction in cardiovascular disease risk with ERT of almost 2 years and a reduction of 
approximately 30% in the cost per discounted life year gained when treatment is 
increased from 10 to 15 years.   
      Tosteson100 presented “Hormone Replacement Therapy: Benefit, Risk and Cost 
Considerations” at the Clinical Therapeutic Conference on Postmenopausal Osteoporosis.  
Her presentation included an update of the previous cost-effectiveness analysis by 
Tosteson and Weinstein97 to reflect new epidemiologic and economic evidence.  She 
performed a cost-effectiveness analysis from a societal perspective.  Tosteson employed 
the same Markov state-transition model used in the earlier study to follow a hypothetical 
population of perimenopausal women over time from age 50 to 99.  The population was 
subdivided into two different treatment populations: 1) women with a previous 
hysterectomy receiving ERT for 15 years, and 2) women with an intact uterus receiving 
PERT for 15 years.  The health effects considered in this model include: endometrial 
cancer, breast cancer, hip fracture, ischemic heart disease.  The assumed relative risks for 
included health effects are provided in Table 1.4.  Risks were based on epidemiologic and 
medical literature and national statistics.  Health resource costs were measured in dollars 
and health benefits were measured in life-years-gained and quality-adjusted life-years.  
QOL adjustments for relief from menopausal symptoms and hip fracture were included in 
the model, but not specified.  A 5% annual discount rate was applied to all costs and 
health benefits were calculated both with and without discounting.  Tosteson concluded 
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that the cost-effectiveness of HRT compares favorably with other generally accepted 
medical interventions.     
      Geelhoed and Harris101 performed a pharmacoeconomic analysis to evaluate the 
overall impact of a public health initiative to treat all postmenopausal women with ERT 
to prevent hip fracture in an Australian context.  The objective of the study was to 
determine the effects of age of treatment, duration of treatment, and lifestyle intervention 
on cost-effectiveness of ERT in the prevention of hip fractures.  A cost-effectiveness and 
cost-utility analysis was performed from a societal perspective.  Geelhoed and Harris 
employed a decision analytic tree model based on a Markov process in a hypothetical 
population of healthy Caucasian women at age 50, differentiated by hysterectomy status 
prior to age 50.  The hypothetical population was further subdivided into four 
intervention populations: 1) ERT for life beginning at age 50, 2) ERT for 15 years (50-
65), 3) ERT for life beginning at age 65, and 4) a lifestyle intervention of calcium 
supplementation and exercise.  The health effects considered in this model include: 
endometrial cancer, breast cancer, hip fracture, uterine bleeding.  The assumed relative 
risks for included health effects are provided in Table 1.4.  Risks were based on 
epidemiologic and medical literature and Australian national statistics. Health resource 
costs were measured in Australian dollars and health benefits were measured in life-
years-gained and quality-adjusted-life-years, and cost per quality-adjusted-life-years 
gained.  QOL adjustments were made for hip fracture sequelae, which are provided in 
Table 1.5.  A 5% annual discount rate was applied to all costs and health benefits were 
calculated both with and without discounting.  Geelhoed and Harris concluded, under 
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Health resource costs were measured in pounds sterling and health benefits were 
measured in averted vertebral fractures.  A 6% annual discount rate was applied to all 
costs and health benefits (averted vertebral fractures).  Francis et al. concluded that HRT 
administered for one-year would reduce the incidence of further vertebral deformation in 
women with vertebral fractures from 33.7 to 15 per 100 patient-years, with a discounted 
cost of ₤138 per averted vertebral fracture.  HRT was the most cost-effective intervention 
of those considered in the analysis and was determined to be cost-effective for the 
prevention of further vertebral deformation in women with established osteoporosis. 
  The U.S. Congress Office of Technology Assessment (OTA)105 conducted a 
pharmacoeconomic analysis of BMD screening and HRT.  The objective of the study was 
to determine the cost-effectiveness of BMD screening once, at age 50 or 65, and initiation 
of HRT in those with low bone density.  The OTA performed a cost-effectiveness 
analysis.  The perspective of the study was not specifically stated, but can be inferred to 
be that of a third party (government).  The OTA employed a Monte Carlo computer 
simulation model of a hypothetical population of women eligible for BMD screening and 
HRT at age 50 and ending either at death or at age 90.  The hypothetical population was 
further subdivided into four intervention populations: 1) BMD screening and HRT for 
those with low BMD at age 50, 2) Universal treatment at age 50, 3) BMD screening and 
HRT for those with low BMD at age 65, 4) Universal treatment at age 65.  For the BMD 
screened populations, the OTA evaluated initiation of therapy based on two different 
BMD treatment thresholds: 1) BMD 1 SD below the young adult reference mean BMD, 
and 2) BMD below the young adult reference mean BMD.  The effects of both ERT and 
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PERT, with different durations of therapy, were evaluated.  The health effects considered 
in this model included: endometrial cancer, breast cancer, gall bladder disease, hip 
fracture, cardiovascular disease.  The assumed relative risks for included health effects 
are provided in Table 1.4.  Risks were based on epidemiologic and medical literature and 
national statistics.  Health resource costs were measured in dollars and health benefits 
were measured in life-years-gained.  No quality adjustments were included in this study.  
A 5% annual discount rate was applied to all costs and health benefits were calculated 
both with and without discounting.   
 The OTA concluded, under model assumptions, that long-term (40 year) ERT at 
age 50 with and without BMD screening was cost-effective in comparison with many 
other interventions currently paid for by public and private third-party payers, with cost 
per life-year gained ratios of $27,000 and $23,000 (1993$), respectively.  The cost per 
added life year declined substantially as the duration of the intervention increased for all 
strategies.  The OTA confirmed findings of previous studies, that the cost-effectiveness 
of HRT is extremely sensitive to the assumed relative risk reduction of cardiovascular 
disease.  When the assumed cardio-protective benefit was removed, cost per life-year-
gained ballooned to $155,000 for ERT with BMD screening and $450,000 for ERT with 
universal treatment.  The cost per added year of life for long-term (40 year) PERT was 
roughly $71,000 and roughly the same as ERT for without and with BMD screening, 
respectively.  Due to a lack of evidence on the cardio-protective effect of HRT initiated in 
women 65 years of age, a relative risk of 1.0 for cardiovascular diseased was assumed.  
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Therefore, the cost-effectiveness of HRT initiated at the age of 65, regardless of BMD 
screening or not, was determined not to be cost-effective.     
      Torgerson et al.106 authored “Using economics to prioritize research: a case study 
of randomized trials for the prevention of hip fractures.”  The study’s objective was to 
demonstrate how a combined clinical and economics approach can be used to help 
prioritize research funds.  The ultimate goal of this analysis was to identify which 
intervention, a priori, research funding ought to be directed towards.  A cost-effectiveness 
analysis was performed.  The perspective of the study was not directly identified but 
assumed to be that of the NHS.  Torgerson et al. modeled each treatment alternative 
(annual vitamin D injection (30,000 IU), thiazide diuretics (50mg HCTZ), HRT, calcium 
and vitamin D, calcium, caclitonin with calcium and vitamin D) for five years in a cohort 
of 100,000 women, under the following assumptions: treatment age 80, cohort has the 
same age related mortality of women in the general population, the annual incidence of 
hip fractures for women aged ≥ 80 is 2.3%.  Health resource costs were measured in 
pounds sterling and health benefits were measured in averted hip fractures.  A 6% annual 
discount rate was applied to all costs and health benefits.  Torgerson et al. concluded that 
vitamin D injection was most worthy of randomized control trial funding.  HRT was 
considered to be too costly and to have an adverse safety profile (breast cancer, 
endometrial cancer).  Torgerson et al. calculated a cost of ₤7,398 per averted hip fracture 
for HRT.  
 Ankjaer-Jensen and Johnell107 conducted a pharmacoeconomic analysis of 
different pharmaceutical programs to prevent osteoporosis from a Danish context.  The 
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objectives of the study were to compare the cost-effectiveness of different pharmaceutical 
programs to prevent osteoporosis, to determine cost-effectiveness with respect to age of 
treatment, and to compare the cost-effectiveness of population-based prevention 
programs with programs targeted at individuals at high risk for fracture identified through 
BMD screening.  This study examined the cost-effectiveness of calcium supplementation, 
etidronate, and calcitonin.  HRT was included as a benchmark.  A cost-effectiveness 
analysis was performed from a societal perspective.  Ankjaer-Jensen and Johnell 
employed a simulation model of a hypothetical cohort of 1,000 50-year old women.  The 
HRT treatment intervention consisted of ERT for 10 years.  Two values of cost-
effectiveness were produced; one under a set of optimistic assumptions and one under a 
set of pessimistic assumptions.  The following cost-effectiveness equation was employed 
E
BC −  
Costs (C) included medication costs, costs of GP visits, and costs of diagnostic tests due 
to treatment.  The effect (E) was the number of hip fractures avoided.  The benefit (B) 
was the change in costs due to wrist, vertebral, and hip fractures averted.  For HRT, the 
model included changes in cost due to changes in incidence of cardiovascular disease and 
breast cancer.  Health effects considered in the model included: wrist, vertebral, and hip 
fracture, breast cancer, and cardiovascular disease.  The assumed relative risks for 
included health effects are provided in Table 1.4.  Risks were based on epidemiologic and 
medical literature and national statistics.  Health resource costs were measured in Danish 
Krones (DKK) and health benefits were measured in averted wrist, vertebral, and hip 
fractures.  No QOL adjustments were made.  A 5% annual discount rate was applied to 
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all costs and health benefits were calculated without discounting.  Ankjaer-Jensen and 
Johnell concluded that etidronate was the most cost-effective alternative and calcitonin 
was the least cost-effective alternative.  HRT was not included in the direct comparison, 
since the extraskeletal effects of HRT were not included in the analysis.  The cost-
effectiveness of the population-based prevention programs with HRT ranged from DKK -
38,909 (optimistic assumption) to DKK 178,100 (pessimistic assumption).  The cost-
effectiveness of programs targeted at individuals at high risk for fracture identified 
through BMD screening with HRT was not reported nor was HRT included in the 
analysis on the effect of treatment age.  However, overall the screening program was 
found to be more cost-effective than the population-based program for all treatment 
alternatives.     
      Norlund110 conducted a pharmacoeconomic analysis of BMD and HRT at the 
request of the University Hospital of Lund, Sweden to evaluate the proposed solution of 
BMD screening and HRT to the problem of increasing rates of fractures among elderly 
women.  The objective of the study was to determine the cost-effectiveness of BMD 
screening and HRT for those patients most at risk and thereby reduce hip, spine, and 
wrist fractures.  A criterion established by the University Hospital board was that the 
program had to have a cost/benefit ratio of one to be implemented.  A cost-benefit 
analysis was performed from the perspective of the University Hospital of Lund.  
Norlund employed a computer simulation model for a cohort of 17,000 Swedish women 
aged 50 to 54, which were followed until the age of 89.  A total of 70% of the population 
was anticipated to be BMD screened and 20% of the screened population was expected to 
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have low BMD requiring HRT, which was to be administered for seven years.  
Compliance with HRT was projected to be 30%.  HRT’s relative risk reduction for 
fracture was assumed to be 50%.  Health effects considered in the model included: wrist, 
vertebral, and hip fracture.  The assumed relative risks for included health effects are 
provided in Table 1.4.  Risks were based on epidemiologic and medical literature and 
national statistics.  Health resource costs were measured in Swedish kronors and health 
benefits were measure in averted fractures of the wrist, spine, and hip.  Norlund included 
direct and indirect costs in his analysis.  A 5% annual discount rate was applied to all 
costs and health benefits.  According to the model, 100 fewer fractures occurred as a 
result of the preventive program, of which 61 were expected to be hip fractures.  
However, the benefit-cost ratio was 0.68, therefore the program was not implemented.               
      Daly et al.102 conducted a pharmacoeconomic analysis of HRT as an update to the 
previous analysis in British context.  The study’s objective was to assess the relative 
benefits of different treatment strategies, and to identify which factors most influence 
cost effectiveness.  A cost-effectiveness analysis was performed from the perspective of 
the NHS.  Daly et al. employed a computer simulation model in a hypothetical population 
of postmenopausal women at age 50.  The hypothetical population was subdivided into 
two intervention populations: 1) treatment of women with a previous hysterectomy with 
ERT, 2) treatment of women with an intact uterus with PERT.  In the standard analysis, 
each treatment intervention was initiated at 50 years of age and continued for 10 years.  
The health effects considered in this model included: endometrial cancer, breast cancer, 
hip fracture, wrist fracture, vertebral fracture, ischemic heart disease, cerebrovascular 
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disease (stroke), hysterectomy, dilatation and curettage.  The assumed relative risks for 
included health effects are provided in Table 1.4.  Risks were based on epidemiologic and 
medical literature and national statistics.  Health resource costs were measured in pounds 
sterling and health benefits were measured in life-years-gained and quality-adjusted-life-
years.  In this study, costs incurred by the NHS of providing health care during extended 
lifetime were included.  QOL adjustments were made but not specified.  A 6% annual 
discount rate was applied to all costs and health benefits were calculated both with and 
without discounting.  Daly et al. reached the similar conclusions as those reached in their 
previous study.  Treatment of symptomatic menopausal women is cost-effective for any 
duration of treatment, whereas treatment of non-hysterectomized asymptomatic women is 
of questionable cost-effectiveness.     
 Visentin et al.,108 conducted a pharmacoeconomic analysis of calcitonin to assess 
the impact of the Italian Health Services removal of calcitonin from the refund list on 1 
January 1994.  The focus of the analysis was calcitonin but included other osteoporosis 
medications licensed in Italy.  The objective of the study was to determine the cost-
effectiveness of calcitonin.  A cost-effectiveness analysis was performed from the 
perspective of the Italian government.  Visentin et al. employed Weinstein and Schiff’s94 
mathematical model to hypothetical population of Italian women.  In the HRT analysis, 
the population received either ERT or PERT for one year.  In addition, the study 
examined the cost-effectiveness therapies with BMD screening.  The following cost-
effectiveness equation was used for Weinstein and Schiff’s mathematical model: 
RXLESEMORBRXPAHF CCCNCC ±+⊗−=  
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Net resource costs per avoided hip fracture (CPAHF) are the sum of the component costs: 
all direct medical and health care costs of one year’s treatment (CRX), the number of 
people requiring treatment to prevent one hip fracture (N), savings in health care, 
rehabilitation and custodial costs due to the preventing or alleviation of disease (CMORB), 
all health care costs associated with the adverse side effects of treatment (CSE), and costs 
of diseases that would not have occurred if the patient had not lived longer as a result of 
the original treatment (CRXLE).  A zero figure for CSE and CRXLE was assumed.  Health 
effects considered in the model only included hip fracture.  Health resource costs were 
measured in Italian prices and expressed in U.S. dollars and health benefits were 
measured in averted hip fractures.  No QOL adjustments were made.  Use of a discount 
rate was not used since the study only examined costs and benefits incurred in a one-year 
period.  Visentin et al. concluded that not only was ERT cost-effective but it was the most 
cost-effective of the treatment alternatives considered (calcitonin, bisphosphonates, 
anabolic steroids, vitamin D metabolites, fluorides, and flavonoid glycosides) for the 
prevention of hip fractures.  PERT was found not to be cost-effective.  In addition, 
Visentin et al. concluded that BMD screening, which identified the lowest quartile for 
treatment, was cost-effective if annual treatment costs did not exceed $91 (1995$).  
Pharmacoeconomic Analyses of Alendronate 
      A total of four111-114 pharmacoeconomic analyses of alendronate were found, of 
which three were CUAs111, 112, 114 and one was a CEA.113  Three 111, 112, 114 of the four 
studies were similar in that each: examined the cost-effectiveness of alendronate in older 
postmenopausal women (≥ 65 years of age); who were at an increased risk of 
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osteoporotic fracture (BMD: 2 to 2.5 SD below mean, or previous vertebral fracture); and 
the duration of intervention was 5 to 10 years.  Under base-case assumptions, each of 
these studies, found alendronate to be cost-effective.  Buckley and Hillner113 examined 
the cost-effectiveness of alendronate in the prevention of vertebral fractures in women 
taking corticosteroids and concluded that alendronate was the most effective and most 
costly intervention.  A brief review of the four studies is provided below. 
 Kristiansen et al.111 conducted a pharmacoeconomic analysis of alendronate in a 
Norwegian context.  The objective of the study was to determine the cost-effectiveness of 
a five-year alendronate intervention in women aged 65 years with a BMD of the femoral 
neck 2.5 SD below peak bone mass.  A cost-utility analysis was performed and a societal 
perspective was adopted.  Kristiansen et al. used a computer simulation model.  The risk 
of fracture was based on epidemiologic and medical literature.  A discount rate was not 
specified.  The discounted cost per quality-adjusted-life year was Norway Kroner (NOK 
[1 NOK = approximately 0.15 US dollars) 528,000, NOK 291,000, and NOK 147,000 
when BMD was 1.5, 2.5, and 3.5 below peak bone mass, respectively.  Kristiansen et al. 
concluded that alendronate was cost-effective when administered to women at high risk 
of osteoporotic fractures.  (Abstract, original in Norwegian). 
      Coyle et al.112 conducted a pharmacoeconomic analysis of calcitonin from a 
Canadian context.  The objective of the study was to determine the cost-effectiveness of 
nasal calcitonin in the treatment of postmenopausal women with a previous fracture who 
either cannot or will not take hormone replacement therapy.  Both a cost-effectiveness 
and cost-utility analysis were performed from the perspective of a provincial government.  
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A decision analytical framework, based on a Markov process with a cycle length of one-
year, was used to determine the cost-effectiveness of calcitonin, alendronate, and 
etidronate in women with a previous fracture.  The base-case analysis looked at treatment 
durations of five and ten years, initiation of therapy at age 65, 50% compliance after one-
year of treatment, and a linear reduction in benefit after cessation of treatment equal to 
duration of treatment.  The efficacy of the treatment alternatives: calcitonin 200IU once 
daily, alendronate 10mg once daily, and cyclical etidronate (400mg daily for 2 weeks) 
was obtained from a meta-analysis of randomized controlled clinical trials.  One of the 
inclusion criteria in the meta-analysis was trials with postmenopausal women with either 
prevalent fractures or a BMD score less than 2 SD below the mean.  The health effects 
considered in the model included: wrist, vertebral, and hip fracture.  Risks were based on 
national statistics.  Health resource costs were measured in Canadian dollars and health 
benefits were measured in averted wrist, vertebral, and hip fractures and quality adjusted 
life years.  Cost estimates included in the model were costs of drug therapy, treatment of 
drug side effects, and treatment costs of fractures.  The following quality adjustments 
were made for health states post fracture: normal health (0.92), hip fracture first year 
(0.40), hip fracture following year (0.50), wrist fracture first year (0.90), vertebral 
fracture first year (0.64), which were obtained from an ongoing study at the Ottawa 
Hospital.  A 5% annual discount rate was applied to costs and health benefits.   
 Coyle et al. found that the cost-effectiveness of alendronate, in comparison with 
calcitonin, was dependent upon whether a study by Black et al. was included in 
alendronate’s meta-analysis.  The study by Black et al. decreased the cost-effectiveness 
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of alendronate because one-third of the patients in the randomized clinical trial did not 
meet the inclusion criteria of prevalent fractures or a BMD score less than 2 SD below 
the mean, thereby decreasing efficacy.  If the study by Black et al. is excluded from the 
meta-analysis, then alendronate was shown to be more cost-effective than calcitonin and 
overall was considered to be of moderate cost-effectiveness. 
      In 1990, Buckley and Hillner113 conducted a pharmacoeconomic analysis of 
medications used in the prevention of vertebral fractures in women taking corticosteroids.  
The objective of the study was to determine the cost-effectiveness of calcium and vitamin 
D, cyclic etidronate, and alendronate in the prevention of vertebral fractures in women 
with either normal bone density or osteopenia who initiate moderate dose corticosteroid 
therapy.  A cost-effectiveness analysis was performed from the perspective of the patient 
or insurer.  Buckley and Hillner employed a model in a hypothetical population of 
Caucasian women, which was divided into the following cohorts based on lumbar spine 
BMD (LS BMD):  aged 30 normal (T-score = 0.0), aged 50 borderline osteopenia (T-
score = -1), aged 60 moderate osteopenia (T-score = -1.5), aged 70 severe osteopenia (T-
score = -2).  The hypothetical cohorts initiated one-year of prednisone treatment at a 
mean dose of 10mg/day.  To prevent corticosteroid induced vertebral fractures, the 
hypothetical cohort received one of four treatments for one-year: 1) no treatment, 2) 
calcium (500 - 1000 mg/day) and vitamin D (400 IU/day), 3) cyclic etidronate (400 
mg/14 days of every 3 months), and 4) alendronate (10 mg/day).  Cost-effectiveness was 
examined at two endpoints, 10 years after treatment and at age 80.  Health resource costs 
were measure in dollars and health benefits were measured in averted vertebral fractures.  
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Costs included both direct medical and indirect costs (lost productivity for patient and 
caregiver).  A 3% discount rate was applied to all costs and health benefits were not 
discounted. 
 The authors concluded that alendronate prevented the most vertebral fractures but 
the cost per averted vertebral fracture was high.  The marginal cost-effectiveness of 
alendronate compared to cyclic etidronate at the ten-year point ranged from $121,125 (LS 
BMD at age 50, T-score -1) to $7,883 (LS BMD at age 70, T-score -2) per averted 
vertebral fracture and at the age of 80 ranged from $ 4,533 (LS BMD at age 50, T-score -
1) to $7,883 (LS BMD at age 70, T-score -2) per averted vertebral fracture. 
      Johnell et al.114 conducted a pharmacoeconomic analysis of alendronate for the 
treatment of osteoporotic women in Sweden.  The objective of the study was to determine 
the cost-effectiveness of alendronate in the treatment of osteoporotic women using data 
from the FIT trial.  A cost-effectiveness analysis was performed from the societal 
perspective.  Johnell et al. employed a Markov model, with a cycle length of one-year, to 
determine the cost-effectiveness of alendronate for a hypothetical cohort of Swedish 
women comparable to those in the FIT vertebral fracture arm (i.e., age 71, low bone mass 
with at least one previous vertebral fracture).  In the base-case analysis, women were 
simulated until the age of 100 or death, the treatment duration was assumed to be five-
years, the duration of effect declined linearly over a five-year period following cessation 
of treatment.  The health effects considered in the model included: wrist, vertebral, and 
hip fractures.  Age-specific relative risks for fractures of the wrist, vertebrae, and hip 
were obtained from Swedish epidemiologic studies.  The relative risk reductions of 
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fracture for patients treated with alendronate were obtained from the vertebral fracture 
arm of the FIT trial (51% for hip, 55% for vertebral, and 48% for wrist).  Health resource 
costs were initially measured in Swedish kronors then converted to U.S. dollars and 
health benefits were measured in averted hip fractures, life-years gained, and quality- 
adjusted-life-years.  Both direct medical and non-medical costs were included in the 
model.  The quality of life weights used in the base-case analysis were age-specific and 
ranged from: [well 0.90 (age 50-64) to 0.63 (75 years +), hip fracture 0.70 (age 50 – 64) 
to 0.43 (75 years +), spine fracture 0.81 (age 50 – 64) to 0.57 (age 75 years +), wrist 
fracture 0.86 (age 50-64) to 0.60 (age 75 years +), post-hip fracture 0.80 (age 50-64) to 
0.53 (age 75 years +)].  A 5% annual discount rate was applied to costs and health 
benefits.  A threshold for acceptable cost-effectiveness was established as a range 
between $20,000 - $40,000 per QALY gained (1996$).  Johnell et al. concluded that 
alendronate was “good value for the money” for the treatment of osteoporosis and 
prevention of fractures.  Alendronate met the $30,000 threshold for acceptable cost-
effectiveness for the base-case analysis and for a cohort of somewhat lower risk patients 
in a sensitivity analysis. 
Pharmacoeconomic Analyses of Hormone Replacement Therapy and Alendronate 
 Three2, 85, 115 analyses examined the cost-effectiveness of alendronate and HRT in 
the same economic evaluation.  All three economic evaluations were CUA’s.  Each 
analysis concluded that HRT was more cost-effective than alendronate under base-case 
assumptions.  The National Osteoporosis Foundation (NOF) conducted a study to 
develop a set of evidence and outcomes-based recommendations for the diagnosis and 
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treatment of osteoporosis in postmenopausal Caucasian women.  The study included a 
pharmacoeconomic analysis of HRT, calcium, vitamin D, calcitriol, calcitonin, 
bisphosphonates, fluoride, and exercise.  A cost-effectiveness analysis was performed 
from the societal perspective.  Since the primary purpose of this study was to develop 
recommendations for the diagnosis and treatment of osteoporosis and not a 
pharmacoeconomic analysis, the specific details of the model employed were not 
available.  However, certain assumptions incorporated into the model were described.  
The age-specific relative risk for fracture of the wrist, vertebrae, and hip were obtained 
from a model developed by Black et al. based on data obtained from the Study of 
Osteoporotic Fractures (SOF).  Investigators assumed a 50% relative risk reduction for 
fracture of the hip, wrist, and vertebrae with alendronate and a 50% relative risk 
reduction for vertebral fracture and a 25% reduction for hip and wrist fracture for HRT.  
Health resource costs were measured in U.S. dollars and health benefits were measured in 
quality-adjusted life-years.  No discounting was performed.  Thirty different quality-of-
life weights, developed by the NOF committee, were used in the base-case analysis to 
account for the QALYs lost due to an event. A threshold for acceptable cost-effectiveness 
was established at $30,000 per QALY gained (1998$).  The NOF concluded that overall 
HRT was the most cost-effective treatment of osteoporosis.  The NOF recommended 
HRT use in women with a hip BMD T score of less than -2 without risk factors and in 
women with a T score of less than -1.5  with a history of nonvertebral fracture.  The NOF 
recommended that alendronate should be reserved for women only at the highest risk of 
fracture.  The NOF concluded that alendronate is cost-effective for women with hip T 
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scores below -2.5 without prior history of fracture and for women who have experienced 
a nonvertebral fracture and who have T scores between -2.5 and -1, depending on age and 
number of risk factors. 
      Rosner et al.115 conducted a pharmacoeconomic analysis of both HRT and 
alendronate in a Canadian context.  The objective of the study was to evaluate the cost-
effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures 
in postmenopausal women with osteoporosis.  The multi-therapy treatment strategies 
were designed to reflect clinical practice where patients are free to decline, accept, and 
discontinue therapies.  A cost-utility analysis was performed from a societal perspective.  
Rosner et al. employed a computer simulation model in a hypothetical cohort of 1,000 
postmenopausal (at least eight years postmenopause) who had established osteoporosis 
(diagnosed by either a BMD score 2.5 SD below the mean or ≥ 2 vertebral fractures).  
The number of vertebral fractures which occurred and costs incurred were evaluated 
every six months over three years for nine different multi-therapy treatment strategies, 
which were composed of sequentially ordered combinations of five different medications 
(ERT, PERT, alendronate, etidronate, and calcium).  The only health effect incorporated 
into the model was vertebral fracture (i.e., the non-skeletal effects of HRT were not 
included).  Risks were based on epidemiologic and medical literature and national 
statistics.  The assumed vertebral fracture relative risks reduction for HRT was 0.45 and 
for alendronate was 0.37.  In addition, Rosner et al. incorporated patients’ willingness to 
initiate and continue therapy into the model.  Health resource costs were measured in 
Canadian dollars and health benefits were measured in averted vertebral fractures and 
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quality adjusted life years.  In addition to direct medical costs, Rosner et al. included 
indirect costs (lost productivity) for patient and caregiver.  A 5% annual discount rate 
was applied to costs and health benefits.   
 Rosner et al. concluded that the sequential treatment pattern of ERT → calcium→ 
no therapy treatment strategy was most cost-effective.  The cost-effectiveness of this 
treatment strategy fell just below the $Can20,000/QALY gained threshold, which is a 
standard that has been applied in other Canadian pharmacoeconomic evaluations 
indicating strong evidence for program adoption.  The ERT → alendronate → calcium → 
no therapy treatment alternative exceeded the $Can20,000 - $Can100,000/QALY 
threshold, which is a standard that indicates moderate evidence for adoption.  
 Kanis et al.85 conducted a pharmacoeconomic analysis of bisphosphonates, 
vitamin D, 1-alpha hydroxylated derivatives of vitamin D, calcium, estrogen, estrogen 
like agents, anabolic steroids, fluoride salts, thiazide diuretics, raloxifene, vitamin K2, 
protein supplements, and exercise.  The objective of the study was to model the cost-
effectiveness of these agents in established osteoporosis from a British context.  A cost-
utility analysis was performed from a societal perspective.  Kanis et al. employed 
Sheffield Economics Model for Osteoporosis (SHEMO), which is an individual-based, 
transition state, osteoporosis model created in Excel 97©.  The transition states included: 
fracture states, death from hip fracture, nursing home admission due to hip fracture, fatal 
and non-fatal CHD, fatal and non-fatal breast cancer, and death from other causes.  The 
model was applied to hypothetical cohorts of postmenopausal women, with established 
osteoporosis, aged 50, 60, 70, and 80 years of age.  The duration of treatments was five 
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years plus a five-year offset, except for calcium and calcitonin, for which a three-year 
offset was used (offset = duration for which an effect persists).  The annual risk of hip, 
spine, distal forearm, and humerus osteoporotic fractures was determined from 
epidemiological data for United Kingdom (UK) women.  QOL adjustments were based 
on a set of reference case health state value (HSV) multipliers developed by Braizer et 
al.116 which were subsequently applied to population normative data described by Kind et 
al.117  In addition to fracture, the health effects considered in the model included breast 
cancer, and coronary heart disease where appropriate (HRT).  Health resource costs were 
measure in pounds sterling.  A 6% discount rate was applied to all costs and a 1.5% 
discount rate was applied to QALYs.  Kanis et al. concluded under the base-case 
assumptions (vertebral fracture (RR, 0.58), no effect appendicular fracture, breast cancer, 
or CHD), HRT was not cost-effective in women aged 50 but was at 60 years or more.  A 
series of different estimates of cost-effectiveness were obtained when sensitivity analyses 
were performed on HRT’s base-case assumptions: 1) HRT was cost-effective at all ages 
with hip fracture risk adjustment (RR, 0.86; 95% CI, 0.42 to 1.75); 2) HRT’s cost-
effectiveness improved when additional protective effects on CHD were included; 3) 
HRT’s cost-effectiveness decreased but remained cost-effective with a breast cancer risk 
adjustment (RR, 1.35); and 4) HRT’s cost-effectiveness improved when risk adjustments 
were made both for CHD and breast cancer.  For alendronate, under base-case 
assumptions (hip fracture (RR, 0.61), vertebral fracture (RR, 0.54), and humeral fracture 
(RR, 0.83), the cost-effectiveness of alendronate improved with age and became cost-
effective at age 70 years or more. 
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METHODOLOGY LITERATURE 
Net-Benefit Regression Method of Cost-Effectiveness Analysis 
      A net-benefit regression (NBR) method of cost-effectiveness analysis (CEA) is 
employed in this research.  The net-benefit regression method is a novel approach to a 
CEA, which incorporates a net-benefit statistic within a standard regression type 
framework to solve the cost-effectiveness problem.  The net-benefit statistic is the 
product of the net-benefit framework - a reformulation of the traditional cost-
effectiveness problem that replaces incremental cost-effectiveness ratios (ICERs), along 
with their inherent statistical problems, with the net-benefit statistic, along with its more 
attractive statistical properties.  This method of CEA was selected for this analysis for 
two reasons: 1) it provides the ability to evaluate the importance of covariates on the 
marginal cost-effectiveness of an intervention, thus allowing the identification of 
important patient subgroups, and 2) it provides the ability to account for the 
heterogeneous nature of observational data.  Since this methodology is new, the 
remainder of this sub-section will be devoted to providing an overview of this 
methodology.  This overview is primarily based on Hoch’s118 article, which first 
introduced this new methodology in 2002.  This overview will focus on: the problems 
associated with analyzing ICERs in a stochastic framework; the net-benefit framework 
approach to cost-effectiveness; the advantages and disadvantage of the net-benefit 
approach compared to a traditional CEA; the net-benefit regression method approach to 
cost-effectiveness; and the advantages of the net-benefit regression approach to cost-
effectiveness. 
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      To understand the problems associated with the traditional CEA, a review of the 
fundamental elements of a CEA is appropriate.  In a traditional medical CEA, results 
comparing a new treatment intervention (TA) with an alternative treatment intervention 
(TB) are expressed in the form of an ICER, which compares the incremental cost per 














where CAµ , CBµ , EAµ ,  and EBµ represent the mean cost and effects of interventions A and 
B, respectively, in the population and EC ∆∆ µµ represents the ICER.  Since the true 














where kC and kE  represent sample mean cost and effects of interventions A and B, 
respectively, and EC ∆∆  represents the REIC ˆ (parameter estimate). In a traditional CEA, 
a more costly but more effective intervention should be implemented if the ICER of the 









where λ represents the maximum acceptable willingness to pay per unit gain of health.  In 
the traditional CEA, λ is unknown to the analyst and no attempt is made to address it.   
 An analysis of uncertainty surrounding the ICER estimate is a key component of 
any CEA.  However, the inability of the traditional CEA to easily manage uncertainty is 
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well documented in health economic literature.120-123  Theoretical problems arise in the 
interpretation of the ICER, in the construction of confidence intervals (CIs) for an ICER 
probability distribution that covers more than one quadrant of the cost-effectiveness plane 
(CE), and in the construction and interpretation of CIs for negative ICERs.124  
      The interpretation of an ICER is ambiguous unless it is presented in the context of 
the quadrant of the cost-effectiveness plane (the CE plane is illustrated in Figure 1.1) to 
which it corresponds (or if the sign of the numerator and denominator are known).  For 
example, a positive ICER, less than λ, is favorable for intervention A in the NE quadrant, 
but is unfavorable in the SW quadrant.  Likewise, a negative ICER in the SE quadrant is 
favorable for intervention A, but is unfavorable in the NW quadrant.  Of greater concern, 
is when the joint probability distribution of cost and effects extend to more than one 
quadrant of the CE plane.  In this situation, attempts to construct confidence intervals by 
employing the bootstrapping methods may lead to misleading confidence limit 
estimates.124  As a result, analysts must often employ the cost-effectiveness acceptability 
curve approach to summarizing uncertainty.118  Finally, negative ICERs present 
important complications for the construction and interpretation of CIs.  For example, for 
an ICER distribution in the SE quadrant (intervention A is less costly and more effective) 
a large magnitude is desirable for both the numerator and the denominator.  However, 
these two desirable features drive the ICER in opposite directions, thus ICER distribution 
in quadrant II does not lend itself to meaningful interpretation.124  
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model assumptions, that ERT initiated at 65 years of age was the most cost-effective 
option.  This treatment option was superior to ERT for life because the duration of 
treatment intervention was shorter (less cost), whereas the benefits for hip fracture and 
heart disease were maintained at the time of peak disease incidence.  The cost-
effectiveness of ERT for 15 years from the age of 50 was the least cost-effective of the 
ERT interventions, because the protective effects had subsided by the time of peak 
disease incidence.  The cost-effectiveness of the lifestyle intervention was the least cost 
effective, because of the high cost of exercise and the relatively low gains in life-years.   
      Francis et al.104 conducted a pharmacoeconomic analysis of vertebral fracture 
prevention strategies.  The objective of the study was to determine the cost-effectiveness 
of different treatment strategies (HRT, cyclic etidronate, and calcitonin) for the 
prevention of further vertebral fractures in women with a previous vertebral fracture.  A 
cost-effectiveness analysis was performed.  The perspective of the study was not 
specified but can be inferred to be that of the National Health Service (NHS).  Francis et 
al. employed a model that incorporated underlying fracture incidence, effectiveness of 
intervention, and costs of therapy.  The incidence of vertebral fractures was obtained 
from placebo controlled groups participating in randomized controlled clinical trails of 
various osteoporosis treatments.  The effectiveness of the interventions was gained from 
their respective controlled clinical trails.  From the randomized controlled trials, it was 
determined that HRT was associated with a 60% reduction of vertebral fractures.  Model 
output was used in the following cost-effectiveness equation  
Total discounted costs of treatment x 100 
Discounted number of vertebral fractures averted per 100 patient-years 
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Figure 1.1 The cost-effectiveness (CE) plane118 
      The net-benefit approach was developed to better manage uncertainty in the 
economic evaluation of health interventions.124,125 The net-benefit framework is a 
reformulation of the traditional CEA equation, which incorporates λ directly into the 
equation.  The net-benefit equation provides a measure of ‘net-benefit’ and a simple 
decision rule, which states that an intervention should be implemented only if the ‘net-
benefit’ is positive.  An important result of this reformulation is the conversion of the 
traditional CEA’s ratio statistic, the ICER, to the net benefit’s linear statistic. 
     There are two different formulations of net-benefit, the net-monetary-benefit 
(NMB)125 and the net-health-benefit (NHB).124  Both statistics are a direct function of λ.  
An intervention’s net-monetary-benefit (NMB) is calculated by subtracting the additional 
cost from the additional effect valued in dollars: 
0>−•= ∆∆ CENMB µµλ  
An intervention’s net-health-benefit (NHB) is calculated by subtracting the additional 
cost valued in effects from the additional effect: 
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0>−= ∆∆ λ
µµ CENHB  
Sample analogues are used to estimate mean effect and mean cost differences to provide 
the estimated net-benefit statistics ( BMN ˆ  and BHN ˆ ) 
CEBMN ∆−∆•= λˆ  
λ
CEBHN ∆−∆=ˆ  
      The net-benefit framework has many advantages compared to the traditional 
CEA, of which only three primary ones will be discussed, followed by one potential 
disadvantage.  One of the primary advantages is its ability to better manage uncertainty in 
CEAs.    This ability is a result of the more attractive statistical properties associated with 
its linear form compared to previously discussed statistical problems associated with 
ICER ratio statistics.  In contrast to the traditional CEA’s ICER, it is relatively simple to 
construct parametric confidence intervals to manage uncertainty in a stochastic CEA 
within the net-benefit framework.  Unlike the ICER, variance of net benefits can be 
directly estimated from sample mean cost and effects.  The variance of NMB is 
determined by:  
),cov(2)var()var(ˆ 2 CECEBMN ∆∆−∆+∆= λλ  
and the variance of NHB is determined by: 
),cov(2)var(1)var(ˆ 2 CECEBHN ∆∆−∆+∆= λλλ
 
With variance known and help from the central limit theorem ( BN ˆ is asymptotically 
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where BN ˆ is the estimated net-benefit measure with variance NB2σ and
2
αz is the critical 
value obtained from the standard normal distribution.118  Another primary advantage of 
the net-benefit framework is that it does not suffer from the interpretation ambiguities 
associated with the traditional CEA’s ICER.  An intervention’s positive net-benefit is 
unambiguously favorable.124  The last primary advantage of the net-benefit framework, 
which is due to its linear nature, is that it opens the door to a myriad of econometric 
techniques that can be employed for economic analysis to include the formulation of the 
cost-effectiveness problem within a standard regression type framework.118  The net-
benefit’s many other advantages include additional statistical advantages over the ICER 
and its relative ease in performing stochastic analyses with multiple comparators.124    
      A potential disadvantage of the net-benefit statistic is that, as discussed, it is a 
direct function of γ, a value unknown to the analyst in some cases.  This potential 
disadvantage can be addressed by obtaining a range of potential values for γ from the 
literature and/or expert opinion and applying sensitivity analyses.124  Paradoxically, this 
disadvantage of having to specify the maximum willingness to pay per unit of health gain 
is related to an additional criticism of the ICER ratio.  Namely, the ICER ratio by itself 
does not, in the case of an intervention in the Southwest and Northeast quadrants of the 
cost-effectiveness plane, provide sufficient information to health care policy decision 
makers to adopt a particular treatment intervention.118, 124  
 78
      The net-benefit regression framework involves the integration of the net-benefit 
statistic into the standard regression type framework.  This integration enables the 
estimation of cost-effectiveness within a standard type regression framework.  Cost-
effectiveness is estimated by employing the net-benefit framework to define a net-benefit 
value for each subject.   
iii CENMB −•= λ  
where iE and iC are the observed effect and cost for subject i.  An example of a linear 
model for subject i’s net-monetary-benefit can be expressed as: 
iii tNMB εδα ++=  
where α is the intercept term, t a treatment dummy taking the value zero for the standard 
treatment and the value of one for the treatment under consideration, and ε is a stochastic 
error term.  The regression coefficient δ on the treatment dummy provides the estimate of 
the incremental net-benefit (cost-effectiveness).  The significance of the net-benefit 
regression methodology is that additional explanatory variables can be added to the 




ijji tNMB εδχβα +++= ∑
=1
  
where there are p covariates χ .  In this case, the coefficient δ provides the incremental 
net-benefit of implementing the new treatment while controlling for confounding 











where the final summation represents the interaction between the treatment variable and 
the covariates.  The magnitude and significance of the coefficients jγ  on the interaction 
term indicate how cost-effectiveness of treatment is expected to vary at the margin; large 
and statistically significant sj 'γ point towards important patient subgroups.
118   
      There are two distinct advantages of the net-benefit regression method, which 
prompted the selection of this methodology of a CEA for this research.  First, the 
incorporation of the net-benefit statistic into a regression type framework allows for the 
addition of covariates in the model.  This ability enables the researcher to control for 
heterogeneous groups in observational studies.  Second, as discussed, the addition of 
interaction terms in the net-benefit regression type framework enables the researcher to 
examine the marginal impact of covariates on incremental cost-effectiveness, thus 
allowing the identification of important patient subgroups. 
      For this study, the net-benefit regression method of CEA will be incorporated into 
a cost-utility analysis (CUA) framework.  Therefore, it will be necessary to identify 
health state values for the effect variable of the net-benefit statistic in addition to a range 
of conditional λs.   
Health State Values 
      The majority of pharmacoeconomic studies conducted in the field of osteoporosis 
research have been cost-utility analyses.2, 126 The cost-utility approach has been favored 
by health economists because it enables them to convert the multiple clinical outcomes of 
osteoporotic fracture (hip, vertebral, and wrist fracture), each associated with different 
consequences for morbidity into a single currency, quality-adjusted life-years (QALYs).  
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The conversion of outcomes to the single currency of QALYs enables comparisons of 
cost-effectiveness of osteoporosis interventions with other diseases and with established 
thresholds of cost-effectiveness.  The NOF guidelines suggest an osteoporotic fracture 
intervention is cost-effective if it produces a cost per quality-adjusted life-year (QALY) 
of $30,000 a year or less.127  A key component of the QALY measure is the health state 
value (HSV) or utility.  
 A QALY is the product of the HSV assigned to each state associated with an 
intervention’s outcome multiplied by the length of time spent in each state.  A HSV is the 
weight assigned to a particular health state, ranging from 0 to 1, where a weight of 0 
corresponds to a health state judged to be equivalent to death and 1 corresponds to perfect 
health.  In general, the HSV’s employed in previous pharmacoeconomic studies for the 
key health events associated with osteoporosis have been primarily based on expert 
opinion, rather than from empirical evidence.2,126  Yet, sensitivity analyses of these 
studies have revealed that the cost per QALY estimates are highly sensitive to the HSV 
values used.128  To identify empirically derived HSV estimates for use in this study, a 
systemic review of published literature reporting empirical estimates of HSVs for key 
osteoporosis health states was conducted.  A total of only six published papers66, 129-133 
were found to report HSVs for one or more osteoporosis related conditions. 
      The empirically derived HSV estimates reported in these studies differed 
significantly from NOF values2 obtained from a panel of experts and with each other.  
The between study differences can be attributed to differences in the derivation of the 
estimates.116  Two recently published reviews116, 134 and the Washington Panel on Cost-
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effectiveness135 recommend the use of generic preference-classification systems, such as 
the EQ-5D136 and the Health Utility Index (HUI)-III,137 as the preferred preference-based 
health outcome measures for health-policy decision making.  Only four129-132 of the six 
studies reported HSVs obtained from generic preference-classification systems for one of 
the three osteoporosis health states: hip fracture, vertebral fracture, and wrist fracture.  
Table 1.6 below identifies the fracture type, study, generic preference classification 
system, and HSVs obtained in these studies.  The HSVs derived by the NOF2 are 
provided for comparison purposes. 






Health State Value (SD) 
Hip NOF Review2 NA – Expert panel 1st year: 0.3817; subsequent years: 0.855 
 Gabriel et al.129  HUI-II 0.68 (0.18) 
 Brazier et al.132 EQ-5D 1st 6 mo: 0.49 (0.32); 12 mo: 0.48 (0.38) 
Vertebral NOF2 NA – Expert panel 0.97 
 Gabriel et al.129  HUI-II 0.80 (0.16) 





≥ 4 0.66 
Lumbar 0.78 
Thoracic 0.68  
Wrist NOF2 NA – Expert panel 1st year 0.96; subsequent years 0.98 
 Dolan et al.130  EQ-5D 0.981 
  
     The HSVs for hip fracture obtained by Brazier et al.132 were significantly lower 
than the values obtained by Gabriel et al.129  The lower scores can be partially attributed 
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to Brazier et al.’s use of the time-trade-off technique as opposed to the other study’s use 
of the standard-gamble technique, and the fact that Brazier et al.’s population was 
significantly older and had lower HSVs at baseline compared to EQ-5D normative 
values.117  Even though the HSVs differed significantly between the two studies, the 
proportionate loss between the two studies was similar when comparing Gabriel et al.’s 
HUI estimate of 0.68 to the age/sex norm found in Canada of 0.82.138  The HSVs for 
vertebral fracture obtained by Gabriel et al.129 and Oleksik et al.131 were similar.  Dolan et 
al.130 provide the only empirically derived HSV for wrist fracture. 
 A current limitation of the generic preference-classification system derived HSVs 
for osteoporosis related conditions, is the use of these values in specific age groups that 
were not included in the original studies.  In order to extrapolate the HSVs from these 
studies to specific age groups, Brazier et al.116 proposed the use of a set of reference case 
HSVs.  This proposal is based upon the assumption of a constant proportional effect of 
fractures on HSVs, and assumes that the better the health status, the more the individual 
has to lose.  Brazier et al.116 developed a set of reference case HSVs, based on generic 
preference-classification system derived HSVs, to be used as multipliers of age-specific 
HSV population norms to estimate the proportionate effect of fracture on HSVs in the 
first year.  In the development of the set of reference case HSVs, Brazier et al.116 favored 
the incorporation of HSVs derived from the EQ-5D over HUI-II because the EQ-5D is 
available on more osteoporosis related conditions than the HUI-II.  The reference case 
values recommended by Brazier et al.116 are provided in Table 1.7 below.  The reference 
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case HSVs are the multipliers for the proportionate effect of fracture on HSVs in the first 
year. 
Table 1.7 Reference case HSVs to be applied to population norms116 
Health State Value Source 
Hip Fracture 0.797 (95% CI, 0.651-1.1012) Brazier et al.132 
Vertebral Fracture 0.909 (95% CI, 0.84-0.97) Oleksik et al.131 
Wrist Fracture 0.981 (95% CI, 0.978-0.986) Dolan et al.130 
  
 The reference case values set forth by Brazier et al.116 for use as multipliers for 
the proportionate effect of fracture on HSVs were adopted for use in a recent osteoporosis 
cost-utility analysis performed by Kanis et al.85  In this study, Kanis et al.85 applied the 
reference case values to population norms derived by Kind et al.117 (see Table 1.8 below).  
The population norms derived by Kind et al.117 were obtained from the administration of 
the EQ-5D to over 3,000 representative members of the UK general population.  The use 
of population norms derived by Kind et al.117 were ideal for this cost-utility analysis, 
since the population of interest for both studies was the same. 














 Two potential problems arise in the application of Brazier et al.’s116 set of 
reference case HSVs.  First, is the extension of health state valuations for subsequent 
years.  Second, is a possible lack of population normative data for the study population of 
interest.  As previously discussed, the set of reference case values developed by Brazier 
et al.116 are to be applied to the first year of the fracture event.  Brazier et al.116 did not 
provide a set of reference case HSVs for subsequent years, but instead suggested the 
development of a set of guesstimates, which allow for some degree of recovery. 
 The other potential problem with the application of the set of reference case HSVs 
set forth by Brazier et al.116 is a lack of population normative data for the study 
population of interest.  For example, there is not any EQ-5D or other generic preference-
classification system normative data for the U.S. population.  However, this concern may 
be minimal.  Johnson et al.139 determined “that differences in health-state valuations are 
unlikely to have important implications when using EQ-5D population norms derived for 
one population to be used in another, in the absence of population-specific normative 
data.”  
Maximum Acceptable Willingness to Pay (λ) 
      Stinnett and Mullhay124 recommend conducting a net-benefit analysis for a range 
of values for  λ and to report estimated net-benefit as a function of  λ.  In 1998, the NOF2 
established $30,000 per QALY gained as an acceptable threshold for cost-effectiveness.  
Since that time, several studies114, 140-142 have used $30,000 as a threshold for cost-
effectiveness.  Therefore, a range of values centered-around the $30,000 threshold for 
cost-effectiveness would be reasonable.   
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STATINS AND FRACTURE RISK 
Introduction 
 Statins, a class of drugs used in the management of hypercholesterolemia, may be 
of value in the management of osteoporotic fractures.  Statins have been shown to have a 
mechanism of action similar to aminobisphosphonates, a class of drugs used in the 
management of osteoporosis.  Aminobisphosphonates supposedly exert their anti-
osteoporosis effect by inhibiting the farnesyl diphosphonate enzyme in the melvalonate 
pathway, which leads to osteoclast apoptosis, thus resulting in decreased bone 
resorption.143, 144 Statins exert their lipid lowering effect through the melvalonate pathway 
also, by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase.  Thus, it is 
believed that statins may also act as inhibitors of osteoclast formation.  Moreover, the 
possible anti-osteoporosis effect of statins has been supported by the finding that some 
statins also stimulate bone formation. 
 Mundy et al.145 first discovered the bone forming potential of 
hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in December of 
1999, during their search for anabolic agents that enhanced osteoblast differentiation and 
bone formation.  In their research, Mundy et al. employed a screening technique to isolate 
compounds that activated the promoter of the bone morphogenetic protein-2 (BMP-2) 
gene, which is known to enhance osteoblast differentiation and bone formation.  After 
screening over 30,000 compounds, the investigators discovered that members of the 
statin drug class (lovastatin, fluvastatin, simvastatin, and mevastatin) activated the 
promoter of the BMP-2 gene.  Mundy et al. conducted two in vivo experiments in rats to 
 86
assess the osteoblast differentiation and bone formation potential of statins.  In the first 
experiment, lovastatin and simvastatin were injected into subcutaneous tissue overlying 
murine calvaria and demonstrated a 50% increase in new bone formation after only 5 
days of treatment.  In the second experiment, the statins were orally administered to 
ovariectomized as well as rats with intact ovaries, which resulted in increased trabecular 
bone volume of the femur and lumbar vertebrae between 39% and 94% after 35 days of 
treatment.  Although Mundy et al. observed a decrease in the number of osteoclasts, they 
believed this effect was minimal compared to the effect on bone formation and osteoblast 
maturation.  As a result of these studies suggesting the biologic plausibility of a statin 
effect on bone, a number of epidemiological studies have been conducted to assess the 
association of statin use with bone density and fracture incidence. 
Epidemiological Studies 
 A systematic literature review of published epidemiological studies exploring the 
association between statin use with bone density and fracture incidence was conducted.  
In all, eight studies were identified, five case-control studies,146-150 one retrospective chart 
review,151 one prospective study,152 and one secondary analysis of RCT data.153  In 
addition, a meta-analysis154 examining the use of statins and fractures has recently been 
published.  The results from these observational studies are inconsistent.  Five146-148, 150, 
151 of the eight studies provided evidence of an association between statin use and 
reduced risk of fracture.  In contrast, three of the studies149, 152, 153 provide no evidence of 
an association.  To even further muddy the evidence pool, two case-control studies,147, 149 
conducted on the same data base, reached opposite conclusions.  The overall results of a 
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meta-analysis152 suggest that there is an association between statin use and reduced risk 
of fracture.  The remainder of this section provides an overview of the eight observational 
studies.  One of the first published observational studies was conducted by Chung et al. 
 Chung et al.151 conducted a retrospective chart-review study to assess the effect of 
statins on BMD in 69 Korean patients with Type II diabetes mellitus.  Statin users (n = 
36) were matched (age, sex, body weight, postmenopausal status, and fasting blood 
glucose levels) with controls (n = 33).  Both treatment group patients and controls were 
excluded if they had any disease related to bone mineral metabolism or were taking any 
medication that affected bone mineral metabolism.  Exposure to the study statins 
(lovastatin, pravastatin, and simvastatin) was obtained via chart review.  The outcome, 
BMD of the lumbar spine, femoral trochanter, Ward’s triangle, femoral neck, and total 
hip, were measured at baseline and at follow-up, with a mean follow-up time for the 
exposure group of 15 months ( ± 3 months) and for the control group of 12 months ( ± 2 
months).  In addition to the matching employed, potential confounders controlled for 
included age and body mass index (BMI).  Both univariate and multiple regression 
statistics were employed in the analysis. 
 At follow-up, men in the control group (n = 15) did not experience a significant 
change in BMD from baseline, whereas women experienced a significant decrease in 
BMD of the spine (p < 0.05).  In contrast, all statin users experienced a significant 
increase in BMD of the femoral neck (p < 0.001).  Males statin users (n = 14) 
experienced a significant increase in BMD of both the femoral neck (p < 0.05) and 
femoral trochanter (p < 0.05), whereas female statin users (n = 22) only experienced a 
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significant increase in BMD of the femoral neck (p < 0.05).  The percentage of statin 
users with a 2% or more increase in BMD of the spine and total hip was 30.6%, whereas 
the percentages for the control group was 15.6% and 9.1%, respectively.  The percentage 
of male statin users who experienced a 2% increase in BMD of the spine and total hip 
was greater than the percentage of women.  The investigators attributed the gender- 
related differences to the fact that bone loss in males is primarily secondary to a 
physiological decrease in osteoblastic function, whereas bone loss in postmenopausal 
women is due more from increased bone resorption.  The results of this study are limited 
for primarily two reasons: 1) the retrospective clinical record review design, and 2) the 
extremely small sample size.  Another possible limitation of the study was the use of 
subjects with type-II diabetes mellitus, who may have altered bone mineral metabolism. 
 Three large case-control studies,146-148 all published within a week of each other, 
followed the clinical study by Chung et al.,151 which today provide the best evidence 
supporting an association between statin use and decreased risk of fractures.  Chan et 
al.146 conducted a population based, case-control study using pharmacy and claims data 
obtained from six health-maintenance organizations (HMOs) located in different regions 
of the U.S. to determine the relationship between statin use and fracture risk among older 
women.  Data were collected on women ≥ 60 years of age who were members of one of 
the selected six HMOs between October 1994 and September 1997.  Patients who met 
inclusion criteria and had a hospital or outpatient diagnosis code for non-pathological 
fracture of the hip, humerous, distal tibia, vertebrae, or wrist between October 1996 and 
September 1997 and had no diagnosis code for any of these fracture sites between 
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October 1994 and September 1996 (cases; n = 928) were matched (age and HMO) with 
controls (n = 2,747) who did not sustain such fractures.  Both cases and controls were 
excluded if they had a diagnosis code for major trauma, cancer of the bone, breast, colon, 
or lung, multiple myeloma, metastatic cancer, or pathological fracture.  They were also 
excluded if they received a prescription for hormone replacement therapy, 
bisphosphonates, calcitonin, anticonvulsant drugs, or thyroid hormones.  Exposure to 
statins and other antilipidemic agents was determined from automated pharmacy claims 
for the two-year period prior to the fracture date.  The number of statin dispensings was 
used as a surrogate measure for cumulative statin exposure.  In addition to the matching, 
additional potential confounders controlled for by restriction and regression modeling 
included concomitant medications (antipsychotics, long-acting hypnotics, 
antidepressants, thiazide diuretics, hypoglycemic agents, and corticosteroids) and the 
number of hospital admissions during the 12 months preceding the fracture date.  Logistic 
regression models were used to develop adjusted odds-ratios (ORs) to assess the 
association between statin use and fracture risk. 
 Study results revealed a significant reduction in the risk of fracture in women with 
≥ 13 dispensings of statins (exposure approximately equal to one year) in the two-year 
period prior the fracture date (OR, 0.48; 95% CI, 0.27 to 0.83).  The group of patients 
who received < 13 dispensings of a statin or who received other antilipidemic agents did 
not show a significant reduction in the risk of fractures. Although this study controlled 
for a number of potential confounders, potential confounders not controlled for included: 
body mass index (BMI), smoking, and physical activity.  Other limitations of the study 
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were that it excluded women taking medications known to treat osteoporosis and no 
BMD measurements were obtained. 
 Meier et al.147 conducted a large population based, nested case-control analysis 
using the UK-based General Practice Research Database (GPRD) to determine whether 
use of statins or other antilipidemic medications were associated with a reduced risk of 
fractures.  Within the GPRD, a base population of 91,611 patients, ages 50-89, stratified 
into three separate groups: group 1 - patients with at least one prior prescription for an 
antilipidemic agent (n = 28,340); group 2 - patients with a hyperlipidemic diagnosis but 
no antilipidemic agent (n = 13,271); and group 3 - patients without a hyperlipidemic 
diagnosis or treatment (n = 50,000), was followed from the start of follow-up until the 
person developed a fracture, left the practice, or died.  Start of follow-up was defined as 
the date of the first prescription for any antilipidemic agent for group one or the date 
exactly one year after computer recording of prescriptions began for groups two and 
three.  Patients who sustained a fracture (cases; n = 3,940) were matched (age, sex, 
general practice visited, calendar time, years of GPRD history prior to index date) with 
controls (n = 23,379) who did not sustain a fracture.  Both cases and controls were 
excluded if they had a diagnosis of osteoporosis, osteomalacia, cancer, or alcoholism or 
had a previous prescription for bisphosphonates.  The degree of exposure to a statin was 
determined by exposure timing and duration of use.  Patients were categorized according 
to exposure timing into one of three categories based on last statin prescription received 
prior to index date: current use (< 30 days), recent use (30-89 days), and past use (> than 
90 days).  Patients were also categorized according to exposure duration by number of 
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statin prescriptions into one of four categories: 1-4, 5-9, 10-19, and > 20.  In addition to 
the matching employed, potential confounders controlled for included: medications 
affecting fracture risk (corticosteroid use, hormone replacement therapy), smoking status, 
BMI, and number of general practice visits prior to index date.  Logistic regression 
models were used to develop adjusted ORs to assess the association between statin use 
and fracture risk. 
 The results of this study demonstrated that current statin use was associated with a 
significant reduction in the risk of all fractures (OR, 0.55; 95% CI, 0.44 to 0.69; p < 
0.001).  This association was present after only one to four months of treatment.  Current 
use of other antilipidemic agents was not associated with a significant fracture risk 
reduction.  One of the limitations of this study was that it did not control for level of 
physical activity and diet as potential confounders.  In addition, this study also excluded 
women with a diagnosis of osteoporosis and no BMD measurements were obtained. 
 Wang et al.148 conducted a similar case-control analysis using the New Jersey 
Medicare, Medicaid, and Pharmacy Assistance for the Aged and Disabled Program data 
to determine whether the use of statins was associated with reduced hip fracture risk in a 
population of 6,110 New Jersey residents ≥ 65 years of age.  Patients who sustained a hip 
fracture during 1994 (cases; n = 1,222) were matched (age and gender) with controls (n = 
4,888) to determine the risk of hip fracture in the 180 days or three-years prior to surgery 
for hip fracture (index date).  Both cases and controls were required to have to no 
evidence of previous hip fracture prior to their index date.  The degree of exposure to 
statins was determined by exposure and quantity of use.  Exposure to statins was 
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determined by the presence of at least one prescription for a statin 180 days and 3 years 
prior to index date.  Patients were also categorized into quartiles based on calculated 
medication possession ratios (MPRs) for the 180 days prior and three years prior to index 
date.  In addition to the matching criteria employed, potential confounders controlled for 
included race, insurance status, medications known to effect fracture risk (hormone 
replacement therapy, oral corticosteroids, thiazide diuretics, psychoactive agents), 
medications known as markers for specific clinical conditions, medical conditions 
(ischemic heart disease, congestive heart failure, hypertension, diabetes, and cancer), a 
modified Charlson comorbidity index, and extent of health care utilization.  Logistic 
regression models were used to develop adjusted ORs to assess the association between 
statin exposure and hip fracture risk. 
 Study results revealed that use of a statin was associated with a significant 
reduction in the risk of hip fracture 180 days and three-years prior (OR, 0.50; 95% CI, 
0.33 to 0.76) and (OR, 0.43; 95% CI, 0.40 to 0.82), respectively.  In addition to the 
overall results, this study provided three pieces of evidence that the relationship between 
statin use and fracture risk may be both causal and related to the biological activity of 
statins.  First, in contrast to use of statins, current use of other antilipidemic agents was 
not associated with a risk reduction in fracture – same indication as statins but different 
mechanism of action.  Second, this study demonstrated a clear use-response relationship 
for both short-term and longer-term use.  The short-term use-response relationship 
established in this study further supports the findings of Meier et al.147 who demonstrated 
the benefits of statin therapy after short-term use.  Third, current use of statins was 
 93
associated with the greatest reduction in risk (OR, 0.29; 95% CI, 0.10 to 0.81), even after 
adjusting for total extent of statin use.  Although this study controlled for a plethora of 
potential confounders, investigators noted that all potential confounders may not have 
been controlled for.  Other limitations of this study included the lack of BMD 
measurements and diagnosis of osteoporosis. 
 A more recent study providing evidence of a relationship between statins and a 
reduced risk of fracture was conducted by Pasco et al.,150 who performed a cross-
sectional case-control study using data from the Geelong Osteoporosis Study to 
determine whether statins decrease the risk of fracture and whether there is an association 
between statin use and BMD.  Data were analyzed for the period February 1994 through 
February 1996.  Patients who were ≥ 50 years of age and with non-pathological incident 
fractures (n = 573) were matched (age) to women without incident fractures (n = 802).  
Exposure, current use of, and duration of statin use information was obtained from self-
reported questionnaires along with information on other medications, lifestyle, diet, 
calcium intake, alcohol consumption, smoking, and exercise.  The fracture outcomes 
were identified from radiological reports and BMD of the femoral neck, lumbar spine, 
anterior-posterior projection, and total body was measured at baseline and follow-up.  
Potential confounders addressed for fracture associated with statin use included BMD, 
age, weight, dietary calcium, alcohol use, smoking (current and ever), activity levels, and 
exposure to hormone replacement therapy, corticosteroids, and calcium and/or vitamin D 
supplements.  Potential confounders addressed for BMD changes associated with statin 
 94
use included age, weight, and fracture/non-fracture status.  Univariate and multivariate 
statistics were used to assess the risk of fracture and changes in BMD among statin users.     
 There were fewer statin users in the fracture group (16) compared to the non-
fracture group (53).  The results revealed a significant reduction in fracture risk (OR, 
0.45; 95% CI, 0.25 to 0.80) and a 3% greater adjusted BMD at the femoral neck (p = 
0.08).  Although there was an increase in BMD among statin users, the reduction in 
fracture risk was not completely explained by the increase in BMD.  A limitation of this 
study was the small number of statin users, which limited the power to detect changes in 
BMD.   
 In contrast to the five observational studies providing evidence of a relationship 
between statin use and decreased the risk of fracture and increased BMD, three studies 
provide evidence of no relationship.  Reid et al.153 conducted a secondary analysis on data 
from an RCT on the effect of statin use on mortality due to coronary heart disease, the 
Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study.  In this 
study, 9,014 patients with ischemic heart disease were randomly assigned to either 
pravastatin 40mg/day or placebo and followed for a mean of six years.  Reid et al. 
obtained the frequency of fracture from adverse-event reports. 
 A total of 183 patients in the placebo group sustained a fracture compared with 
175 in the pravastatin group.  The results revealed no significant reduction in the risk of 
fracture in overall rates of fracture (HR, 0.94; 95% CI, 0.77 to 1.116), in women only 
(HR, 0.80; 95% CI, 0.55 to 1.18), nor in patients older than 65 years of age (HR, 0.93; 
95%CI, 0.68 to 1.27).  There are two major limitations with this study.  First, the study 
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population was at low risk of fracture.  Patients were not recruited on the basis of fracture 
history or low bone density, and only 17% of the population was women.  The second 
limitation, and probably the most significant, was this study assessed the risk of fracture 
only with pravastatin.  In vitro studies suggest that pravastatin has virtually no effect on 
the BMP-2 promoter gene, which is thought to be responsible for statin’s osteoblastic 
effect.155       
 Van Staa et al.149 performed a population-based case-control study using the UK-
based GPRD, the same database used by Meier et al., to determine the risk of fracture 
among statin users.  Data were analyzed from 1987 to July 1999.  Patients who were ≥ 50 
years of age and with a diagnosis code for a fracture of the vertebrae, clavicle, humerous, 
radius/ulna, carpus, hip, ankle, or foot during their enrollment (cases; n = 81,880) were 
matched (age, gender, and medical practice visited) with an equal number of controls of 
fracture.  Exposure to statins was determined by reviewing patients’ prescription history 
prior to fracture date.  Patients were categorized as either current users (statin prescription 
within 6 months of fracture date), past users (statin users who stopped therapy 6 months 
prior fracture date), or non-users.  A similar method was used to assess exposure to other 
non-statin antilipidemic medications.  The daily dose of statin was obtained from written 
instructions for the last statin prescription prior to the fracture date.  In addition to the 
matching employed, potential confounders addressed included smoking and BMI when 
known, medications associated with fracture risk (anticonvulsants, non-steriodal anti-
inflammatory drugs, methotrexate, hormone replacement therapy, thiazide diuretics, 
anxiolytics/hypnotics, antipsychotics, anti-depressants, anti-Parkinson drugs, systemic 
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and inhaled corticosteroids, and bronchodilators), and clinical conditions associated with 
fracture risk (diabetes mellitus, rheumatoid arthritis, hyperthyroidism, congestive heart 
failure, seizures, anemia, dementia, depression, psychotic disorders, cerebrovascular 
accident, and chronic obstructive pulmonary disease).  Conditional logistic regression 
models were used to estimate adjusted odds ratios (ORs). 
 The results revealed no reduction in fracture risk among current statin users (OR, 
1.01; 95% CI, 0.88 to 1.16), past statin users (OR, 1.01; 95%CI, 0.78 to 1.32), among 
long-term (> 12 months) statin users (OR, 1.17; 95%CI, 0.99 – 1.40), among short-term 
users (OR, 0.71; 95% CI, 0.50 to 1.01), or in users of statins at higher doses compared to 
those at lower doses.  The results of this study contradict the findings of Meier et al.147  
There are several potential explanations for the difference in findings.  First, statin users 
may have been monitored more closely than non-statin users, thus increasing the 
probability of a reported fracture (measurement bias).  Second, exposure to statins 
increased substantially over time.  Lastly, no information on medication adherence was 
collected (compliance bias).    
 LaCroix et al.152 conducted a prospective cohort study of the Women’s Health 
Initiative (WHI) Observational Study group.  A total of 93,716 postmenopausal women, 
aged 50 to 79, were enrolled in the observational group from 1994 to 1998.  Investigators 
followed the group for the occurrence of clinical fractures of any type and a subset of the 
group (n = 6,442) for changes in BMD of the total hip, anterior-posterior spine, and total 
body.  The follow-up time ranged from two to six years with a median duration of 3.9 
years.  Hip fractures were confirmed by centralized review of radiology reports whereas 
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all other fractures were self-reported.  Fractures were classified into three mutually 
exclusive categories: hip fractures, lower arm or wrist fractures, and other clinical 
fractures.  Exposure to statins was categorized into three categories by duration (< 1 year, 
1 to 3 years, or > 3 years) and by demonstrated lipid-lowering potency (low, medium, or 
high).  Potential confounders controlled for included medications associated with risk of 
fracture (thiazide diuretics, alendronate, corticosteroids, hypnotics, and hormone 
replacement therapy), clinical conditions (history of fracture, coronary heart disease), 
dietary supplements, calcium and/or vitamin D, race/ethnicity, current and past smoking, 
coffee consumption, alcohol consumption, activity level, physical function, and BMI.  
Multivariate Cox proportional hazards survival models were employed in the statistical 
analysis. 
 The results of the study revealed no reduction in the risk of fracture or increase in 
BMD among statin users.  The multivariate-adjusted rates hazard ratios for current statin 
use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (95% CI, 0.85 to 1.27) for 
lower arm or wrist fracture, and 1.11 (95% CI, 1.00 to 1.22).  This study shared a 
limitation of the study conducted by Reid et al.153  Approximately 23% of statin users 
(1.9% of the 8.4% statin users) were taking pravastatin.  Other study limitations included: 
information on dose was not recorded, low use of statins long-term, and did not account 
for statins taken in the past which were no longer being taken at base-line. 
 Bauer et al.154 performed a series of meta-analyses to determine the effect of statin 
use on BMD and fracture rates.  The first meta-analysis examined four prospective 
studies: the Study of Osteoporotic Fractures (SOF), the Fracture Intervention Trial (FIT), 
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the Heart and Estrogen/Progestin Replacement Study (HERS), and the Rotterdam Study, 
all of which had baseline measurements of medication use, BMD, other health related 
information, and subsequent fracture outcomes.  The results of this meta-analysis 
revealed that after adjustment for age, BMI, physical activity or physical disability, 
smoking, health status, and use of estrogen and bisphosphonates, BMD was significantly 
higher among statin users in the HERS study but not in the other three studies and that 
there was a trend (not statistically significant after adjustment) towards lower risk of new 
hip and nonspine fractures among statin users.154 
 In the second meta-analysis, the investigators combined the data from the four 
prospective studies with four previously reported observational studies.  The results of 
this meta-analysis revealed a reduced risk of hip fracture (summary OR, 0.43; 95% CI, 
0.25 to 0.75) and non-spine fractures (summary OR, 0.69; 95% CI, 0.75 to 0.88).  The 
summary results obtained were robust when the meta-analysis was restricted to studies 
with adjusted results, prospective cohort studies, or were limited to women.154 
 The final meta-analysis was conducted on combined data from two placebo-
controlled clinical trials with cardiovascular endpoints: the Lipid study (Long-term 
Intervention with Pravastatin in Ischemic Disease) and the 4S Study (Scandinavial 
Simvastin Survival Study), which captured self-reported fractures.  This meta-analysis 
failed to demonstrate a reduced risk of hip fracture (summary OR, 0.87; 95% CI, 0.48 to 
1.58) or nonspine fracture (summary OR, 1.02; 95%CI, 0.83 to 1.26).  The failure to 
show a significant risk reduction of fracture was not surprising, considering the meta-
analysis included the Lipid Study (pravastatin). 
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 Results from the recent epidemiologic research, regarding the association between 
fracture risk and the use of statins, are inconsistent.  Current evidence suggests that either 
more observational studies or better yet large, randomized, controlled, prospective studies 
need to be conducted to establish the certainty of the reported association between statins 
and fracture risk.  Given the unknown association between statin use and fracture risk, 
statin use should be considered for inclusion as a confounding variable in any study 
assessing the effectiveness of an intervention in preventing osteoporotic fractures.  
RETROSPECTIVE DATABASE STUDIES IN OUTCOMES RESEARCH 
 In a world of limited resources and health care budgets, health care decision-
makers are increasingly relying on information obtained from retrospective database 
studies, in addition to that provided by RCTs, to make more informed decisions about the 
cost and effectiveness of medical treatments.  Although retrospective database studies 
provide a wealth of “real-world” information, both researchers and decision-makers need 
to be conscious of the limitations and methodological challenges of this type of research.  
This section provides an overview of some of the design and interpretation issues 
associated with retrospective database studies.  The first part of this overview is based on 
an article by Motheral et al.,156 which discusses the advantages, limitations, and 
methodological challenges of retrospective database studies, particularly in regards to 
validity.  The second part of the overview, provides a checklist for retrospective database 
studies, produced by the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Task Force,157 that was developed to assist decision-makers in 
evaluating the quality of retrospective database studies. 
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 Although RCTs represent the gold standard for research, the methodological 
approach employed in RCTs often limits generalizability of study findings.  The 
methodological approaches which limit generalizability include: the inclusion/exclusion 
criteria used in patient selection methods, which result in a non-representative subset of 
the population; treatment settings and measurement approaches that limit generalizability 
to routine clinical settings; and the short follow-up period of most RCTs, which limits 
their ability to address issues of long-term cost-effectiveness.  An additional limitation is 
the expense involved in conducting an RCT.  In contrast, retrospective database research 
allows researchers to examine “real world” medical care utilization, in large study 
populations for longer observation periods, thus allowing for examination of specific 
subpopulations.  Moreover, compared to RCTs, retrospective database studies provide 
decision-makers with a relatively inexpensive and quick approach to answering the time-
sensitive questions. 
 Some of the methodological challenges encountered in retrospective database 
studies can potentially impact the internal, construct, and external validity of study 
results.  Internal validity concerns making appropriate inferences about the relationship 
between a study’s dependent and independent variables.  Motheral et al.156 identified the 
following potential threats to internal validity: the Diagnostic Information coding system 
(e.g., the International Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM)), influenced by incentive and reimbursement systems, provider behavior, 
and/or documentation systems, may lead to under- and over-coding, thus making coding 
unreliable or invalid; failure to take Compliance with treatment interventions into account 
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may lead to misinterpretation of relationship between treatment intervention and outcome 
variable; Exposure Misclassification may reduce the likelihood detecting a significant 
difference (when one actually exists) when the misclassification is random or may 
introduce bias if misclassification is systematically related to exposure-outcome 
relationship; Referral Bias may distort the exposure-outcome relationship when patient 
referral is influenced by drug exposure status; Protopathic Bias confuses the relationship 
between cause and effect and occurs “if a particular maneuver was started, stopped, or 
otherwise changed because of the baseline manifestation caused by a disease or other 
outcome event…”; 158 finally, Confounding by other risk factors may distort a true effect 
or relationship when present. 
 Construct validity refers to “the degree to which a variable accurately reflects the 
phenomenon that it purports to measure.”156 Motheral et al.156 identified several examples 
of construct validity problems.  The common source of the construct validity problems in 
the examples provided was the operational definition used to define a variable.  For 
instance, in one example the operational definition used to define a diagnosis was not 
jointly exhaustive and mutually exclusive, and thus led to the incorrect categorization of 
patients with the disease of interest. 
 External validity is the “validity with which we can infer that the presumed causal 
relationship can be generalized to and across alternate measures of the cause and effect 
and across different types of persons, settings, and times.”159  Even though retrospective 
database studies are less likely than RCTs to have external validity problems, there are a 
number of issues in retrospective database studies which may limit generalizability.  
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Regarding threats to external validity, Motheral et al.156 made the following points: 
Characteristics of the Study Population such as demographics, insurance coverage, and 
rate of disease or injury need to be considered before making generalizations to other 
populations; health Plan Design characteristics such as copays, formularies, and access to 
providers and Regional Practice Patterns can influence cost and utilization, and therefore 
may limit generalizability of findings to other populations with different health plan 
designs; finally, Cost Differences exist across place and time and thus may limit 
generalizability.  
 Other important considerations for health care decision-makers interpreting 
retrospective database studies were outline in a recent ISPOR publication.  The ISPOR 
Task Force on Retrospective Databases published a “Checklist for Retrospective 
Database Studies.”157  The checklist, consisting of 27 questions, was developed to assist 
decision makers in the evaluation of a published retrospective database study’s quality; 
however, the checklist is also of value to investigators designing such a study.  The 
checklist (Table 1.9) focuses on three areas of the retrospective database study: the 







Table 1.9 Checklist for retrospective database studies157 
Database 
Q1) Relevance: Have the data attributes been described in sufficient detail for decision 
makers to determine whether there was a good rationale for using the data source, the 
data source’s overall generalizability, and how the findings can be interpreted in the 
context of their own organization? 
Q2) Reliability and Validity: Have the reliability and validity of the data been described, 
including any data quality checks and data cleaning procedures? 
Q3) Linkages: Have the necessary linkages among data sources and/or different care sites 
been carried out appropriately, taking into account differences in coding and reporting 
across sources? 
Q4) Eligibility: Have the authors described the type of data used to determine member 
eligibility? 
Methods 
Q5) Data analysis plan: was a data analysis plan, including study hypotheses, developed a 
priori? 
Q6) Design selection: Has the investigator provided a rationale for a particular research 
design? 
Q7) Research design limitations: Did the author identify and address potential limitations 
of that design? 
Q8) Treatment effect: For studies that are trying to make inferences about the effects of 
an intervention, does the study include a comparison group and have the authors 
described the process for identifying the comparison group and the characteristics of the 
comparison group as they relate to the intervention group? 
Q9) Sample selection: Have the inclusion and exclusion criteria and the steps used to 
derive the final sample from the initial population been described? 
Q10) Eligibility: Are the subjects eligible for the time period over which measurement is 
occurring? 
Q11) Censoring: Were inclusion/exclusion or eligibility criteria used to address censoring 
and was the impact on study findings discussed? 
Q12) Operational definitions: Are case (subjects) and end point (outcomes) criteria 
explicitly defined using diagnosis, drug markers, procedure codes, and/or other criteria? 
Q13) Definition validity: Have the authors provided a rationale and/or supporting 
literature for the definitions and criteria used and were sensitivity analyses performed for 
definitions or criteria that are controversial, uncertain, or novel? 
Q14) Timing of outcome: Is there a clear temporal relationship between the exposure and 
outcome? 
Q15) Event capture: Are the data, as collected, able to identify the intervention and 
outcomes if they actually occurred. 
Q16) Disease history: Is there a link between the natural history of the disease being 
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Q17) Resource validation: For studies that examine costs, have the authors defined and 
measured an exhaustive list of resources affected by the intervention given the 
perspective of the study and have resource prices been adjusted to yield consistent 
valuation that reflects the opportunity cost of the resources? 
Q18) Control variables: If the goal of the study is to examine treatment effects, what 
methods have been used to control for other variables that may affect the outcome of 
interest? 
Q19) Statistical model: Have the authors explained the rationale for the model/statistical 
method used? 
Q20) Influential cases: Have the authors examined the sensitivity of the results to 
influential cases? 
Q21) Relevant variables: Have the authors identified all variables hypothesized to 
influence the outcome of interest and included all available variables in their model? 
Q22) Testing statistical assumptions: Do the authors investigate the validity of the 
statistical assumptions underlying their analysis? 
Q23) Multiple tests: If analyses of multiple groups are carried out, are the statistical tests 
adjusted to reflect this? 
Q24) Model prediction: If the authors utilize multivariate statistical techniques in their 
analysis, do they discuss how well the model predicts what it is intended to predict? 
Discussion/Conclusion 
Q25) Theoretical Basis: Have the authors provided a theory for the findings and have 
they ruled out other plausible alternative explanations for findings? 
Q26) Practical versus statistical significance: Have statistical findings been interpreted in 
terms of their clinical or economic relevance? 
Q27) Generalizability: Have the authors discussed the populations and settings to which 
the results can be generalized? 
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STUDY RATIONALE AND OBJECTIVES 
 Osteoporosis poses an increasingly substantial clinical, economic, and health-
related quality-of-life (HRQOL) burden to the individual, the U.S. health care system, 
and society in general, as the U.S. population continues to age.  In response, the 
pharmaceutical industry continues to introduce new medications to meet the growing 
demand for effective osteoporosis treatment interventions, which has and continues to 
increase costs for the treatment and prevention of osteoporosis.  Given the growing 
clinical and economic burden of the disease and faced with the dilemma of making 
formulary decisions about new treatment interventions, there is an increasing demand 
among health care policy decision-makers for economic evaluations of the new 
interventions being introduced into the market and for their own current osteoporosis 
intervention strategies.  
 To date, the majority of published osteoporosis pharmacoeconomic studies 
employ some method of economic modeling, typically Markov modeling, to evaluate the 
prospective, long-term cost-effectiveness of various osteoporosis interventions.  The 
purpose of these economic evaluations is to serve as a guide to efficient long-term 
resource allocation for healthcare policy decision-makers.  While these types of economic 
evaluations are important, especially for organizations contemplating initiation of a new 
resource intensive intervention, retrospective economic evaluations also provide valuable 
information to health care policy decision-makers about the impact of previous decisions 
and cost-effectiveness of current osteoporosis prevention and treatment strategies. 
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 In January 2000, the TRICARE Management Activity (TMA) and the Department 
of Defense (DoD) Pharmacy Board of Directors determined that funds allocated to 
military treatment facility (MTF) pharmacies through Program Budget Decision (PBD) 
No. 041 should be used to increase and standardize the availability of drugs at MTF 
pharmacies.  In response, the DoD Pharmacoeconomic Center (PEC) developed a set of 
recommended changes and additions to the DoD Basic Core Formulary (BCF) for the 
DoD Pharmacy and Therapeutics (P&T) Committee to consider.  The BCF is a list of 
medications that are required to be on all MTF formularies.  On 26 January 2000, the 
DoD P&T committee added alendronate, along with seven other medications, to the 
BCF.160  Since the addition of alendronate to the BCF, alendronate utilization has 
increased exponentially, with annual expenditures exceeding $61 million.  Alendronate 
accounts for approximately 58% of the DoD’s 6th highest expenditure drug class, bone 
resorption inhibitors.  To date, no formal health economic evaluation of alendronate or 
other current osteoporosis interventions has been performed to determine the costs and 
effects of current osteoporosis treatment interventions employed by the DoD.161 
 The goal of this study is to evaluate the economic, clinical and humanistic 
outcomes of current osteoporosis interventions employed in the prevention of 
osteoporotic fractures in the Department of Defense population.  The perspective taken in 
this health economic evaluation is that of the DoD PEC.  The results of this study will 
provide the DoD PEC with valuable information regarding the incidence of osteoporotic 
fracture in the DoD population, the clinical effectiveness of current treatment 
interventions, and both the aggregate and marginal cost-effectiveness of current treatment 
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interventions.  Armed with this information, the PEC will be able to make more informed 
decisions about how to best optimize the economic, clinical, and humanistic outcomes of 
osteoporosis treatment interventions in a health system with limited resources and health 
care budgets.   
Epidemiology of Osteoporotic Fracture in the DoD Population  
Objective 1 
 Determine the cumulative incidence and relative risk of osteoporotic fractures and 
by fracture type for the cohort as a whole and stratified by intervention group - 
Osteoporosis Diagnosis/Alendronate (ODA), Osteoporosis Diagnosis/HRT (ODHRT), 
Osteoporosis Diagnosis/AHRT (ODAHRT) (combination of alendronate and HRT), 
Osteoporosis Diagnosis/No Treatment (ODNOTX), and No Osteoporosis Diagnosis/No 
Treatment (NOODTX) and by risk factors (age, osteoporosis diagnosis, oral 
corticosteroid use, previous fracture history, and < 80% compliance) and statin use during 
the observation period. 
Effectiveness of Treatment Interventions 
Objective 2 
 Determine the odds ratio for osteoporotic fracture and by fracture type for each 
active intervention group (ODA, ODHRT, ODAHRT) versus ODNOTX and compare the 





 Objective 3 
 Determine the significance of risk factors (age, fracture history, oral corticosteroid 
use, and < 80% compliance) and statin use, for the prediction of osteoporotic fracture, 
while controlling for intervention group. 
Objective 4 
 Compare the time to fracture for the treatment groups.  There are two general 
goals of this objective: 1) to describe the proportion of cases free of a fracture event at 
various points in time, and 2) to assess the relationship between survival time and the set 
of covariates (risk factors [age, fracture history, corticosteroid use, and < 80% 
compliance] and statin use) to determine whether treatment differences are present after 
statistically controlling for the other covariates. 
Economic and Humanistic Outcomes Analysis 
Objective 5 
 To determine the incremental cost-effectiveness of treatment interventions, using 
the net-benefit regression method of CEA. 
Objective 6 
 Explore the importance of covariates on the marginal cost-effectiveness of an 
intervention, thus identifying important patient subgroups. 
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 HYPOTHESES 
 The following section lists the null hypotheses for those objectives that involve 
comparison of groups (Objectives 2 and 4) 
Objective 2  
• HO(1)  The odds ratio (OR) of osteoporotic fracture for intervention group ODA = 
ODHRT = ODAHRT = ODNOTX = 1. 
• HO(2)  The odds ratio (OR) of osteoporotic hip fracture for intervention group 
ODA = ODHRT = ODAHRT = ODNOTX = 1. 
• HO(3)  The odds ratio (OR) of osteoporotic vertebral fracture for intervention 
group ODA = ODHRT = ODAHRT = ODNOTX = 1. 
• HO(4)  The odds ratio (OR) of osteoporotic wrist fracture for intervention group 
ODA = ODHRT = ODAHRT = ODNOTX = 1. 
Objective 4  
• HO(5)  There is no difference in the proportion of cases free of a osteoporotic 
fracture event at various points in time between the four intervention groups 
(ODA, ODHRT, ODAHRT, ODNOTX). 
• HO(6)  There is no difference in the proportion of cases free of a osteoporotic hip 
fracture event at various points in time between the four intervention groups 
(ODA, ODHRT, ODAHRT, ODNOTX). 
• HO(7)  There is no difference in the proportion of cases free of a osteoporotic 
vertebral fracture event at various points in time between the four intervention 
groups (ODA, ODHRT, ODAHRT, ODNOTX). 
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• HO(8)  There is no difference in the proportion of cases free of a osteoporotic wrist 
fracture event at various points in time between the four intervention groups 
(ODA, ODHRT, ODAHRT, ODNOTX). 
• HO(9)  There is no difference between treatments (ODA, ODHRT, ODAHRT, 
ODNOTX) in time to osteoporotic fracture after statistically controlling for other 
covariates (risk factors and statin use). 
• HO(10)  There is no difference between treatments (ODA, ODHRT, ODAHRT, 
ODNOTX) in time to osteoporotic hip fracture after statistically controlling for 
other covariates (risk factors and statin use). 
• HO(11)  There is no difference between treatments (ODA, ODHRT, ODAHRT, 
ODNOTX) in time to osteoporotic vertebral fracture after statistically controlling 
for other covariates (risk factors and statin use). 
• HO(12) There is no difference between treatments (ODA, ODHRT, ODAHRT, 
ODNOTX)in time to osteoporotic wrist fracture after statistically controlling for 
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 This chapter presents a discussion of the study’s institutional review board 
approval, data sources, time frame, population, design, data collection process, and the 
data analysis for each of the study’s objectives.  The discussion of the study’s design is 
presented in the context of the net-benefit regression method of cost-effectiveness 
analysis (CEA) framework, the method of CEA selected for this study. 
INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL 
 This study was reviewed by The University of Texas Institutional Review Board 
(IRB) as well as the Brooks City Base IRB.  Approval was granted from both institutions 
on 16 February 2004 and 11 February 2004, respectively. 
DATA SOURCES 
 Data for this study were obtained from the Department of Defense (DoD) 
Pharmacoeconomic Center (PEC), located at Ft Sam Houston, Texas.   The PEC is a tri-
service (Air Force, Army, Navy) organization whose mission is to improve the clinical, 
economic, and humanistic outcomes of drug therapy in support of the readiness and 
managed healthcare missions of the Military Healthcare System (MHS).    
 Three different databases were used in this study: the Uniformed Services 
Prescription Database (USPD), the Pharmacy Data Transaction Service (PDTS), and the 
Military Health Service (MHS) Management and Analysis Reporting Tool (M2).  The 
USPD, PDTS, and M2 databases capture demographic and health care information on 
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active duty military members, retirees and their family members who are enrolled in 
TRICARE, the military health care plan.  DoD beneficiaries have the option of selecting 
from three different TRICARE health care plans which provide varying levels of access 
to both military and civilian medical facilities and pharmacies.  All beneficiaries have 
access to military treatment facility (MTF) pharmacies, regardless of TRICARE health 
plan option selected. 
 The USPD database is a centralized repository of all MTF prescription 
transactions since October 1998.  MTFs upload their prescription transactions to the 
USPD database on a weekly basis.  The USPD database includes the customary 
prescription information fields along with other demographic information fields (see 
Table 2.1 for a list data fields obtained from the database for this study).  The USPD 
database was used to collect part of the prescription data used in this study (01 October 
1998 through 30 June 2001).  The primary limitation of the USPD database is that it does 
not capture prescription transactions which occur outside the MTF.  Although all 
beneficiaries can obtain prescriptions from an MTF pharmacy at no cost, some elect to 
their obtain prescriptions through TRICARE retail network pharmacies (TRNP) and/or 
the TRICARE mail order pharmacy (TMOP) for an additional copay.   During fiscal year 
2003, 20.4% of the 6,187,185 beneficiaries who used their pharmacy benefit, obtained 
their prescriptions solely from TRNP and an additional 1.4% through TMOP.1  
Therefore, to ensure a more comprehensive representation of a patient’s prescription 
transaction history, prescription utilization data was also obtained from PDTS. 
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 The Pharmacy Data Transactions Service (PDTS) tracks all prescriptions filled at 
MTFs, the TRNP, and the TMOP.  Unfortunately, the PDTS database only includes 
prescription information as of 23 June 2001, the date that the database was deemed to be 
fully operational.  For this study, data from PDTS was collected from 01 July 2001 
through 30 September 2003 (see Table 2.1 for a list data fields obtained from the 
database for this study). 
 The M2 database is a centralized database maintained by the DoD Health Affairs 
Executive Information/Decision Support (EI/DS) Program Office.  The M2 database is a 
centralized repository of all ambulatory care and hospitalization health care transactions 
across military healthcare services.  It includes demographic, enrollment data, diagnostic 
and procedural codes and other claims data from both MTF and commercial network 
facilities.  For the purposes of this study, the M2 database was used to identify diagnostic 











Table 2.1 Summary of data fields by database source for this study 
Source Database Data Field 
Cost (Price Raw, Amount Paid 
Raw) 
Service Date 

























Rx Status (New or Refill) 
Fill Number  
Rx Number 
Service Category (Retail Network, 
Mail Order, MTF) 
PDTS 
Total Submitted Amount Due  
STUDY TIME FRAME 
 The final data set used in this study consisted of diagnostic and prescription data 
from 1 October 1998 through 30 September 2003, fiscal years (FY) 1999 through 2003 
(the DoD fiscal year begins 1 October and ends 30 September). 
 127
STUDY POPULATION 
 The target population for this study was female TRICARE beneficiaries aged 50 
and older.  However, the PEC does not have access to a comprehensive database that 
identifies all eligible TRICARE beneficiaries.  In place of such a database, the PEC uses 
transaction records from the USPD database and/or the PDTS database as a proxy to 
define the population of enrolled TRICARE beneficiaries.  Therefore, the accessible 
study population was restricted to patients for whom there was a record of at least one 
MTF prescription filled during the FY99 to FY00 period (1 October 1998 through 30 
September 2000) in the USPD database.   In other words, female TRICARE beneficiaries 
aged 50 and older who did not have at least one prescription filled during the FY99 to 
FY00 period were ineligible for inclusion in the study.  The general criteria used to 
determine inclusion of patients’ records from the accessible population were: female 
gender, age ≥ 50, and continuous TRICARE enrollment from FY99 to FY03.  The 
decision to use age ≥ 50 was based on the age criteria used in previous 
pharmacoeconomic studies.  Healthcare claims data from the M2 database were used as a 
proxy to define continuous enrollment in TRICARE.  Patients who had at least one claim 
during the assessment period (FY99 to FY00) and at least one claim in FY01, FY02, and 
FY03 were defined as being continuously enrolled during the study. 
STUDY DESIGN 
 A sample-based retrospective cohort study was performed to evaluate the clinical, 
economic, and humanistic outcomes of osteoporotic fractures in the DoD population.  
Cohort studies are observational studies which identify subsets of a defined population 
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and follow them over time, looking for differences in outcome.  In a retrospective cohort 
study, all relevant events (both exposures and outcomes of interest) have already 
occurred when the study is initiated.  In this study, patient subsets were defined by 
exposure to treatment intervention.  Five intervention groups were selected for 
observation: Osteoporosis Diagnosis/Alendronate (ODA), Osteoporosis Diagnosis/HRT 
(ODHRT), Osteoporosis Diagnosis/AHRT (ODAHRT) (combination of alendronate and 
HRT), Osteoporosis Diagnosis/No Treatment (ODNOTX), and No Osteoporosis 
Diagnosis/No Treatment (NOODTX).  The outcomes of interest were osteoporotic 
fractures, specifically osteoporotic fractures of the hip, vertebrae, and wrist.  Along with 
the exposure and outcomes variables of interest, this study also examined the impact of 
the following risk factors for osteoporotic fracture that were identifiable through the 
administrative and prescription databases: age, fracture history, oral corticosteroid use, 
and intervention compliance.  The statin drug class was included as a possible 
confounding variable, given the recent reports in the literature of an association between 
statin use and osteoporotic fracture. 
 The five-year sample based retrospective cohort study was subdivided into two 
periods, an assessment period (FY99 to FY00) and an observation period (FY00 to 
FY03).  During the assessment period, intervention groups were identified by exposure to 
intervention.  The ODA group included all patients who received their first alendronate 
prescription during FY00, which is subsequently referred to as the index-prescription and 
the date on which it was filled as the index-date.  An additional inclusion criterion 
applied to this group was that they did not receive HRT in FY99 or FY00.  The 
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ODAHRT group consisted of patients who were first prescribed alendronate during FY00 
and who received and continued to receive HRT at least 90 days after their first 
alendronate prescription.  Since alendronate is almost exclusively used to treat 
osteoporosis, with the exception of Paget’s disease, all alendronate patients were 
considered to have a diagnosis of osteoporosis.  The ODHRT group included all patients 
who were first prescribed HRT during FY00 and had an existing diagnosis of 
osteoporosis.  The ODNOTX group consisted of all patients who had an existing 
diagnosis of osteoporosis and who were not taking either alendronate or HRT during the 
assessment period.  The NOODTX group consisted of a sample of patients without an 
existing diagnosis of osteoporosis and who were not taking either alendronate or HRT.  
An additional exclusion criterion applied to all intervention groups was prior or current 
use of other osteoporosis medications, with the exception of calcium or vitamin D.  In 
addition to a diagnosis of osteoporosis, exposure to other risk factors and covariates (age, 
fracture history, oral corticosteroid use, and stain) use was identified during the 
assessment period.     
 During the three-year observation period, each patient was followed for the 
occurrence of osteoporotic fractures.  In addition, continued or new exposure to 
corticosteroids and statins was also determined.  The three-year observation period for 
the active intervention groups ODA, ODAHRT, and ODHRT started with the first index-
prescription in FY00 (rolling enrollment), whereas the observation period for ODNOTX 
and NOODTX started at the beginning of FY00.  Figure 2.1 below provides a diagram of 
the study design. 
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Figure 2.1 Study Design Diagram 
 Using this study design, epidemiologic analyses were performed to determine the 
incidence and relative risk of osteoporotic fractures in the DoD population, the 
significance of risk factors for osteoporotic fracture that are identifiable from 
administrative and prescription claims databases, and the time to osteoporotic fracture 
event.  Finally, a net-benefit regression method of cost-effectiveness analysis was 
employed to assess the overall cost-effectiveness of alendronate, HRT, and AHRT, and to 
explore the importance of covariates on the marginal cost-effectiveness of the 
interventions, thus identifying important patient subgroups.   
 All analyses were performed from both an intent-to-treat (ITT) and non intent-to-
treat (Non-ITT) study design. For the intent-to-treat study design, exposure to treatment 
intervention was measured at the onset of the observation period.  In the non intent-to-
treat design, exposure was measured throughout the observation period.  Patients who 
deviated from index-intervention during observation period were removed from the 
analysis.  The net-benefit regression method of CEA serves as a logical framework to 
further describe the methodology employed in this study. 
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NET-BENEFIT REGRESSION COST-EFFECTIVENESS ANALYSIS METHOD 
 As previously discussed, in this methodology a net-monetary-benefit statistic: 
iii CENMB −•= λ  
where Ei and Ci are the observed effect and cost for subject i and  λ is the maximum 













where α is the intercept term, the first summation represents the p covariates χ, t is a 
treatment dummy taking on the value zero for the standard treatment and the value of one 
for the treatment under consideration, δ is the regression coefficient on the treatment 
dummy, the final summation represents the interaction between the treatment variable 
and the covariates, and ε is a stochastic error term.  The two primary advantages of the 
net-benefit regression method of CEA are derived from the equation above.  First, 
additional explanatory variables can be added to the model to directly assess their impact 
on cost-effectiveness.  The regression coefficient δ provides the estimate of the 
incremental net-benefit (cost-effectiveness) while controlling for confounding variables.  
Second, the addition of interaction terms to the regression model provides an estimate of 
the impact of covariates on the marginal cost effectiveness, hence the ability to identify 
important patient subgroups.  The magnitude and significance of the coefficients γj on the 
interaction term indicate how the cost-effectiveness of treatment is expected to vary at the 
margin; large and statistically significant γj’s point towards important patient subgroups.  
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The following sub-section describes how the variables will be obtained for the net-benefit 
regression equation.  
Net-Monetary-Benefit Statistic Variables ( iii CENMB −•= λ )  
 Maximum Acceptable Willingness to Pay (λ) - As recommended by Stinnett and 
Mullhay,2 this NMB analysis was conducted for a range of values for  λ and the estimated 
NMB was reported as a function of  λ.  A range from $0 to $100,000 per QALY for λ 
was used.  This range was selected because it included the National Osteoporosis 
Foundation’s (NOF)3 established acceptable threshold for cost-effectiveness of $30,000 
per QALY and provided an upper sensitivity limit over three times that of  the cost-
effectiveness threshold. 
 Effect (Ei) – As previously discussed, a cost-utility analysis (CUA) was selected 
as the approach for health economic evaluation in this study.  This approach enables the 
multiple clinical outcomes of osteoporotic fracture (hip, vertebral, and wrist fracture), 
each with different consequences for morbidity, to be converted into a single currency, 
quality-adjusted life-years (QALYs).  Therefore, it was necessary to convert the effect 
variable (fracture outcomes), obtained from the M2 database, from a binary variable 
(fracture, no fracture) to a continuous QALY variable.  A QALY is the product of the 
health state value (HSV) assigned to each state associated with an intervention’s outcome 
multiplied by the length of time spent in each state.  A HSV is the weight assigned to a 
particular health state, ranging from 0 to 1, where a weight of 0 corresponds to a health 
state judged to be equivalent to death and 1 corresponds to perfect health. The HSVs used 
in this study to estimate QALYs were calculated by the application of a set of reference 
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case HSV multipliers, described by Brazier et al.,4 to a set of age-adjusted population 
norms, defined by Kind et al.5 Refer to Tables 1.7 & 1.8 for the set of reference case 
values and age-adjusted population norms, respectively. 
 Using the set of reference case values and age-adjusted population norms, a 
QALY was calculated for each individual patient for the assessment period (baseline) and 
each year of observation.  Since the observation period was subdivided into year units, 
each year’s QALY was equivalent to the HSV(s) assigned that year.  The HSV assigned 
to a particular patient was dependent upon: the presence of and type of fracture event; 
previous fracture events, since some fractures impact the quality-of-life beyond the event-
year; and age of patient.  For patients who sustained a fracture, the subsequent years’ 
HSVs were adjusted by half to account for some degree of recovery.  The change in 
QALY scores from baseline for each observation year was summed across the three years 
of observation to yield a total change in QALY score.  An example of the calculation of 
QALYs is provided below in Table 2.2. 
Table 2.2 Calculation of QALYs example 
*Mrs. Smith, a 65 year old woman, sustained a hip fracture in year two and a vertebral 








First 1 (no event) 0.806 0.806 
Second 0.797( hip fracture) 0.806 0.642 
Third 0.899 (hip fracture, 
subsequent year) – 
(1- 0.909 [vertebral 
fracture]) = 0.808 
0.806 0.651 
Total Change in Three-Year QALY Score  
Due to Fractures                                              2.418                           -2.099 = 0.319 
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      The operational definition used to identify osteoporotic fracture events from the 
M2 database is a modification of the operational definition employed by Westfall et al.6  
The operational  definition used for this study uses the same four criteria employed by 
Westfall et al.6 but adds an additional fifth inclusion criterion.  The first four criteria used 
by Westfall et al.6 and in this study used both ICD-9 diagnosis and procedure codes and 
CPT-4 procedure codes to identify fracture by type.  A claim was considered to be an 
osteoporotic fracture if it met one of the following criteria: 
• The primary diagnosis is a pathological fracture (ICD-9 codes 733.1-733.19); 
• The primary diagnosis is a fracture of a specific site of the vertebrae (805.00-
805.9; 806.0-806.91), wrist (813.0-813.93; 814.0-814.19), or hip (820-821.39) or 
there is a CPT-4 procedure code for fracture of the vertebrae (22305-22328), wrist 
(25600-25624), or hip (27193-27248; 27500-27514) or there is an ICD-9 
procedure code for fracture of the vertebrae (0353), wrist (7902-7992; 7842), or 
hip (7925-7995; 7845) and the secondary diagnosis is a pathological fracture; 
• The primary diagnosis is osteoporosis (ICD-9 codes 733.0-733.09) and the 
secondary diagnosis was a specific site fracture or there was a CPT-4 or ICD-9 
procedure code for fracture; or 
• The secondary diagnosis is osteoporosis (ICD-9 codes 733.0-733.09) and the 
primary diagnosis was a specific site fracture or there was a CPT-4 or ICD-9 
procedure code for fracture 
The additional fifth criterion used in this study was: 
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• Patients in intervention groups ODA, ODAHRT, ODHRT, and ODNOTX by 
definition have an existing diagnosis.  Therefore, any patient with a primary 
diagnosis of fracture of the hip, vertebrae, or wrist was assumed to have an 
osteoporotic fracture, although a secondary diagnosis of a pathological fracture or 
osteoporosis was not present. 
Westfall et al.6 employed a series of criteria, based on CPT-4 procedure codes, to 
distinguish a new osteoporotic fracture claim from an existing osteoporotic fracture 
claim.  Unfortunately, the same criteria employed by Westfall et al.6 could not be used in 
this study, primarily as a result of poor MTF procedure coding.  A total of 2,767 out of 
33,512 claims meeting the operational definition of fracture did not include a primary 
procedure code.  As a result, this study employed a single criterion to distinguish a new 
osteoporotic fracture claim from an existing osteoporotic claim: 
• A claim was considered a new osteoporotic fracture episode if it was the first 
claim for a subject following a 6-month period with no osteoporotic fracture 
claims for the same specific fracture site. 
Westfall et al.6 also used a 6-month interval as one of the criteria for determining a new 
osteoporotic fracture event.   
 Costs (Ci) – Only direct medical costs, cost of medication and fracture treatment 
costs, were included in the analysis.  The medication treatment cost reflects the final cost 
to the MHS from each point of service. For medication treatment costs, if a prescription 
was dispensed from an MTF, the cost is the acquisition cost of the medication.  If a 
prescription was dispensed from either the National Mail Order Pharmacy or TRICARE 
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Retail Network Pharmacy, the cost reflects the “Total Submitted Amount Due” to the 
MHS from the managed care contractor.  Since the USPD database did not contain any 
type of medication cost field, medication costs were determined by multiplying the sum 
total units (tablets, capsules, transdermal systems) dispensed for each medication by its 
FY03 average weighted unit cost, which was obtained from the PDTS database.  The 
average weighted unit cost was calculated from the average cost incurred at each point of 
service (MTF, Mail Order, and Retail Network) weighted by their percentage of all 
transactions.   
 Fracture treatment costs were obtained from the M2 database.  In the M2 
database, the MHS reports several different types of costs, dependent upon the point of 
service and method used to calculate cost.  Two different costs were used in this study to 
determine fracture treatment costs, “Price Raw” and “Amount Paid Raw.” If the MTF is 
the point of service, the cost reported is “Price Raw.”  In general, “Price Raw” reflects 
the worldwide average full cost across all MTFs for a particular type of care.  If the point 
of service is the managed care network, the cost reported is “Amount Paid Raw” which is 
the amount paid by the MHS to the managed care network provider for a particular claim.  
All fracture treatment costs were compounded by a 5% interest rate to FY03 costs.  
Covariates – ( χj ) 
 In the net-benefit regression methodology, the inclusion of covariates in the 
regression model enables the researcher to control for the presence of confounding 
variables.  This ability is especially significant in an observational study given the 
potential heterogeneous nature of the intervention groups.  The osteoporosis net-benefit 
 137
regression model employed in this research included covariates that were known risk 
factors for osteoporotic fracture, could be readily obtained and allowed discrete 
categorization using an administrative claims or prescription database, and were 
previously found to be either statistically significant or were recommended for future 
economic studies.  The following risk factors met the inclusion criteria and were 
operationalized using claims markers in the administrative claims or prescription 
databases: age, osteoporosis diagnosis, history of previous osteoporotic fracture, 
corticosteroid use, statin use, and intervention compliance. 
 Age – The age of the patient was the age of the patient at the start of the 
observation period (01 October 1999).  This information was obtained from the M2 
database. 
 Previous Osteoporotic Fracture – Patients with a previous osteoporotic fracture 
were identified during the risk assessment period, FY99 to FY00, using the same 
operational definition employed for the effect variable (Ei).  This information was also 
obtained from the M2 database.  
 Corticosteroid Use - Two variables were created to assess the oral corticosteroid- 
induced risk of osteoporotic fracture, dose and duration.  Patients were categorized 
according to the weighted average daily dose of prednisone or prednisone dosage 
equivalents into one of four categories (≤ 5mg, > 5mg ≤ 10mg, > 10 ≤ 20mg, and > 
20mg) (see Table 2.3 for prednisone strengths and dosage equivalents used as claims 
markers for steroid use).  Each subject was also categorized according to duration of use 
into one of three categories (≤ 180 days, > 180 days ≤ 365 days, > 365 days).  The 
 138
duration of use variable is defined as total days of therapy during the study period 
(continuous or not).  These two variables were then used to form 12 dose-duration 
categorical variables, one for each possible combination of dose and duration. The drug, 
dose, and days supply information was obtained from the USPD and PDTS databases. 
Table 2.3 Prednisone strengths and dosage equivalents6 






























































 Intervention Compliance - The compliance with each intervention was measured 
by determining the medication possession ratio (MPR).  The MPR definition employed in 
this study was the same definition used by Okano et al.7 in a previous study utilizing the 
USPD database.  The MPR was defined for each patient as the supply of medication 
dispensed, measured in days, divided by the number of days in a 36-month study period.  
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Since this study was performed on an intent-to-treat basis, any purposely discontinued 
treatment was not accounted for in the MPR. 
 Statin Use – Statin use was included as a potential confounding variable.  Like 
corticosteroid use, two variables were used to assess the statin-induced risk of 
osteoporotic fracture, dose and duration.  Patients were categorized according to the 
weighted average daily dose of statin into one of two categories, low-dose or high-dose 
therapy, based upon percent reduction in low density lipoprotein cholesterol (LDL-C) 
(see Table 2.4).  Patients receiving statin medication doses capable of achieving a 35% 
reduction or more in LDL-C were considered to be on high-dose therapy.  More 
specifically, high-dose and low-dose therapy was defined as follows: high-dose = doses 
of simvastatin ≥ 40mg, doses of atorvastatin ≥ 20mg, doses of cerivastatin > 0.4mg, doses 
of fluvastatin > 80mg,  and doses of lovastatin ≥ 80mg.  All other statin doses were 
considered to be low-dose therapy.  Each subject was also categorized according to 
duration of statin exposure into one of three categories (≤ one-year, > one-year ≤ two 
years, > two-years).  The duration of exposure variable is defined as total days of therapy 
during the study period (continuous or not).  As with the corticosteroid variables, these 
two variables were then used to form six dose-duration categorical variables, one for each 
possible combination of dose and duration. The drug, dose, and days supply information 
was obtained from the USPD and PDTS databases.  Patients who received pravastatin 
were not included, since earlier in vitro studies suggest that pravastatin has virtually no 
effect on the BMP-2 promoter gene, which is thought to be responsible for statin’s 
osteoblastic effect.  
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Table 2.4 Statin dose equivalency chart8 
% LDL-C 
Reduction HMG-CoA Reductase Inhibitor
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Interventions ( δti )  
 As previously noted, five intervention groups were identified during the risk 
assessment period and were followed during the three-year observation period: 
Osteoporosis Diagnosis/Alendronate (ODA), Osteoporosis Diagnosis/HRT (ODHRT), 
Osteoporosis Diagnosis/AHRT (ODAHRT) (combination of alendronate and HRT), 
Osteoporosis Diagnosis/No Treatment (ODNOTX), and No Osteoporosis Diagnosis/No 
Treatment (NOODTX).  However, only four of the intervention groups were included in 
the net-benefit regression CEA: ODA, ODHRT, ODAHRT, and ODNOTX, with the 
ODNOTX group serving as a control for the active treatment groups.   
 Operational definitions were constructed to define the intervention groups.  The 
intervention groups for active treatment were limited to women who first started the 
treatment in FY00 to avoid any potential for confounding due to duration of treatment 
intervention.  In other words, women who were currently taking the medication prior to 
the beginning of the observation period were excluded from the intervention groups.  The 
operational definitions used to form the intervention groups from the study population are 
as follows: 
• ODA – Women who filled an alendronate prescription FY00, but who did not 
have a prescription for alendronate in FY99.  Any patient who was prescribed 
alendronate was assumed to have a diagnosis of osteoporosis;  
• ODHRT – Women who filled an HRT prescription FY00, but who did not have a 
prescription for HRT in FY99.  Since HRT can be prescribed for conditions other 
than osteoporosis, these patients were also required to have a diagnosis of 
osteoporosis in either FY99 or FY00; 
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• ODAHRT – Women who filled an alendronate prescription FY00, but who did 
not have a prescription for alendronate in FY99 and who were currently taking 
HRT and continued to take HRT at least 90 days after their index alendronate 
prescription; 
• ODNOTX - Women with a diagnosis of osteoporosis in either FY99 or FY00, 
who did not have a prescription for any osteoporosis treatment with the exception 
of calcium and/or vitamin D in FY99 or FY00; and 
• NOODTX – Women without a diagnosis of osteoporosis and any type of 
osteoporosis treatment, except for calcium and vitamin D, were identified from a 
random sample of women ≥ 50 years of age (as of 1 October 1999), who filled 
any prescription in FY 1999 or FY 2000. 
 Gender and prescription history were obtained from the USPD database, whereas 
age, continuous enrollment information, ICD-9 diagnosis and procedure codes, and CPT-
4 codes were obtained from the M2 database.   
Interaction Terms ( ti*χij ) 
 Interaction terms between each specific covariate found to be significant and each 
intervention were formed to estimate the marginal effect of a particular covariate on the 
intervention while statistically controlling for the presence of other covariates. 
DATA COLLECTION PROCESS 
 A data analyst at the PEC extracted the data from the three databases, patient 
matched the data via a unique identifier, and then presented the data for this study in a de-
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identified format.  The following protocol was used to extract the data from the study 
population to form the study sample. 
• Step 1 - Identified women with an osteoporosis diagnosis (ICD-9 Codes 733.0 to 
733.09) during the risk assessment period FY99 through FY00.  From this 
population, two of the four intervention groups were identified, ODHRT and 
ODNOTX. 
• Step 2 - ODHRT - Identified women, who filled an HRT prescription in FY00, 
who did not have a prescription for HRT in FY99. 
• Step 3 - ODNOTX  - Identified women who did not have a prescription for any 
osteoporosis treatment with the exception of calcium and/or vitamin D in FY99 
and FY00. 
• Step 4 - ODA - Identified women who filled an alendronate prescription in FY00, 
who did not have a prescription for alendronate in FY99.  From this population 
another intervention group was identified, ODAHRT. 
• Step 5 – ODAHRT - Identified women who filled an HRT prescription in FY99 
and/or FY00, and who had a prescription for alendronate in FY00 but not in 
FY99.  
• Step 6 - NOODTX – Identified via random sampling method using the last digit 
of the SSN a group of women without a diagnosis of osteoporosis and any 
osteoporosis related treatment in FY 1999 and FY 2000. 
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DATA ANALYSIS 
 All data manipulation and analyses were performed using SAS version 8.02-
software.  The a priori level of significance (alpha) was set at 0.05.  The following 
section is a description of the data analysis procedures for each study objective. 
Epidemiology of Osteoporotic Fractures in the Accessible DoD Population  
Objective 1 
      The cumulative incidence of osteoporotic fracture and the cumulative incidence of 
osteoporotic fracture by type was determined for the cohort as a whole and stratified by 
intervention group and risk factors during the observation period.  The frequency of new 
osteoporotic fractures was identified from the M2 database employing the previously 
described operational definition of a new osteoporotic fracture.  The cumulative 
incidence of new osteoporotic fractures during the observation period for the cohort as a 
whole was defined as: 
New cases of osteoporotic fracture occurring during the observation period 
All susceptible people present in the sample at the beginning of the observation period 
 
The cumulative incidence of new osteoporotic fractures during the observation period for 
each intervention group and risk factor was defined as: 
New cases of osteoporotic fracture occurring during the observation 
period stratified by  treatment group or risk factor 
All susceptible people present in the sample at the beginning of the observation 
period stratified by treatment group or risk factor 
 
In addition, the relative risk of any type of osteoporotic fracture and for each specific type 
of fracture was determined for intervention groups ODA, ODAHRT, and ODHRT by 
dividing the cumulative incidence of osteoporotic fracture for those specific intervention 
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groups by the cumulative incidence for the reference intervention group ODNOTX.  The 
relative risk of any type of osteoporotic fracture and for each specific type of fracture was 
also determined for the various risk factors by dividing cumulative incidence of 
osteoporotic fracture in the risk factor exposed group by cumulative incidence of 
osteoporotic fracture in the non-exposed group. 
Effectiveness of Treatment Interventions 
Objectives 2 & 3 
 A series of analyses were performed to determine the relative risk of osteoporotic 
fractures and the relative risk by type of fracture (hip, vertebral, and wrist) for each 
treatment group and the significance of risk factors and statin use (confounding variable) 
in the prediction of osteoporotic fracture events for the cohort.  A logistic regression 
model was used to perform the analyses.  This form of regression analysis was selected 
because it allows one to predict a discrete outcome (fracture, no fracture) from a mix of 
discrete, dichotomous, and continuous variables.  The analyses were performed using the 
SAS LOGISTIC procedure. 
 To determine the relative risk of osteoporotic fractures and the relative risk by 
type of fracture for each intervention group and assess the statistical significance of risk 
factors and statin use in the prediction of osteoporotic fracture events, a logistic 
regression model was created.  In this model, the dependent variable was a dichotomous 
variable, which represented whether a patient sustained any type of osteoporotic fracture 
event.  Any patient who sustained one or more osteoporotic fractures was coded as 1 for 
each fracture occurrence whereas any patient who did not sustain any type of 
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osteoporotic fracture was coded as 0.  The independent variables included the following 
risk factors and statin use.  The patient’s: age was treated as a categorical variable; 
history of previous osteoporotic fracture was treated as a dichotomous variable (1 = yes, 
0 = no); corticosteroid use, and statin use were treated as categorical variables; and 
intervention compliance, as determined by the MPR was treated as a dichotomous 
variable (compliance = 1 (MPR of ≥ 80%), 0 = non-compliant).  
Objective 4 
 A series of survival analyses were performed to compare the time to fracture for 
the treatment groups.  There were two general goals of these analyses: 1) to describe the 
proportion of cases free of a fracture event at various points in time; and 2) to assess the 
relationship between survival time and a set of covariates (risk factors, and statin use) to 
determine whether treatment differences are present after statistically controlling for the 
other covariates. 
 The Kaplan-Meier method of life tables was used to describe the proportion of 
cases free of a fracture event at various points in time.  The dependent variable, days, was 
the number of days a case was free of a fracture event during the three-year observation 
period.  Fracture event was the censoring variable that indicated whether a case is 
fracture free at the end of the observation period.  Life tables and survival plots were 
created for each treatment group for time to first fracture, first hip fracture, first vertebral 
fracture, and first wrist fracture.  The SAS LIFETEST procedure was used to perform the 
statistical analyses. 
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 A direct Cox proportional-hazards model was used to assess the relationship 
between survival time and the set of covariates to determine whether treatment 
differences are present after statistically controlling for the other covariates.  In the direct 
Cox proportional-hazards model, all covariates enter the equation simultaneously and 
each is assessed as if it entered last.  Therefore, each covariate was evaluated as to what it 
adds to the prediction of survival time that is different from the prediction afforded by all 
the other covariates.  The primary purpose of this analysis was to determine if there was a 
difference in time to fracture between the treatment groups after adjusting for the effects 
of the covariates.  SAS PHREG was used to perform the Cox proportional-hazards 
model.  As with the Kaplan-Meier method, the dependent variable, days, was the number 
of days a case was free of a fracture event during the three-year observation period.  
Fracture event was the censoring variable that indicated whether a case was fracture-free 
at the end of the observation period.     
Economic and Humanistic Outcomes Analysis  
Objective 5 
 The net-benefit regression method of CEA was employed to determine the cost-
effectiveness of the DoD’s osteoporosis treatment interventions.  Four intervention 
groups were examined: Osteoporosis Diagnosis/Alendronate (ODA), Osteoporosis 
Diagnosis/HRT (ODHRT), Osteoporosis Diagnosis/AHRT (ODAHRT), and 
Osteoporosis Diagnosis/No treatment (ODNOTX).  The direct treatment costs across the 
three year observation period were examined from the perspective of the DoD.  The 
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number and type of osteoporotic fracture events were selected as the main effectiveness 
measure, and were subsequently converted to QALYs as previously described.  
 The NBR approach was employed to estimate the cost-effectiveness of the 
intervention groups by estimating: 
ii ODAHRTODHRTODAcompliancestatinsteroidprevfracageNMB εδδδβββββα +++++++++= 54321
 
 Net monetary benefits were calculated employing λ values of $ 0, $15,000, $30,000, 
$60,000, and $100,000.  SAS REG was used to perform the net-benefit regression. 
Objective 6 
  To examine the impact of covariates on the estimate of the intervention’s 
incremental net-benefit, a model was employed that interacts the treatment dummy with 
covariates which were found to have a statistically significant increased risk of 
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 This chapter reports the results of the study including frequency distributions and 
descriptive statistics of the study population and data analysis for objectives one through 
six.  For each objective, two separate analyses are reported, one using an intent-to-treat 
(ITT) study design and another using a non intent-to-treat (Non-ITT) study design.  The 
non intent-to-treat analysis excluded patients from the cohort who deviated from their 
index-treatment regimens during the observation period. 
After application of the general study and intervention criteria, a total of 49,851 
patients were included in the study.  The study sample consisted of 4,645 patients in the 
ODA intervention group, 4,391 patients in the ODAHRT intervention group, 1,620 
patients in the ODHRT intervention group, 7,568 patients in the ODNOTX intervention 
group, and 31,627 patients in the NOODTX intervention group.  
 INTENT-TO-TREAT VERSUS NON INTENT-TO-TREAT 
 During the observation period, patients were monitored for deviations from their 
respective index-treatment regimens.  Deviations from index-treatment regimens were 
identified for each patient via a retrospective review of the patient’s prescription history.  
A deviation from the index-treatment regimen was identified by the dispensing of any 
other osteoporosis agent during the observation period, other than the index-treatment.  A 
total of 11,568 patients deviated from their respective index-treatment regimen during the 
observation period, with more deviations occurring in the ODNOTX (43.01%) and 
ODHRT intervention groups (34.94%) compared to the NOODTX (20.09%), ODA 
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(17.22%) and ODAHRT (13.53%) intervention groups.  Table 3.1 shows the total number 
of patients in each cohort and the percent decrease in patients for each intervention group 
from the intent-to-treat (ITT) analysis to the non intent-to-treat (Non-ITT) analysis.  
Table 3.1 Frequency distribution and percent decrease from the ITT to Non-ITT cohorts 










from ITT to 
Non-ITT 
ODA 4,645 3,845 17.22 
ODAHRT 4,391 3,797 13.53 
ODHRT 1,620 1,054 34.94 
ODNOTX 7,568 4,313 43.01 
NOODTX 31,627 25,274 20.09 
Total 49,851 38,283 23.21 
FREQUENCY DISTRIBUTIONS AND DESCRIPTIVE STATISTICS 
 The following sub-section reports the frequency distributions and where 
appropriate descriptive statistics of the dependent and independent variables for both the 
intent-to-treat cohort and non intent-to-treat cohort.  To facilitate the comparison between 
cohorts, the frequency distributions and descriptive statistics for the non intent-to-treat 
cohort will immediately follow those of the intent-to-treat cohort for the dependent and 
each independent variable.  Reported first are frequency distributions of the dependent 
variables. 
Dependent Variable   
Intent-To-Treat Cohort 
 In the intent-to-treat analysis, a total of 1,812 fracture events were reported during 
the study (assessment period 574; observation period 1,238).  Tables 3.2 and 3.3 show the 
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frequency distributions of fracture type for the study and observation periods, 
respectively.  During the observation period, vertebral fracture was the most commonly 
reported fracture type (39.42%), followed by wrist (34.89%) and hip fracture (25.69%).   
Table 3.2 ITT: Frequency distribution of fractures by fracture type during study 





Hip 525 28.97 525 28.97 
Vertebral 574 31.68 1,099 60.65 
Wrist 713 39.35 1,812 100.00 
 
Table 3.3 ITT: Frequency distribution of fractures by fracture type during observation 
period 





Hip 318 25.69 318 25.69 
Vertebral 488 39.42 806 65.11 
Wrist 432 34.89 1,238 100.00 
 
Table 3.4 shows the frequency distribution of patients who experienced a fracture 
event during the assessment period and each observation year by fracture type.  More 
patients experienced a fracture event during the third observation year (510) than in the 
previous two observation years (first observation year 320; second observation year 354). 
The proportion of patients who experienced a fracture event during any observation year 





Table 3.4 ITT: Frequency distribution of the cohort by fracture type for the assessment 
period and each observation year 






None 49,302 98.90 49,302 98.90 
Hip 188 0.38 49,490 99.28 
Vertebral 77 0.15 49,567 99.43 
Wrist 259 0.52 49,826 99.95 
Hip & Vertebral 3 0.01 49,829 99.96 
Hip & Wrist 16 0.03 49,845 99.99 
Vertebral & Wrist 6 0.01 49,851 100.00 
Observation Year 1 
None 49,531 99.36 49,531 99.36 
Hip 68 0.14 49,599 99.49 
Vertebral 118 0.24 49,717 99.73 
Wrist 125 0.25 49,842 99.98 
Hip & Vertebral 5 0.01 49,847 99.99 
Hip & Wrist 3 0.01 49,850 100.00 
Vertebral & Wrist 1 0.00 49,851 100.00 
Observation Year 2 
None 49,497 99.29 49,497 99.29 
Hip 87 0.17 49,584 99.46 
Vertebral 120 0.24 49,704 99.71 
Wrist 133 0.27 49,837 99.97 
Hip & Vertebral 5 0.01 49,842 99.98 
Hip & Wrist 4 0.01 49,846 99.99 
Vertebral & Wrist 4 0.01 49,850 100.00 
Hip, Vertebral & Wrist 1 0.00 49,851 100.00 
Observation Year 3 
None 49,341 98.98 49,341 98.98 
Hip 131 0.26 49,472 99.24 
Vertebral 213 0.43 49,685 99.67 
Wrist 145 0.29 49,830 99.96 
Hip & Vertebral 6 0.01 49,836 99.97 
Hip & Wrist 4 0.01 49,840 99.98 
Vertebral & Wrist 10 0.02 49,850 100.00 
Hip, Vertebral & Wrist 1 0.00 49,851 100.00 
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Non Intent-To-Treat Cohort 
In the non intent-to-treat analysis a total of 1,145 fracture events were reported 
during the study (assessment period 408; observation period 737).  Tables 3.5 and 3.6 
show the frequency distributions of fracture type for the study and observation periods, 
respectively.  Wrist fracture was the most commonly reported fracture type (38.53%), 
followed by vertebral (32.29%) and hip fracture (29.17%) during the observation period.   
Table 3.5 Non-ITT: Frequency distribution of fractures by fracture type during study 





Hip 361 31.53 361 31.53 
Vertebral 299 26.11 660 57.64 
Wrist 485 42.36 1,145 100.00 
 
Table 3.6 Non-ITT: Frequency distribution of fractures by fracture type during 
observation period 





Hip 215 29.17 215 29.17 
Vertebral 238 32.29 453 61.47 
Wrist 284 38.53 737 100.00 
 
Table 3.7 shows the frequency distribution of patients who experienced a fracture 
event during the assessment period and for each observation year by fracture type.  More 
patients experienced a fracture event during the third observation year (288) than in the 
previous two observation years (first observation year 206; second observation year 216). 
The proportion of patients who experienced a fracture event during any observation year 
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ranged from 0.54% to 0.75%.  Less than 0.05% of patients experienced multiple fractures 
within a given observation year. 
Table 3.7 Non-ITT: Frequency distribution of the cohort by fracture type during the 
assessment period and each observation year 






None 37,894 98.98 37,894 98.98 
Hip 131 0.34 38,025 99.33 
Vertebral 55 0.14 38,080 99.47 
Wrist 184 0.48 38,264 99.95 
Hip & Vertebral 2 0.01 38,266 99.96 
Hip & Wrist 13 0.03 38,279 99.99 
Vertebral & Wrist 4 0.01 38,283 100.00 
Observation Year 1 
None 38,077 99.46 38,077 99.46 
Hip 51 0.13 38,128 99.60 
Vertebral 66 0.17 38,194 99.77 
Wrist 86 0.22 38,280 99.99 
Hip & Vertebral 3 0.22 38,283 100.00 
Observation Year 2 
None 38,067 99.44 38,067 99.44 
Hip 67 0.18 38,134 99.61 
Vertebral 56 0.15 38,190 99.76 
Wrist 84 0.22 38,274 99.98 
Hip & Vertebral 2 0.01 38,276 99.98 
Hip & Wrist 3 0.01 38,279 99.99 
Vertebral &Wrist 4 0.01 38,283 100.00 
Observation Year 3 
None 37,995 99.25 37,995 99.25 
Hip 82 0.21 38,077 99.46 
Vertebral 98 0.26 38,175 99.72 
Wrist 98 0.26 38,273 99.97 
Hip & Vertebral 2 0.01 38,275 99.98 
Hip & Wrist 3 0.01 38,278 99.99 
Vertebral & Wrist 5 0.01 38,283 100.00 
 
 156
 Comparing the intent-to-treat cohort to the non intent-to-treat cohort, the two 
cohorts were similar in that more fracture events were reported during the third 
observation year than in the previous two years.  However, the two cohorts differed in the 
proportion of patients who experienced any type of fracture and also in the most 
commonly reported fracture type.  The proportion of patients who experienced any type 
of fracture was higher in the intent-to-treat cohort compared to the non intent-to-treat 
cohort.  Vertebral fracture was the most commonly reported fracture event in the intent-
to-treat cohort, whereas wrist fracture was the most commonly reported fracture event in 
the non intent-to-treat cohort. 
Independent Variables 
 The independent variables collected from prescription and health claims data 
included age, previous osteoporotic fracture, corticosteroid use, statin use, and 
intervention compliance.  The frequency distributions and descriptive statistics of the 
independent variables are provided below. 
Age 
Intent-To-Treat Cohort 
The mean age of the intent-to-treat cohort was 63.05 years (SD = 8.94).  A 
general linear model showed significant differences in mean age between the intervention 
groups F (4, 49,846) = 207.50, p < 0.0001.  Application of Duncan’s multiple-range test 
revealed that significant differences exist in mean age between each intervention group 
except for the ODNOTX and NOODTX intervention groups.  Table 3.8 shows the 
descriptive statistics of patient age for the cohort and intervention groups. 
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Deviation Minimum Maximum 
ODA 4,645 66.69 8.50 50.00 93.00 
ODAHRT 4,391 63.66 7.60 50.00 90.00 
ODHRT 1,620 59.96 6.44 50.00 92.00 
ODNOTX 7,568 62.41 8.26 50.00 96.00 
NOODTX 31,627 62.74 9.29 50.00 99.00 
Cohort 49,851 63.05 8.94 50.00 99.00 
* F (4, 49,846) = 207.50, p < 0.0001 
 Objectives one through four categorize patients into age categories; therefore; the 
distribution of patients by intervention group and age categories was examined.  A Chi-
Square test for independence revealed that the relationship between intervention groups 
and age categories was not independent χ2 (28, n = 49,851) = 2713.87, p < 0.0001.  
Examination of observed cell frequencies vs. expected cell frequencies and cell chi-
squares revealed significant differences for the distribution of patients by intervention 
group and age category.  In fact, the ODA and ODHRT intervention groups had opposite 
age category distributions.  The ODA intervention group had lower than expected cell 
frequencies for the first three age categories and higher than expected cell frequencies in 
the last five age categories, whereas the ODHRT intervention group had higher than 
expected cell frequencies first three age categories and a lower than expected cell 
frequencies in the last five age categories.  In other words, the ODA intervention group 
had a higher distribution of older patients compared to the ODHRT intervention group.  
No significant distribution pattern of age categories was noted for the other intervention 
groups.  Table 3.9 shows the distribution of the cohort by intervention groups and age 
categories.   
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Table 3.9 ITT: Frequency distribution of cohort by intervention group and age categories 
Age Categories Frequency Expected 
Cell Chi-Square 
Row %




































































































































































































* χ2 (28, n = 49,851) = 2713.87, p < 0.0001
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Non Intent-To-Treat Cohort 
The mean age of the non intent-to-treat cohort was 63.32 (SD = 9.12).  A general 
linear model showed significant differences in mean age between the intervention groups 
F (4, 38,278) = 204.47, p < 0.0001.  Application of Duncan’s multiple-range test revealed 
that significant differences exist in mean age between each intervention group except for 
the ODNOTX and NOODTX intervention groups.  Table 3.10 shows the descriptive 
statistics of patient age for the cohort and intervention groups. 











ODA 3,845 66.81 8.54 50.00 93.00 
ODAHRT 3,797 63.56 7.58 50.00 89.00 
ODHRT 1,054 59.40 6.19 50.00 92.00 
ODNOTX 4,313 63.07 8.87 50.00 96.00 
NOODTX 25,274 62.97 9.41 50.00 99.00 
Cohort 38,283 63.32 9.12 50.00 99.00 
* F (4, 38,278) = 204.47, p < 0.0001 
 
     A Chi-square test for independence revealed that the relationship between intervention 
groups and age categories was not independent χ2 (28, n = 38,283) = 1,800.95, p < 
0.0001.  As observed in the intent-to-treat cohort, the ODA and ODHRT intervention 
groups had opposite age category distributions.  Table 3.11 shows the distribution of the 
cohort by intervention groups and age categories. 
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Table 3.11 Non-ITT: Frequency distribution of the cohort by intervention group and age categories 
Age Categories Frequency Expected 
Cell Chi-Square 
Row %




































































































































































































* χ2 (28, n = 38,283) = 1800.95, p < 0.0001
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     With respect to the independent variable age, the intent-to-treat cohort and the non 
intent-to-treat cohorts were similar. 
Previous Osteoporotic Fracture 
Intent-To-Treat Cohort 
 A total of 549 (1.10%) patients in the intent-to-treat cohort experienced a fracture 
during the assessment period and were thereby coded as having a previous osteoporotic 
fracture event.  A Chi-Square test for independence revealed that the relationship 
between intervention groups and previous osteoporotic fracture was not independent χ2 
(4, n= 49,851) = 933.02, p < 0.0001.  Examination of observed cell frequencies vs. 
expected cell frequencies and cell chi-squares revealed significant differences for the 
distribution of patients with a previous osteoporotic fracture by intervention group.  The 
ODA, ODAHRT, ODHRT, and ODNOTX intervention groups, or those with a diagnosis 
of osteoporosis, had higher than expected frequency of previous osteoporotic fracture, 
whereas the NOODTX intervention group had a lower than expected frequency of 
previous osteoporotic fracture.  Table 3.12 shows the frequency distribution of the cohort 















































































* χ2 (4, n= 49,851) = 933.02, p < 0.0001 
Non Intent-To-Treat Cohort 
A total of 389 (1.02%) patients in the non intent-to-treat cohort experienced a 
fracture during the assessment period and were thereby coded as having a previous 
osteoporotic fracture event.  A Chi-Square test for independence revealed that the 
relationship between intervention groups and previous osteoporotic fracture was not 
independent χ2 (4, n= 38,283) = 734.48, p <0.0001.  Examination of observed cell 
frequencies vs. expected cell frequencies and cell chi-squares revealed significant 
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differences for the distribution of patients with a previous osteoporotic fracture by 
intervention group.  As with the intent-to-treat cohort, the ODA, ODAHRT, ODHRT, 
and ODNOTX intervention groups had higher than expected frequency of previous 
osteoporotic fracture, whereas the NOODTX intervention group had a lower than 
expected frequency of previous osteoporotic fracture.  Table 3.13 shows the frequency 
distribution of the cohort by intervention groups and previous osteoporotic fracture. 
Table 3.13 Non-ITT: Frequency distribution of the cohort by intervention group and 







































































*χ2 (4, n= 38,283) = 734.48, p < 0.0001 
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 The intent-to-treat and non intent-to-treat cohorts were similar in regards to the 
distribution of patients in the intervention groups with a previous osteoporotic fracture.  
The higher than expected cell frequencies of patients with previous osteoporotic fracture 
in the ODA, ODAHRT, ODHRT, and ODNOTX intervention groups was consistent for 
both intervention groups, with little variance in row percentages between cohorts. 
Corticosteroid Use 
Intent-To-Treat Cohort 
 In the intent-to-treat cohort, a total of 9,797 (19.65%) patients used an oral 
corticosteroid during the study (assessment period and/or observation period).  A chi-
square test for independence revealed that the relationship between intervention groups 
and oral corticosteroid use was not independent χ2 (4, n = 49,851) = 603.56, p < 0.0001.  
Examination of observed cell frequencies vs. expected cell frequencies and cell chi-
squares revealed significant differences for the distribution of patients who used an oral 
corticosteroid by intervention group.  A frequency distribution pattern similar to the 
previous (intervention group by previous osteoporotic fracture) was observed for 
corticosteroid use.  The ODA, ODAHRT, ODHRT, and ODNOTX intervention groups, 
or those with a diagnosis of osteoporosis, had a higher than expected cell frequencies of 
oral corticosteroid use, whereas the NOODTX intervention group had a lower than 
expected cell frequency of oral corticosteroid use. From a different perspective, oral 
corticosteroid users were more likely to have a diagnosis of osteoporosis.  An additional 
noteworthy difference was that although the ODNOTX intervention group had a higher 
than expected cell frequency of oral corticosteroid use, relative to the other osteoporosis 
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diagnosis intervention groups, the ODNOTX intervention group had a smaller row 
percentage and cell chi-square, indicating fewer oral corticosteroid users relative to the 
other intervention groups.  The corticosteroid use cell chi-square for the ODAHRT 
intervention contributed most to the overall chi-square.  Table 3.14 shows the frequency 
distribution of the cohort by intervention group and oral corticosteroid use. 
Table 3.14 ITT: Frequency distribution of the cohort by intervention group and oral 
corticosteroid use 





































































*χ2 (4, n = 49,851) = 603.56, p < 0.0001 
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 The above frequency distribution describes the distribution of intervention groups 
by oral corticosteroid use.  However, as previously described, this study assesses the 
impact of this risk factor by categorizing oral corticosteroid use by dose and duration.  
Therefore, of more interest, is the distribution of patients by oral corticosteroid dose and 
duration categories and intervention groups (patients not on an oral corticosteroid were 
excluded from the analysis).  A chi-square test for independence showed that the 
relationship between intervention groups and oral corticosteroid dose and duration 
categories was not independent χ2 (44, n = 9,797) = 469.86, p < 0.0001.  Examination of 
observed cell frequencies vs. expected cell frequencies and cell chi-squares revealed 
significant differences for the distribution of patients by corticosteroid dose and duration 
categories within each intervention group and between intervention groups.  In general, 
active intervention groups (ODA, ODAHRT, and ODHRT) had higher than expected cell 
frequencies for the oral corticosteroid dose and duration categories, where corticosteroid 
duration exceeded one-year, indicating that long-term oral corticosteroid users were more 
likely to receive an active intervention.  Table 3.15 shows the distribution of the cohort 








Table 3.15 ITT: Frequency distribution of the cohort by intervention group and oral corticosteroid dose and duration categories 


























































































































































* χ2 (44, n = 9,797) = 469.86, p < 0.0001 
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Table 3.15 ITT: Frequency distribution of the cohort by intervention group and oral corticosteroid dose and duration categories 
(cont’d) 









































































































































































* χ2 (44, n = 9,797) = 469.86, p < 0.0001 
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Non Intent-To-Treat Cohort 
In the non intent-to-treat cohort, a total of 7,193 (18.79%) patients used an oral 
corticosteroid during the study (assessment period and/or observation period).  A chi-
square test for independence revealed that the relationship between intervention groups 
and oral corticosteroid use was not independent χ2 (4, n = 38,283) = 530.83, p < 0.0001.  
Examination of observed cell frequencies vs. expected cell frequencies and cell chi-
squares revealed significant differences for the distribution of patients who used an oral 
corticosteroid by intervention group.  The same oral corticosteroid use distributional 
differences observed for the intent-to-treat cohort were present in the non intent-to-treat 
cohort.  Table 3.16 shows the frequency distribution of the cohort by intervention group 













Table 3.16 Non-ITT: Frequency distribution of the cohort by intervention group and oral 
corticosteroid use 





































































* χ2 (4, n = 38,283) = 530.83, p < 0.0001 
Table 3.17 shows the frequency distribution of the cohort by intervention group 
and oral corticosteroid dose and duration categories.  A chi-square test for independence 
showed that the relationship between intervention groups and oral corticosteroid dose and 
duration categories was not independent χ2 (44, n = 7,193) = 385.04, p < 0.0001.  In the 
non intent-to-treat cohort, only the ODA and ODAHRT intervention groups had higher 
than expected cell frequencies in oral corticosteroid dose and duration categories, where 
corticosteroid duration exceeded one-year. 
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Table 3.17 Non-ITT: Frequency distribution of the cohort by intervention group and oral corticosteroid dose and duration 
categories 


























































































































































* χ2 (44, n = 7,193) = 385.04, p < .0001 
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Table 3.17 Non-ITT: Frequency distribution of the cohort by intervention group and oral corticosteroid dose and duration 
categories (cont’d) 











































































































































































In the intent-to-treat cohort, a total of 16,665 (33.41%) patients used a statin 
during the study (assessment period and/or observation period).  A chi-square test for 
independence revealed that the relationship between intervention groups and statin use 
was not independent χ2 (4, n = 49,851) = 168.49, p < 0.0001.  Examination of observed 
cell frequencies vs. expected cell frequencies and cell chi-squares revealed significant 
differences for the distribution of patients who used a statin by intervention group for the 
ODA and NOODTX intervention groups.  The ODA intervention group had a higher than 
expected cell frequency of statin use, whereas the NOODTX intervention group had a 
lower than expected cell frequency of statin use.  Table 3.18 shows the frequency 












Table 3.18 ITT: Frequency distribution of the cohort by intervention group and statin use 




































































* χ2 (4, n = 49,851) = 168.49, p < 0.0001 
 As with oral corticosteroid use, this study assesses the impact of this risk factor by 
categorizing statin use by dose and duration.  A chi-square test for independence showed 
that the relationship between intervention groups and statin dose and duration categories 
was not independent χ2 (20, n = 16,655) = 381.15, p < 0.0001.  Examination of observed 
cell frequencies vs. expected cell frequencies and cell chi-squares revealed significant 
differences for the distribution of patients by statin dose and duration categories for 
intervention groups ODA, ODAHRT and NOODTX. The ODA and ODAHRT 
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intervention groups had higher than expected cell frequencies in the low dose duration > 
2-years category and the  high dose duration > 2-years category whereas the ODNOTX 
intervention group had a lower than expected cell frequencies in the same statin dose and 
duration categories.  Other statin dose and duration category distributional differences 
were not overtly apparent for the other intervention groups. Table 3.19 shows the 




Table 3.19 ITT: Frequency distribution of the cohort by intervention group and statin dose and duration categories  









































































































































































* χ2 (20, n = 16,655) = 381.15, p < 0.0001
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Non Intent-To-Treat Cohort 
In the non intent-to-treat cohort, a total of 12,473 (32.58%) patients used a statin 
during the study (assessment period and/or observation period).  A chi-square test for 
independence revealed that the relationship between intervention groups and statin use 
was not independent χ2 (4, n = 38,283) = 178.84, p < 0.0001.  The significant differences 
observed for the distribution paralleled those of the intent-to-treat cohort.  Table 3.20 
















Table 3.20 Non- ITT: Frequency distribution of intervention group by statin use 





































































* χ2 (4, n = 38,283) = 178.84, p < 0.0001 
 A chi-square test for independence showed that the relationship between 
intervention groups and statin dose and duration categories was not independent χ2 (20, n 
= 16,655) = 278.74, p < 0.0001.  Examination of observed cell frequencies vs. expected 
cell frequencies and cell chi-squares revealed the same significant differences for the 
distribution of patients by statin dose and duration categories for intervention groups 
ODA, ODAHRT and NOODTX as observed in the intent-to-treat cohort. Table 3.21 
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Table 3.21 Non-ITT: Frequency distribution of the cohort by intervention group and statin dose and duration categories 













































































































































































 The frequency of three-year intervention compliance was determined for the 
ODA, ODAHRT, and ODHRT intervention groups.  Patients were defined as being 
compliant with the intervention if they maintained an 80% or greater medication 
possession ratio (MPR) during the three-year observation period.  For the intent-to-treat 
cohort, the ODA intervention group had the highest compliance (21.79%), followed by 
the ODAHRT (19.45%) and ODHRT (14.44%) intervention groups.  A chi-square test 
for independence revealed that the relationship between intervention groups and 
intervention compliance was not independent χ2 (2, n = 10,656) = 41.24, p < 0.0001.  
Examination of observed cell frequencies vs. expected cell frequencies and cell chi-
squares revealed significant differences for the distribution of patients who were 
compliant by intervention group.  The ODA intervention group had a higher than 
expected cell frequency for compliance, whereas the ODHRT intervention group had a 
lower than expected cell frequency for compliance.  Table 3.22 shows the frequency 








Table 3.22 ITT: Frequency distribution of the cohort by intervention group and 
intervention compliance  













































* χ2 (2, n = 10,656) = 41.24, p < 0.0001 
 
 To further examine the extent of compliance for the three active intervention 
groups, frequency distributions were performed for each active intervention group by 
intervention compliance for the intent-to-treat cohort only.  The frequency distribution of 
intervention compliance for the ODAHRT intervention group reflects intervention 
compliance with alendronate only, since the intervention inclusion criteria for ODAHRT 
intervention group did not require an index-prescription date for the HRT component.  
The majority of patients in each intervention group had medication possession ratios < 
50% (ODA = 64.76%, ODHRT = 67.78%, and ODAHRT = 62.10%).  Tables 3.23 to 
3.25 show the frequency distributions of intervention compliance for the ODA, ODHRT, 
and ODAHRT intervention groups, respectively.  
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Table 3.23 ITT: Frequency distribution of the ODA intervention group by intervention 
compliance 





0 to <10 784 16.89 784 16.89 
10 to <20 544 11.72 1328 28.60 
20 to <30 472 10.17 1800 38.77 
30 to <40 626 13.48 2426 52.25 
40 to <50 581 12.51 3007 64.76 
50 to <60 254 5.47 3261 70.23 
60 to <70 178 3.83 3439 74.07 
70 to <80 192 4.14 3631 78.20 
80 to <90 183 3.94 3814 82.15 
> 90 829 17.85 4643 100.00 
Table 3.24 ITT: Frequency distribution of the ODHRT intervention group by intervention 
compliance  





0 to <10 299 18.46 299 18.46 
10 to <20 179 11.05 478 29.51 
20 to <30 169 10.43 647 39.94 
30 to <40 242 14.94 889 54.88 
40 to <50 209 12.90 1098 67.78 
50 to <60 114 7.04 1212 74.81 
60 to <70 99 6.11 1311 80.93 
70 to <80 75 4.63 1386 85.56 
80 to <90 76 4.69 1462 90.25 







Table 3.25 ITT: Frequency distribution of the ODAHRT intervention group by 
compliance 





0 to <10 516 11.75 516 11.75 
10 to <20 468 10.66 984 22.41 
20 to <30 505 11.50 1489 33.91 
30 to <40 649 14.78 2138 48.69 
40 to <50 589 13.41 2727 62.10 
50 to <60 249 5.67 2976 67.78 
60 to <70 159 3.62 3135 71.40 
70 to <80 149 3.39 3284 74.79 
80 to <90 195 4.44 3479 79.23 
> 90 912 20.77 4391 100.00 
 
Non Intent-To-Treat Cohort 
For the non intent-to-treat cohort, the ODA intervention group (22.81%) also had 
the highest compliance, followed by the ODAHRT (20.44%) and ODHRT (15.56%) 
intervention groups.  A chi-square test for independence revealed that the relationship 
between intervention groups and intervention compliance was not independent χ2 (2, n = 
8,696) = 27.15, p < 0.0001.  Examination of observed cell frequencies vs. expected cell 
frequencies and cell chi-squares revealed the same significant differences for the 
distribution of patients who were compliant by intervention group that was observed in 
the intent-to-treat cohort for the non intent-to-treat cohort. Table 3.26 shows the 





Table 3.26 Non-ITT: Frequency distribution of the cohort by intervention group and 
intervention compliance 



























































 The purpose of this objective was to assess the epidemiology of osteoporotic 
fracture in the study population.  In the first part, the simple (unadjusted for covariates) 
three-year cumulative incidence and relative risk of an osteoporotic fracture was 
determined for the cohort as a whole and by intervention group.  In the second part, the 
simple three-year cumulative incidence and relative risk of an osteoporotic fracture was 
determined for each risk factor.  As previously discussed, two analyses were performed, 
one using an intent-to-treat study design and another using a non intent-to-treat study 
design. 
Cumulative Incidence and Relative Risk of Osteoporotic Fracture for the Cohort 
and Intervention Groups 
Intent-To-Treat Cohort 
In the intent-to-treat cohort, 49,851 patients were at risk for osteoporotic fracture 
during the observation period.  The three-year cumulative incidence of any osteoporotic 
fracture for the cohort was 2.48% (6.1% in patients with an osteoporosis diagnosis; 
0.40% in patients without an osteoporosis diagnosis).  Examination of the three-year 
cumulative incidence by fracture type revealed that vertebral fracture had the highest 
cumulative incidence 0.98%, followed by wrist (0.87%) and hip (0.64%).   
 Using the ODNOTX intervention group as the reference intervention group for 
the other intervention groups, the relative risk of osteoporotic fracture was calculated in 
addition to the three-year cumulative incidence for each intervention group.  With few 
exceptions (hip), the ODA intervention group had a higher relative risk of osteoporotic 
fracture and for each specific type of osteoporotic fracture and the ODAHRT, ODHRT, 
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and NOODTX groups had a lower relative risk for osteoporotic fracture and for each 
specific type of osteoporotic fracture when compared to the ODNOTX intervention 
group.  Among the active intervention groups, the ODHRT intervention group had the 
lowest relative risk for hip and wrist fracture, whereas the ODAHRT intervention group 
had the lowest relative risk for vertebral fracture.  Table 3.27 shows the three-year 


















Table 3.27 ITT: Three-year cumulative incidence and relative risk of fracture for cohort 











Hip 82 4,645 1.77 0.91 
Vertebral 114 4,645 2.45 1.04 
Wrist 136 4,645 2.93 1.27 ODA 
Total 332 4,645 7.15 1.08 
Hip 51 4,391 1.16 0.60 
Vertebral 64 4,391 1.46 0.62 
Wrist 84 4,391 1.91 0.83 ODAHRT 
Total 199 4,391 4.53 0.69 
Hip 15 1,620 0.93 0.48 
Vertebral 37 1,620 2.28 0.97 
Wrist 29 1,620 1.79 0.78 ODHRT 
Total 81 1,620 5.00 0.76 
Hip 147 7,568 1.94  
Vertebral 179 7,568 2.37  
Wrist 174 7,568 2.30  ODNOTX 
Total 500 7,568 6.61  
Hip 23 31,627 0.07 0.04 
Vertebral 94 31,627 0.30 0.13 
Wrist 9 31,627 0.03 0.01 NOODTX 
Total 126 31,627 0.40 0.06 
Hip 318 49,851 0.64  
Vertebral 488 49,851 0.98  
Wrist 432 49,851 0.87  Cohort 
Total 1,238 49,851 2.48  
* Reference group: ODNOTX 
 
Non Intent-To-Treat Cohort 
 
In the non intent-to-treat cohort, 38,283 patients were at risk for osteoporotic 
fracture during the observation period.  The three-year cumulative incidence of 
osteoporotic fracture for the cohort was 1.93% (5.2% in patients with an osteoporosis 
diagnosis; 0.24% in patients without an osteoporosis diagnosis).  In contrast to the intent-
 189
to-treat cohort, wrist fracture had the highest cumulative incidence 0.74%, followed by 
vertebral (0.62%) and hip (0.56%).   
As observed in the intent-to-treat cohort, the ODA intervention group had a 
higher relative risk of osteoporotic fracture and the ODAHRT, ODHRT, and NOODTX 
groups had a lower relative risk for osteoporotic fracture compared to the ODNOTX 
intervention group.  Also as observed in the intent-to-treat cohort, among the active 
intervention groups, the ODHRT intervention group had the lowest relative risk for hip 
and wrist fracture, whereas the ODAHRT intervention group had the lowest relative risk 
for vertebral fracture.  Table 3.28 shows the three-year cumulative incidence and relative 


























Hip 68 3,845 1.77 0.90 
Vertebral 72 3,845 1.87 1.15 
Wrist 97 3,845 2.52 1.21 ODA 
Total 237 3,845 6.16 1.09 
Hip 45 3,797 1.19 0.60 
Vertebral 36 3,797 0.95 0.58 
Wrist 76 3,797 2.00 0.96 ODAHRT 
Total 157 3,797 4.13 0.73 
Hip 5 1,054 0.47 0.24 
Vertebral 15 1,054 1.42 0.88 
Wrist 18 1,054 1.71 0.82 ODHRT 
Total 38 1,054 3.61 0.63 
Hip 85 4,313 1.97  
Vertebral 70 4,313 1.62  
Wrist 90 4,313 2.09  ODNOTX 
Total 245 4,313 5.68  
Hip 12 25,274 0.05 0.02 
Vertebral 45 25,274 0.18 0.11 
Wrist 3 25,274 0.01 0.01 NOODTX 
Total 60 25,274 0.24 0.04 
Hip 215 38,283 0.56  
Vertebral 238 38,283 0.62  
Wrist 284 38,283 0.74  Cohort 
Total 737 38,283 1.93  
* Reference group: ODNOTX 
 
Cumulative Incidence and Relative Risk of Osteoporotic Fracture by Risk Factor 
Intent-To-Treat Cohort 
 For the intent-to-treat cohort, the cumulative incidence and relative risk of 
osteoporotic fracture was determined for each risk factor by first determining the 
incidence of osteoporotic fracture in the risk factor exposed and non-exposed 
populations, then dividing the incidence of the risk factor exposed population by the 
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incidence of the risk factor non-exposed population.  The exception to this methodology 
was for the risk factor age, where age was categorized by 5-year intervals.  For this risk 
factor, the first age category (50-54) served as the reference category.   
 In the intent-to-treat cohort, literature reports of an increased risk of osteoporotic 
fracture were substantiated for risk factors: age, osteoporosis diagnosis, previous 
osteoporotic fracture, and oral corticosteroid use.  The relative risk of fracture increased 
with each successive increase in age-category, except in the 65-69 age-category, with the 
relative risk of osteoporotic fracture over 8-fold higher in the ≥ 85 age-category.  A 
diagnosis of osteoporosis was shown to substantially increase the risk of osteoporotic 
fracture (RR = 15.32).  Similarly, a prior osteoporotic fracture increased risk of a 
subsequent fracture over 11-fold.  The relative risk of an osteoporotic fracture associated 
with corticosteroid use and statin use was examined two different ways: the first 
examined the relative risk regardless of dose and duration of exposure; the second 
considered dose and duration of exposure.  Exposure to oral corticosteroids, regardless of 
dose and duration, increased the risk of fracture by 36%.  Examination of oral 
corticosteroid dose and duration categories revealed that, in general, the relative risk of 
osteoporotic fracture substantially increased when the duration of exposure exceeded 
one-year at all doses.  Evidence supporting a dose-response relationship was inconsistent.  
Statin use was found to have a protective effect at both low and high doses, more so when 
duration of exposure was less than two years.  Here again, evidence supporting a dose-
response relationship was weak.  Intervention compliance was shown to be protective.   
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Age Category     
  50-54 96 9,360 1.03  
  55-59 183 9,452 1.94 1.89 
  60-64 332 13,121 2.53 2.47 
  65-69 155 6,828 2.27 2.21 
  70-74 150 4,523 3.32 3.23 
  75-79 160 3,965 4.04 3.93 
  80-84 99 1,732 5.72 5.57 
  85 Plus 73 870 8.39 8.18 
Osteoporosis Diagnosis     
  Exposed 1,112 18,224 6.10 15.32 
  Non-exposed 126 31,627 0.40  
Previous Fracture     
  Exposed 136 549 24.77 11.08 
  Non-exposed 1,102 49,302 2.24  
Corticosteroid Use     
  Exposed 309 9,797 3.15 1.36 
  Non-exposed 929 40,054 2.32  
Corticosteroid Use (Dose; Duration)     
  < 5mg; ≤ 180 days 6 494 1.21 0.52 
  < 5mg; > 180 ≤ 365 days 0 38 0.00 0.00 
  < 5mg; > 365 days 37 429 8.62 3.72 
  ≥ 5 ≤ 10mg; ≤ 180 days 44 1,680 2.62 1.13 
  ≥ 5 ≤ 10mg; > 180 ≤ 365 days 3 225 1.33 0.57 
  ≥ 5 ≤ 10mg; > 365 days 47 712 6.60 2.85 
  > 10 ≤ 20mg; ≤ 180 days 44 1,976 2.23 0.96 
  > 10 ≤ 20mg; > 180 ≤ 365 days 8 195 4.10 1.77 
  > 10 ≤ 20mg; > 365 days 27 300 9.00 3.88 
  > 20mg; ≤ 180 days 83 3,587 2.31 1.00 
  > 20mg; > 180 ≤ 365 days 8 114 7.02 3.03 
  > 20mg; > 365 days 2 47 4.26 1.83 
* Reference category for age was the 50-54 age-category 















Statin Use     
  Exposed 308 16,655 1.85 0.66 
  Not Exposed 930 33,196 2.80  
Statin Use (Dose; Duration)     
  Low; ≤ 1 year 60 4,827 1.24 0.44 
  Low; > 1 ≤  2 years 58 3,238 1.79 0.64 
  Low; > 2 years 114 4,598 2.48 0.88 
  High; ≤ 1 year 14 1,316 1.06 0.38 
  High; > 1 ≤  2 years 19 1,103 1.72 0.61 
  High; > 2 years 43 1,573 2.73 0.98 
Intervention Compliance     
  ODA     
    Exposed 59 1,012 5.83 0.78 
    Not Exposed 273 3,633 7.51  
  ODHRT     
    Exposed 27 854 3.16 0.65 
    Not Exposed 172 3,537 4.86  
  ODAHRT     
    Exposed 9 234 3.85 0.74 
    Not Exposed 72 1,386 5.20  
* Reference category was the non-exposed   
Non Intent-To-Treat Cohort 
 Overall, the relative risks associated with the risk factors in the non intent-to-treat 
cohort paralleled those in the intent-to-treat cohort.  However, three discrepancies were 
found.  First, the relative risk associated with a diagnosis of osteoporosis decreased from 
15.32 for the intent-to-treat cohort to 10.55 for the non intent-to-treat cohort.  Second, the 
relative risk associated with previous osteoporotic fracture increased from 11.08 in the 
intent-to-treat cohort to 21.92 in the non intent-to-treat cohort.  Lastly, exposure to high 
dose statin for > 2 years was no longer found to be protective.  Table 3.30 shows the 
three-year cumulative incidence and relative risk of fracture for the cohort by risk factor. 
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Age Category     
  50-54 58 7,044 0.82  
  55-59 101 7,183 1.41 1.71 
  60-64 173 9,659 1.79 2.18 
  65-69 96 5390 1.78 2.16 
  70-74 98 3,636 2.70 3.27 
  75-79 107 3,194 3.35 4.07 
  80-84 56 1,418 3.95 4.80 
  85 Plus 48 759 6.32 7.68 
Osteoporosis Diagnosis     
  Exposed 72 389 18.51 10.55 
  Not Exposed 665 37,894 1.75  
Previous Fracture     
  Exposed 677 13,009 5.20 21.92 
  Not Exposed 60 25,274 0.24  
Corticosteroid Use     
  Exposed 180 7,193 2.50 1.40 
  Not Exposed 557 31,090 1.79  
Corticosteroid Use (Dose; Duration)     
  < 5mg; ≤ 180 days 3 363 0.83 0.46 
  < 5mg; > 180 ≤ 365 days 0 27 0.00 0.00 
  < 5mg; > 365 days 22 293 7.51 4.19 
  ≥ 5 ≤ 10mg; ≤ 180 days 33 1,247 2.65 1.48 
  ≥ 5 ≤ 10mg; > 180 ≤ 365 days 1 159 0.63 0.35 
  ≥ 5 ≤ 10mg; > 365 days 22 485 4.54 2.53 
  > 10 ≤ 20mg; ≤ 180 days 26 1,456 1.79 1.00 
  > 10 ≤ 20mg; > 180 ≤ 365 days 4 145 2.76 1.54 
  > 10 ≤ 20mg; > 365 days 14 213 6.57 3.67 
  > 20mg; ≤ 180 days 51 2,691 1.90 1.06 
  > 20mg; > 180 ≤ 365 days 3 79 3.80 2.12 
  > 20mg; > 365 days 1 35 2.86 1.59 
* Reference category for age was the 50-54 age-category 




Table 3.30 Non-ITT: Three-year incidence and relative risk of fracture for the cohort by 








Statin Use     
   Exposed 189 12,473 1.52 0.71 
  Not Exposed 548 25,810 2.12  
Statin Use (Dose; Duration)     
  Low; ≤ 1 year 36 3,623 0.99 0.47 
  Low; > 1 ≤  2 years 32 2,377 1.35 0.63 
  Low; > 2 years 73 3,546 2.06 0.97 
  High; ≤ 1 year 9 969 0.93 0.44 
  High; > 1 ≤  2 years 10 771 1.30 0.61 
  High; > 2 years 29 1,187 2.44 1.15 
Intervention Compliance     
  ODA     
    Exposed 43 877 4.90 0.75 
    Not Exposed 194 2,968 6.54  
  ODAHRT     
    Exposed 24 776 3.09 0.70 
    Not Exposed 133 3,021 4.40  
  ODHRT     
    Exposed 5 164 3.05 0.82 
    Not Exposed 33 890 3.71  













OBJECTIVES 2 AND 3 
Objective 1 determined the incidence and unadjusted relative risk of osteoporotic 
fracture for the cohort, each intervention group, and for the risk factors and covariates.  
The purpose of objectives 2 and 3 were to determine the effectiveness of the interventions 
in the prevention of osteoporotic fracture (objective 2) and to determine the significance 
of the study’s risk factors and other covariates in the prediction of osteoporotic fracture 
events (objective 3), while controlling for exposure to risk factors.  A series of logistic 
regression analyses was performed to accomplish both of these objectives.  The 
retrospective cohort design used for objectives two and three is shown in Figure 3.1. 
 
Figure 3.1 Retrospective Cohort Study Design 
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 For objectives 2 and 3, the cohort was followed for the occurrence of any type of 
osteoporotic fracture event as well as for the occurrence of the specific types of 
osteoporotic fracture events (hip, vertebral, and wrist).  Data from the cohort were 
analyzed to compare the risk of fracture between the intervention groups.  Exposure to 
treatment intervention was determined, as previously described, using an intent-to-treat 
design (exposure measured at the onset of the observation period) and a non intent-to-
treat design (exposure measured throughout the observation period).   
 Two series of logistic regression analyses were performed for objectives 2 and 3.  
The first series of logistic regression analyses, which were broader in scope, examined 
the risk of fracture for all five intervention groups (ODA, ODAHRT, ODHRT, 
ODNOTX, and NOODTX).  Inclusion of all five intervention groups provided the ability 
to examine the increased risk of osteoporotic fracture associated with a diagnosis of 
osteoporosis.  The first series of logistic regression analyses also explored the 
significance of all the risk factors and covariates; the primary purpose of which was to 
identify a set of more clinically relevant risk factors.   
 The second series of logistic regression analyses were more clinically focused.   
In this series of logistic regression analyses, the NOODTX intervention group was 
removed from the analyses, thus allowing a more focused analysis of the effectiveness of 
the active intervention groups (ODA, ODAHRT, and ODHRT) with the comparator 
intervention group (ODNOTX).  In addition, given the results of the previous analyses, a 
decision was made to treat the risk factor age as a continuous variable instead of as a 
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categorical variable and to only assess the risk of osteoporotic fracture associated with 
long-term corticosteroid use (length of oral corticosteroid use > 1-year, for all doses).    
 In both the first series and second series of logistic regression analyses, four 
separate logistic regressions were performed, one for each type of fracture (any fracture, 
hip fracture, vertebral fracture, and wrist fracture), to determine the risk of fracture 
(intervention effectiveness) for each intervention group   For both the first and second 
series of logistic regression analyses, the significance of the risk factors and other 
covariates in the predication of osteoporotic fracture was determined from the output of 
the logistic regression analysis for any fracture.  While both the treatment categories and 
covariates of interest were included in each regression analysis, the results of the 
treatment effects (objective 2 results) are described in separate tables from the covariate 
results (objective 3 results).  The results from the first series (FS) of logistic regressions 
for intervention effectiveness and risk factor significance will be presented first for the 
intent-to-treat cohort and will be followed by the results for the non intent-to-treat cohort.  
The results from the second series (SS) of logistic regression analyses are presented last 
and will follow the same order as the first.   
First Series of Logistic Regression Analyses 
 Intervention Effectiveness (Intent-To-Treat Cohort) 
The binary logit regression model for the intent-to-treat cohort showed that the 
ODAHRT and NOODTX intervention groups had a significantly lower risk of 
experiencing an osteoporotic fracture event compared to the ODNOTX group (adjusted 
odds ratio (OR) = 0.702, 95% Wald Confidence Limits (CI) = 0.579 to 0.851, p = 0.0003; 
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OR = 0.065, 95% CI = 0.053 to 0.080, respectively).  The ODAHRT and NOODTX 
intervention groups also had a significantly lower risk of experiencing a hip or vertebral 
osteoporotic fracture event compared to the ODNOTX intervention group (hip: OR = 
0.657, 95% CI = 0.463 to 0.934, p = 0.0192; OR = 0.039, 95% CI = 0.025 to 0.061, p < 
0.0001, respectively; vertebral: OR = 0.576, 95% CI = 0.416 to 0.797, p = 0.0009; OR = 
0.140, 95% CI = 0.108 to 0.182, p < 0.0001, respectively).  Only the NOODTX 
intervention group was shown to have a statistically significant lower risk of wrist 
fracture when compared to the ODNOTX intervention group (OR = 0.013, 95% CI = 
0.007 to 0.025, p = < 0.0001).  Table 3.31 shows the logistic regression intervention 
effectiveness parameter estimates. 
 Risk Factor Significance (Intent-To-Treat Cohort) 
Risk factors: age, previous osteoporotic fracture, and oral corticosteroid use were 
shown to significantly increase the risk of osteoporotic fracture, whereas ODAHRT 
intervention compliance and statin use were shown to significantly decrease the risk of 
osteoporotic fracture.  Using age-category 50 to 54 as the reference age-category, the risk 
of experiencing an osteoporotic fracture increased significantly with each successive 
increase in age-category (age-category 55 to 59: OR = 1.412, 95% CI = 1.082 to 1.843, p 
= 0.0112; age-category 60 to 64: OR = 1.601, 95% CI = 1.252 to 2.048, p = 0.0002; age-
category 65 to 69: OR = 1.898, 95% CI = 1.435 to 2.512, p < 0.0001; age-category 70 to 
74: OR = 2.713, 95% CI = 2.042 to 3.604, p < 0.0001; age-category 75 to 79: OR = 
3.108, 95% CI = 2.349 to 4.112, p < 0.0001; age-category 80 to 84: OR = 4.730, 95% CI 
= 3.456 to 6.474, p < 0.0001; age-category ≥ 85: OR = 6.194, 95% CI = 4.307 to 8.910, p 
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< 0.0001).  Likewise, a previous osteoporotic fracture was shown to significantly increase 
the risk of a subsequent osteoporotic fracture (OR = 4.229, 95% CI = 3.358 to 5.326, p < 
0.0001).   
Evidence supporting an increased risk of osteoporotic fracture relative to oral 
corticosteroid dose and duration use was not as conclusive.  Only corticosteroid 
dose/duration categories <5mg/>365 days and >10≤20mg/>365 days were found to 
significantly increase the risk of osteoporotic fracture (corticosteroid dose/duration 
category <5mg/>365 days: OR = 1.674, 95% CI = 1.119 to 2.503, p = 0.0122; 
corticosteroid dose/duration category: >10≤20mg/>365 days: OR = 2.153, 95% CI = 
1.359 to 3.413, p = 0.0011).  Although not statistically significant, corticosteroid 
dose/duration categories ≥5≤10mg/>365 days and >20mg/>180≤365 days approached the 
level of statistical significance.  The parameter estimate for corticosteroid dose/duration 
category <5mg/>180≤ 365 days is probably erroneous due to small sample size and no 
fracture events.  
Those patients who were compliant in the ODAHRT intervention group were 
shown to have a minimal additional protective effect when compared to the overall 
protective effect for the ODAHRT intervention group (OR = 0.616, 95% CI = 0.394 to 
0.963, p = 0.0336 versus OR = 0.702, 95% CI = 0.579 to 0.851, p = 0.0003, respectively).  
Statin use was shown to have a statistically significant protective effective for 
osteoporotic fracture for low dose statin for each level of duration (statin dose/duration 
category: low/≤1 year: OR = 0.417, 95% CI = 0.313 to 0.556, p < 0.0001; statin 
dose/duration category: low/>1≤2 years: OR = 0.626, 95% CI = 0.471 to 0.834, p < 
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0.0013; statin dose/duration category: low/>2 years: OR = 0.653, 95% CI = 0.526 to 
0.811, p = 0.0001) and for high dose statin dose/duration category - high/≤ 1year (OR = 
0.418, CI = 0.239 to 0.731, p = 0.0022).  Table 3.32 shows the logistic regression risk 
factor parameter estimates. 
Table 3.31 FS ITT: Logistic regression intervention effectiveness parameter estimates 
 Adjusted Odds Ratio 
Fracture Type 
  Intervention Group 







  ODA -0.0893 0.3109 0.915 0.770 1.087 
  ODAHRT -0.3537 0.0003 0.702 0.579 0.851 
  ODHRT -0.1405 0.3185 0.869 0.659 1.145 
  NOODTX -2.7299 < 0.0001 0.065 0.053 0.080 
Hip 
  ODA -0.2710 0.0858 0.763 0.560 1.039 
  ODAHRT -0.4195 0.0192 0.657 0.463 0.934 
  ODHRT -0.5186 0.0913 0.595 0.326 1.087 
  NOODTX -3.2398 < 0.0001 0.039 0.025 0.061 
Vertebral 
  ODA -0.1387 0.3180 0.871 0.663 1.143 
  ODAHRT -0.5515 0.0009 0.576 0.416 0.797 
  ODHRT 0.0966 0.6355 1.101 0.739 1.642 
  NOODTX -1.9667 < 0.0001 0.140 0.108 0.182 
Wrist 
  ODA 0.0972 0.4665 1.102 0.848 1.431 
  ODAHRT -0.1950 0.1877 0.823 0.616 1.100 
  ODHRT -0.1522 0.4850 0.859 0.560 1.317 
  NOODTX -4.3611 < 0.0001 0.013 0.007 0.025 






Table 3.32 FS ITT: Logistic regression risk factor parameter estimates 
 Adjusted Odds Ratio 







55 - 59 0.3448 0.0112 1.412 1.082 1.843 
60 – 64 0.4708 0.0002 1.601 1.252 2.048 
65 – 69 0.6410 < 0.0001 1.898 1.435 2.512 
70 – 74 0.9980 < 0.0001 2.713 2.042 3.604 
75 – 79 1.1339 < 0.0001 3.108 2.349 4.112 
80 – 84 1.5540 < 0.0001 4.730 3.456 6.474 
≥ 85 1.8236 < 0.0001 6.194 4.307 8.910 
Intervention Compliance 
ODA 80% MPR -0.3025 0.0636 0.739 0.537 1.017 
ODHRT 80% MPR -0.2645 0.4936 0.768 0.360 1.637 
ODAHRT 80% MPR -0.4851 0.0336 0.616 0.394 0.963 
Corticosteroid Use 
<5mg; ≤180 days -0.6829 0.1017 0.505 0.223 1.144 
<5mg; >180≤365 days -11.2078 0.9629 < 0.0001 < 0.0001 > 999.99 
<5mg; >365 days 0.5150 0.0122 1.674 1.119 2.503 
≥5≤10mg; ≤180 days -0.0159 0.9265 0.984 0.702 1.380 
≥5≤10mg; >180≤ 365 days -0.7365 0.2108 0.479 0.151 1.517 
≥5≤10mg; >365 days 0.3269 0.0671 1.387 0.977 1.967 
>10≤ 20mg; ≤180 days -0.0982 0.5531 0.906 0.655 1.254 
>10≤ 20mg; >180≤365 days 0.3392 0.3664 1.404 0.673 2.930 
>10≤ 20mg; >365 days 0.7671 0.0011 2.153 1.359 3.413 
>20mg; ≤180 days -0.0364 0.7679 0.964 0.757 1.228 
>20mg; >180≤365 days 0.8104 0.0656 2.249 0.949 5.328 
>20mg; >365 days 0.5337 0.4716 1.705 0.399 7.293 
Statin Use      
Low; ≤1 year -0.8743 < 0.0001 0.417 0.313 0.556 
Low; >1≤ 2 years -0.4679 0.0013 0.626 0.471 0.834 
Low; >2 years -0.4263 0.0001 0.653 0.526 0.811 
High; ≤1 year -0.8720 0.0022 0.418 0.239 0.731 
High; >1≤ 2 years -0.4481 0.0756 0.639 0.390 1.047 
High; >2 years -0.2917 0.1025 0.747 0.526 1.060 
Previous Fracture      
Previous Fracture 1.4421 < 0.0001 4.229 3.358 5.326 
* Bolded = p < 0.05 
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Intervention Effectiveness (Non Intent-To-Treat Cohort) 
Comparison of the intervention effectiveness results of obtained for the non 
intent-to-treat cohort to the intent-to-treat cohort revealed two major differences.  First, 
the ODAHRT intervention group was found only to have a statistically significant lower 
risk of vertebral fracture.  Second,   the ODHRT intervention group was found to have a 
statistically significant lower risk of hip fracture.  Table 3.33 provides the intervention 
effectiveness parameter estimates for the non intent-to-treat cohort. 
Table 3.33 FS Non-ITT: Logistic regression intervention effectiveness parameter 
estimates 
 Adjusted Odds Ratio 
Fracture Type 
  Intervention Group 







  ODA -0.0106 0.9235 0.989 0.798 1.228 
  ODAHRT -0.2160 0.0686 0.806 0.639 1.017 
  ODHRT -0.1815 0.3615 0.834 0.565 1.232 
  NOODTX -3.0712 < 0.0001 0.046 0.035 0.062 
Hip 
  ODA -0.1605 0.3827 0.852 0.594 1.221 
  ODAHRT -0.3015 0.1423 0.740 0.494 1.107 
  ODHRT -1.3053 0.0281 0.271 0.085 0.869 
  NOODTX -3.6087 < 0.0001 0.027 0.015 0.050 
Vertebral 
  ODA 0.0589 0.7570 1.061 0.730 1.540 
  ODAHRT -0.5129 0.0263 0.599 0.381 0.941 
  ODHRT 0.2427 0.4209 1.275 0.706 2.302 
  NOODTX -2.0718 < 0.0001 0.126 0.085 0.186 
Wrist 
  ODA 0.0756 0.6507 1.079 0.777 1.496 
  ODAHRT -0.0395 0.8189 0.961 0.685 1.348 
  ODHRT -0.0833 0.7700 0.920 0.527 1.608 
  NOODTX -5.1456 < 0.0001 0.006 0.002 0.018 
* Bolded = p < 0.05 
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Risk Factor Significance (Non Intent-To-Treat Cohort) 
Comparison of risk factor significance results obtained for the non intent-to-treat 
cohort to the intent-to-treat cohort also revealed two major differences.  First, the 
ODAHRT intervention compliance no longer afforded an additional statistically 
significant protective effect.  Second,   the corticosteroid dose/duration category 
≥5≤10mg/>365 days no longer had a statistically significant increased risk of 
osteoporotic fracture.  Table 3.34 provides the logistic regression risk factor parameter 

















Table 3.34 FS Non-ITT: Logistic regression risk factor parameter estimates 
 Adjusted Odds Ratio 







55 - 59 0.2472 0.1573 1.280 0.909 1.804 
60 – 64 0.3784 0.0189 1.460 1.064 2.002 
65 – 69 0.5009 0.0056 1.650 1.158 2.352 
70 – 74 0.8533 < 0.0001 2.347 1.642 3.356 
75 – 79 1.0518 < 0.0001 2.863 2.021 4.055 
80 – 84 1.3157 < 0.0001 3.727 2.493 5.573 
≥ 85 1.7342 < 0.0001 5.665 3.633 8.832 
Intervention Compliance 
ODA 80% MPR -0.2991 0.1091 0.741 0.514 1.069 
ODHRT 80% MPR -0.4004 0.4600 0.670 0.232 1.938 
ODAHRT 80% MPR -0.4112 0.0881 0.663 0.413 1.063 
Corticosteroid Use 
<5mg; ≤180 days -0.8495 0.1477 0.428 0.135 1.351 
<5mg; >180≤365 days -11.0835 0.9699 <0.001 <0.001 >999.999
<5mg; >365 days 0.5497 0.0364 1.733 1.036 2.899 
≥5≤10mg; ≤180 days 0.1995 0.3154 1.221 0.827 1.802 
≥5≤10mg; >180≤ 365 days -1.3050 0.1961 0.271 0.037 1.961 
≥5≤10mg; >365 days 0.0797 0.7498 1.083 0.663 1.768 
>10≤ 20mg; ≤180 days -0.0790 0.7082 0.924 0.611 1.397 
>10≤ 20mg; >180≤365 days 0.1020 0.8448 1.107 0.399 3.076 
>10≤ 20mg; >365 days 0.7400 0.0138 2.096 1.163 3.776 
>20mg; ≤180 days -0.0780 0.6234 0.925 0.678 1.263 
>20mg; >180≤365 days 0.2589 0.7256 1.295 0.305 5.499 
>20mg; >365 days 0.2098 0.8394 1.233 0.162 9.389 
Statin Use      
Low; ≤1 year -0.8817 < 0.0001 0.414 0.284 0.603 
Low; >1≤ 2 years -0.5093 0.0082 0.601 0.412 0.877 
Low; >2 years -0.4071 0.0032 0.666 0.508 0.872 
High; ≤1 year -0.8086 0.0258 0.445 0.219 0.907 
High; >1≤ 2 years -0.4239 0.2186 0.654 0.333 1.286 
High; >2 years -0.2782 0.2153 0.757 0.488 1.176 
Previous Fracture      
Previous Fracture 1.2302 < 0.0001 3.422 2.527 4.634 
* Bolded = p < 0.05 
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Second Series of Logistic Regression Analyses 
 The second series of logistic regression analyses involved only those intervention 
groups with a diagnosis of osteoporosis.  The first series of regression analyses revealed 
that the risk of an osteoporotic fracture event increased with each successive increase in 
age-category.  Therefore, a decision was made to simplify age from a categorical to a 
continuous variable, and thereby capture the ordinal influence of this covariate.  The first 
series of regression analyses also suggested that possibly only long-term use of oral 
corticosteroids was associated with a statistically significant increased risk of 
osteoporotic fracture.  Therefore, in the second series of logistic regression analyses, only 
long-term (length of oral corticosteroid use >1-year, for all doses) oral corticosteroid use 
was assessed as a risk factor. 
 A comparison of the logistic regression intervention effectiveness parameter 
estimates of the second series of logistic regression analyses to the first series for both the 
intent-to-treat cohort and non intent-to-treat cohort revealed no differences as to which 
intervention groups had a statistically significant decreased risk of osteoporotic fracture 
among the active intervention groups.  Furthermore, there was little difference in the 
adjusted odds ratio point estimates. 
 Results from the second series of logistic regression risk factor parameter 
estimates for both the intent-to-treat and non intent-to-treat cohorts revealed that for each 
one-year increase in age there was a statistically significant increased risk of osteoporotic 
fracture (OR = 1.047, 95% CI = 1.039 to 1.055, p < 0.0001; OR = 1.047, 95% CI = 1.037 
to 1.056, p < 0.0001, respectively).  Results for both cohorts also showed that oral 
corticosteroid use for a duration of > 1-year was associated with a statistically significant 
increased risk of osteoporotic fracture (OR = 1.533, 95% CI = 1.220 to 1.977, p = 0.0003; 
OR = 1.379, 95% CI = 1.002 to 1.898, p = 0.0488, respectively).  As for the other risk 
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factors and covariates, the results obtained for the second series of logistic regression risk 
factor parameter estimates paralleled those obtained for their respective cohorts in the 
first series of logistic regression analyses.  Tables 3.35 to 3.38 show the results for the 
second series of logistic regressions.  
Table 3.35 SS ITT: Logistic regression intervention effectiveness parameter estimates 
 Adjusted Odds Ratio 
Fracture Type 
  Intervention Group 







  ODA -0.0810 0.3512 0.922 0.778 1.093 
  ODAHRT -0.3594 0.0002 0.698 0.577 0.845 
  ODHRT -0.1515 0.2819 0.859 0.652 1.132 
Hip 
  ODA -0.2875 0.0632 0.750 0.554 1.016 
  ODAHRT -0.4458 0.0117 0.640 0.453 0.906 
  ODHRT -0.5148 0.0938 0.598 0.327 1.091 
Vertebral 
  ODA -0.1211 0.3775 0.886 0.677 1.159 
  ODAHRT -0.5444 0.0009 0.580 0.421 0.800 
  ODHRT 0.0893 0.6613 1.093 0.733 1.630 
Wrist 
  ODA 0.1412 0.2829 1.152 0.890 1.490 
  ODAHRT -0.1702 0.2448 0.843 0.633 1.124 
  ODHRT -0.1666 0.4442 0.847 0.552 1.297 









Table 3.36 SS ITT: Logistic regression risk factor parameter estimates 
 Adjusted Odds Ratio 







Age 0.0459 < 0.0001 1.047 1.039 1.055 
Intervention Compliance 
ODA 80% MPR -0.2966 0.0682 0.743 0.540 1.022 
ODHRT 80% MPR -0.2498 0.5173 0.779 0.366 1.659 
ODAHRT 80% MPR -0.4951 0.0300 0.610 0.390 0.953 
Corticosteroid Use 
≤ 1-year -0.0980 0.2822 0.907 0.758 1.084 
≥ 1-year 0.4403 0.0003 1.553 1.220 1.977 
Statin Use      
Low; ≤1 year -0.8747 < 0.0001 0.417 0.307 0.566 
Low; >1≤ 2 years -0.4850 0.0018 0.616 0.454 0.834 
Low; >2 years -0.4339 0.0001 0.648 0.518 0.811 
High; ≤1 year -0.7507 0.0087 0.472 0.269 0.827 
High; >1≤ 2 years -0.4688 0.0814 0.626 0.369 1.060 
High; >2 years -0.3765 0.0504 0.686 0.471 1.001 
Previous Fracture      
Previous Fracture 1.4536 < 0.0001 4.279 3.401 5.382 



















Table 3.37 SS Non-ITT: Logistic regression intervention effectiveness parameter 
estimates 
 Adjusted Odds Ratio 
Fracture Type 
  Intervention Group 







  ODA -0.0177 0.8702 0.982 0.794 1.215 
  ODAHRT -0.2289 0.0509 0.795 0.632 1.001 
  ODHRT -0.1803 0.3649 0.835 0.565 1.233 
Hip 
  ODA -0.1695 0.3476 0.844 0.593 1.202 
  ODAHRT -0.3129 0.1235 0.731 0.491 1.089 
  ODHRT -1.2659 0.0333 0.282 0.088 0.905 
Vertebral 
  ODA 0.0569 0.7619 1.059 0.733 1.529 
  ODAHRT -0.5239 0.0222 0.592 0.378 0.928 
  ODHRT 0.2390 0.4287 1.270 0.703 2.296 
Wrist 
  ODA 0.1032 0.5313 1.109 0.803 1.532 
  ODAHRT -0.0201 0.9061 0.980 0.702 1.369 
  ODHRT -0.1005 0.7237 0.904 0.518 1.579 













Table 3.38 SS Non-ITT: Logistic regression risk factor parameter estimates 
 Adjusted Odds Ratio 







Age 0.0455 < 0.0001 1.047 1.037 1.056 
Intervention Compliance 
ODA 80% MPR -0.2963 0.1116 0.744 0.516 1.071 
ODHRT 80% MPR -0.3697 0.4946 0.691 0.239 1.996 
ODAHRT 80% MPR -0.4167 0.0836 0.659 0.411 1.057 
Corticosteroid Use 
≤ 1-year -0.1105 0.3356 0.895 0.715 1.121 
≥ 1-year 0.3214 0.0488 1.379 1.002 1.898 
Statin Use      
Low; ≤1 year -0.8917 < 0.0001 0.410 0.276 0.609 
Low; >1≤ 2 years -0.4669 0.0174 0.627 0.427 0.921 
Low; >2 years -0.4325 0.0023 0.649 0.492 0.857 
High; ≤1 year -0.7131 0.0500 0.490 0.240 1.000 
High; >1≤ 2 years -0.5904 0.1294 0.554 0.258 1.189 
High; >2 years -0.2792 0.2247 0.756 0.482 1.187 
Previous Fracture      
Previous Fracture 1.2372 < 0.0001 3.446 2.548 4.660 













Objective 2 determined the effectiveness of the interventions in the prevention of 
osteoporotic fracture, while controlling for exposure to risk factors using a logistic 
regression analysis.  For this objective, a series of survival analyses were performed to 
compare the time to fracture for the intervention groups.  There were two general goals of 
these analyses: 1) to describe the proportion of cases free of a fracture event at various 
points in time, and 2) to assess the relationship between survival time and a set of 
covariates to determine whether treatment differences exist after statistically controlling 
for the other covariates. 
Kaplan-Meier Life Tables and Survival Plots 
Intent-To-Treat Cohort 
The Kaplan-Meier method of life tables was used to describe the proportion of 
cases free of a fracture event at various points in time.  Life tables were constructed to 
describe the proportion of cases free of any fracture event, hip fracture event, vertebral 
fracture event, and wrist fracture event at various points in time.  Given the lengthy 
output of the life tables, life tables with selected output at 6-month duration intervals 
were constructed.  The dependent variable, days, was the number of days a case was free 
of a fracture event during the three-year observation period.  Fracture event was the 
censoring variable that indicated whether a case was fracture-free at the end of the 
observation period.  In addition, survival plots were constructed to provide a visual 
preliminary examination of the data.   
 212
The results revealed that there were statistically significant differences in survival 
functions between the intervention groups for: any fracture event, hip fracture event, 
vertebral fracture event, and wrist fracture event (p < 0.0001).  As expected, examination 
of the Kaplan-Meier estimates (survival) revealed that the NOODTX intervention group 
had the greatest probability that a patient would be fracture-free at each duration interval 
for any fracture and for each specific type of fracture.  Among intervention groups with 
an existing osteoporosis diagnosis, the ODAHRT intervention group had the greatest 
probability that a patient would be fracture-free at each duration interval for any fracture 
and for vertebral fracture.  For hip fracture, the ODAHRT intervention group had the 
greatest probability that a patient would be fracture-free for up to 1 ½ years.  At 1 ½ 
years or more, the ODHRT intervention group had the highest probability that a patient 
would be fracture-free.  Similarly for wrist fracture, the ODAHRT intervention group had 
the greatest probability that a patient would be fracture-free up to two years.  At two 
years or more, the ODHRT intervention group had the highest probability that a patient 
would be fracture-free.  Survival plots are presented in Figures 3.2 to 3.5 for: any 
fracture, hip fracture, vertebral fracture, and wrist fracture, respectively.  Tables 3.39 to 
3.42 show the Kaplan-Meier life tables for: any fracture, hip fracture, vertebral fracture, 






Figure 3.2 ITT: Kaplan-Meier survival curve for any fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  









Figure 3.3 ITT: Kaplan-Meier survival curve for hip fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Figure 3.4 ITT: Kaplan-Meier survival curve for vertebral fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Figure 3.5 ITT: Kaplan-Meier survival curve for wrist fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Table 3.39 ITT: Kaplan-Meier Life Table for any fracture  
Time Interval 
  Intervention Group 







  ODA 0.9922 0.00775 0.00129 36 4,609 
  ODAHRT 0.9954 0.00455 0.00102 20 4,371 
  ODHRT 0.9895 0.0105 0.00253 17 1,603 
  ODNOTX 0.9874 0.0126 0.00128 95 7,473 
  NOODTX 0.9997 0.000316 0.000100 10 31,617 
1 - Year      
  ODA 0.9879 0.0121 0.00160 56 4,589 
  ODAHRT 0.9907 0.00934 0.00145 41 4,350 
  ODHRT 0.9846 0.0154 0.00306 25 1,595 
  ODNOTX 0.9757 0.0243 0.00177 184 7,384 
  NOODTX 0.9994 0.000569 0.000134 18 31,609 
1 ½ - Years      
  ODA 0.9776 0.0224 0.00217 104 4,541 
  ODAHRT 0.9843 0.0157 0.00188 69 4,322 
  ODHRT 0.9765 0.0235 0.00376 38 1,582 
  ODNOTX 0.9686 0.0314 0.00201 238 7,330 
  NOODTX 0.9991 0.000854 0.000164 27 31,600 
2 - Years      
  ODA 0.9651 0,0349 0.00269 162 4,483 
  ODAHRT 0.9765 0.0235 0.00228 103 4,288 
  ODHRT 0.9710 0.0290 0.00417 47 1,573 
  ODNOTX 0.9602 0.0398 0.00225 301 7,267 
  NOODTX 0.9987 0.00126 0.000200 40 31,587 
2 ½ - Years      
  ODA 0.9522 0.0478 0.00313 222 4,423 
  ODAHRT 0.9672 0.0328 0.00269 144 4,247 
  ODHRT 0.9605 0.0395 0.00484 64 1,556 
  ODNOTX 0.9519 0.0481 0.00246 364 7,204 
  NOODTX 0.9972 0.00278 0.000296 88 31,539 
3 - Years      
  ODA 0.9395 0.0605 0.00350 281 4,364 
  ODAHRT 0.9592 0.0408 0.00298 179 4,212 
  ODHRT 0.9562 0.0438 0.00509 71 1,549 
  ODNOTX 0.9428 0.0572 0.00267 433 7,135 





Table 3.40 ITT: Kaplan-Meier Life Table for hip fracture 
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9976 0.00237 0.000713 11 4,634 
  ODAHRT 0.9989 0.00114 0.000509 5 4,386 
  ODHRT 0.9981 0.00185 0.00107 3 1,617 
  ODNOTX 0.9968 0.00317 0.000646 24 7,544 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 - Year      
  ODA 0.9970 0.00301 0.000804 14 4,631 
  ODAHRT 0.9975 0.00251 0.000754 11 4,380 
  ODHRT 0.9975 0.00247 0.00123 4 1,616 
  ODNOTX 0.9935 0.00647 0.000922 49 7,519 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 ½ - Years      
  ODA 0.9944 0.00560 0.00109 26 4,619 
  ODAHRT 0.9964 0.00364 0.000909 16 4,375 
  ODHRT 0.9957 0.00432 0.00163 7 1,613 
  ODNOTX 0.9913 0.00872 0.00107 66 7,502 
  NOODTX 0.9999 0.000126 0.000063 4 31,623 
2 - Years      
  ODA 0.9905 0.00947 0.00142 44 4,601 
  ODAHRT 0.9941 0.00592 0.00116 26 4,365 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9885 0.0115 0.00123 87 7,481 
  NOODTX 0.9997 0.000253 0.000089 8 31,619 
2 ½ - Years      
  ODA 0.9873 0.0127 0.00164 59 4,586 
  ODAHRT 0.9911 0.00888 0.00142 39 4,352 
  ODHRT 0.9932 0.00679 0.00204 11 1,609 
  ODNOTX 0.9856 0.0144 0.00137 109 7,459 
  NOODTX 0.9993 0.000664 0.000145 21 31,606 
3 - Years      
  ODA 0.9836 0.0164 0.00186 76 4,569 
  ODAHRT 0.9888 0.0112 0.00159 49 4,342 
  ODHRT 0.9920 0.00802 0.00222 13 1,607 
  ODNOTX 0.9820 0.0180 0.00153 136 7,432 




Table 3.41 ITT: Kaplan-Meier Life Table for vertebral fracture 
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9983 0.00172 0.000608 8 4,637 
  ODAHRT 0.9989 0.00114 0.000509 5 4,386 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9947 0.00529 0.000833 40 7,528 
  NOODTX 0.9997 0.000253 0.00089 8 31,619 
1 - Year      
  ODA 0.9968 0.00323 0.000832 15 4,630 
  ODAHRT 0.9970 0.00296 0.000820 13 4,378 
  ODHRT 0.9920 0.00802 0.00222 13 1,607 
  ODNOTX 0.9902 0.00978 0.00113 74 7,494 
  NOODTX 0.9996 0.000443 0.000118 14 31,613 
1 ½ - Years      
  ODA 0.9933 0.00667 0.00119 31 4,614 
  ODAHRT 0.9948 0.00524 0.00109 23 4,368 
  ODHRT 0.9883 0.0117 0.00267 19 1,601 
  ODNOTX 0.9878 0.0122 0.00126 92 7,476 
  NOODTX 0.9994 0.000632 0.000141 20 31,607 
2 - Years      
  ODA 0.9886 0.0114 0.00156 53 4,592 
  ODAHRT 0.9923 0.00774 0.00132 34 4,357 
  ODHRT 0.9864 0.0136 0.00288 22 1,598 
  ODNOTX 0.9849 0.0151 0.00140 114 7,454 
  NOODTX 0.9991 0.000949 0.000173 30 31,597 
2 ½ - Years      
  ODA 0.9841 0.0159 0.00184 74 4,571 
  ODAHRT 0.9900 0.0100 0.00150 44 4,347 
  ODHRT 0.9796 0.0204 0.00351 33 1,587 
  ODNOTX 0.9811 0.0189 0.00157 143 7,425 
  NOODTX 0.9980 0.00196 0.000249 62 31,565 
3 - Years      
  ODA 0.9774 0.0226 0.00218 105 4,540 
  ODAHRT 0.9870 0.0130 0.00171 57 4,334 
  ODHRT 0.9790 0.210 0.00356 34 1,586 
  ODNOTX 0.9781 0.0219 0.00168 166 7,402 




Table 3.42 ITT: Kaplan-Meier Life Table for wrist fracture 
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9955 0.00452 0.000984 21 4,624 
  ODAHRT 0.9973 0.00273 0.000788 12 4,379 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9958 0.00423 0.000746 32 7,536 
  NOODTX 1.000 0.000032 0.000032 1 31,626 
1 - Year      
  ODA 0.9929 0.00710 0.00123 33 4,612 
  ODAHRT 0.9957 0.00433 0.000991 19 4,372 
  ODHRT 0.9938 0.00617 0.00195 10 1,610 
  ODNOTX 0.9911 0.00885 0.00108 67 7,501 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 ½ - Years      
  ODA 0.9884 0.0116 0.00157 54 4,591 
  ODAHRT 0.9927 0.00729 0.00128 32 4,359 
  ODHRT 0.9907 0.00926 0.00238 15 1,605 
  ODNOTX 0.9880 0.0120 0.00125 91 7,477 
  NOODTX 0.9998 0.000158 0.000071 5 31,622 
2 - Years      
  ODA 0.9826 0.0174 0.00192 81 4,564 
  ODAHRT 0.9891 0.0109 0.00157 48 4,343 
  ODHRT 0.9877 0.0123 0.00274 20 1,600 
  ODNOTX 0.9845 0.0155 0.00142 117 7,451 
  NOODTX 0.9998 0.000190 0.000077 6 31,621 
2 ½ - Years      
  ODA 0.9763 0.0237 0.00223 110 4,535 
  ODAHRT 0.9845 0.0155 0.00186 68 4,323 
  ODHRT 0.9846 0.0154 0.00306 25 1,595 
  ODNOTX 0.9818 0.0182 0.00154 138 7,430 
  NOODTX 0.9998 0.000221 0.000084 7 31,620 
3 - Years      
  ODA 0.9724 0.0276 0.00240 128 4,517 
  ODAHRT 0.9813 0.0187 0.00204 82 4,309 
  ODHRT 0.9821 0.0179 0.00329 29 1,519 
  ODNOTX 0.9781 0.0219 0.00168 166 7,402 




Non Intent-To-Treat Cohort 
 The Kaplan-Meier life tables and survival curves obtained for the non intent-to-
treat cohort were similar to those obtained for the intent-to-treat cohort.  One notable 
exception was that the ODHRT intervention group had the greatest probability that a 
patient would be fracture-free for any fracture after approximately 2 ½ years.  Survival 
plots are presented in Figures 3.6 to 3.9 for: any fracture, hip fracture, vertebral fracture, 
and wrist fracture, respectively.  Tables 3.43 to 3.46 show the Kaplan-Meier life tables 

















Figure 3.6 Non-ITT: Kaplan-Meier survival curve for any fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Figure 3.7 Non-ITT: Kaplan-Meier survival curve for hip fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Figure 3.8 Non-ITT: Kaplan-Meier survival curve for vertebral fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Figure 3.9 Non-ITT: Kaplan-Meier survival curve for wrist fracture 
 
* Index_TX 1: ODA intervention group; Index_TX 2: ODAHRT intervention group; 
Index_TX 3: ODHRT intervention group; Index_TX 4: ODNOTX intervention group;  








Table 3.43 Non-ITT: Kaplan-Meier Life Table for any fracture  
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9925 0.00754 0.00140 29 3,816 
  ODAHRT 0.9958 0.00421 0.00105 16 3,781 
  ODHRT 0.9896 0.0104 0.00313 11 1,043 
  ODNOTX 0.9875 0.0125 0.00169 54 4,259 
  NOODTX 0.9997 0.000317 0.000112 8 25,266 
1 - Year      
  ODA 0.9891 0.0109 0.00168 42 3,803 
  ODAHRT 0.9916 0.00843 0.00148 32 3,765 
  ODHRT 0.9858 0.0142 0.00365 15 1,039 
  ODNOTX 0.9757 0.0243 0.00235 105 4,208 
  NOODTX 0.9994 0.000593 0.000153 15 25,259 
1 ½ - Years      
  ODA 0.9808 0.0192 0.00222 74 3,771 
  ODAHRT 0.9868 0.0132 0.00185 50 3,747 
  ODHRT 0.9810 0.0190 0.00420 20 1,034 
  ODNOTX 0.9692 0.0308 0.00263 133 4,180 
  NOODTX 0.9992 0.000752 0.000172 19 25,255 
2 - Years      
  ODA 0.9698 0.0302 0.00276 116 3,729 
  ODAHRT 0.9789 0.0211 0.00233 80 3,717 
  ODHRT 0.9763 0.0237 0.00469 25 1,029 
  ODNOTX 0.9617 0.0383 0.00292 165 4,148 
  NOODTX 0.9990 0.00103 0.000202 26 25,248 
2 ½ - Years      
  ODA 0.9573 0.0427 0.00326 164 3,681 
  ODAHRT 0.9694 0.0306 0.00279 116 3,681 
  ODHRT 0.9687 0.0313 0.00536 33 1,021 
  ODNOTX 0.9566 0.0434 0.00310 187 4,126 
  NOODTX 0.9981 0.00190 0.000274 48 25,226 
3 - Years      
  ODA 0.9467 0.0533 0.00362 205 3,640 
  ODAHRT 0.9621 0.0379 0.00310 144 3,653 
  ODHRT 0.9668 0.0332 0.00552 35 1,019 
  ODNOTX 0.9502 0.0498 0.00331 215 4,098 





Table 3.44 Non-ITT: Kaplan-Meier Life Tables for hip fracture 
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9976 0.00237 0.000713 11 4,634 
  ODAHRT 0.9989 0.00114 0.000509 5 4,386 
  ODHRT 0.9981 0.00185 0.00107 3 1,617 
  ODNOTX 0.9968 0.00317 0.000646 24 7,544 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 - Year      
  ODA 0.9970 0.00301 0.000804 14 4,631 
  ODAHRT 0.9975 0.00251 0.000754 11 4,380 
  ODHRT 0.9975 0.00247 0.00123 4 1,616 
  ODNOTX 0.9935 0.00647 0.000922 49 7,519 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 ½ - Years      
  ODA 0.9944 0.00560 0.00109 26 4,619 
 ODAHRT 0.9964 0.00364 0.000909 16 4,375 
  ODHRT 0.9957 0.00432 0.00163 7 1,616 
  ODNOTX 0.9913 0.00872 0.00107 66 7,502 
  NOODTX 0.9999 0.000126 0.000063 4 31,623 
2 - Years      
  ODA 0.9905 0.00947 0.00142 44 4,601 
  ODAHRT 0.9941 0.00592 0.00116 26 4,365 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9885 0.0115 0.00123 87 7,481 
  NOODTX 0.9998 0.000190 0.000077 6 31,621 
2 ½ - Years      
  ODA 0.9873 0.0127 0.00164 59 4,586 
  ODAHRT 0.9911 0.00888 0.00142 39 4,352 
  ODHRT 0.9932 0.00679 0.00204 11 1,609 
  ODNOTX 0.9856 0.0144 0.00137 109 7,459 
  NOODTX 0.9993 0.000664 0.000145 21 31,606 
3 - Years      
  ODA 0.9836 0.0164 0.00186 76 4,569 
  ODAHRT 0.9888 0.0112 0.00159 49 4,342 
  ODHRT 0.9920 0.00802 0.00222 13 1,607 
  ODNOTX 0.9820 0.0180 0.00153 136 7,432 




Table 3.45 Non-ITT: Kaplan-Meier Life Table for vertebral fracture 
Time Interval 
  Intervention Group 






6- Month      
  ODA 0.9983 0.00172 0.000608 8 4,637 
  ODAHRT 0.9989 0.00114 0.000509 5 4,386 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9947 0.00529 0.000833 40 7,528 
  NOODTX 0.9997 0.000253 0.000089 8 31,619 
1 - Year      
  ODA 0.9968 0.00323 0.000832 15 4,630 
  ODAHRT 0.9970 0.00296 0.000820 13 4,378 
  ODHRT 0.9920 0.00802 0.00222 13 1,607 
  ODNOTX 0.9902 0.00978 0.00113 74 7,494 
  NOODTX 0.9996 0.000443 0.000118 14 31,613 
1 ½ - Years      
  ODA 0.9933 0.00667 0.00119 31 4,614 
  ODAHRT 0.9948 0.00524 0.00109 23 4,368 
  ODHRT 0.9883 0.0117 0.00267 19 1,601 
  ODNOTX 0.9878 0.0122 0.00126 92 7,476 
  NOODTX 0.9994 0.000632 0.000141 20 31,607 
2 – Years      
  ODA 0.9886 0.0114 0.00156 53 4,592 
  ODAHRT 0.9923 0.000774 0.00132 34 4,357 
  ODHRT 0.9864 0.0136 0.00288 22 1,598 
  ODNOTX 0.9849 0.0151 0.00140 114 7,454 
  NOODTX 0.9991 0.000949 0.000173 30 31,597 
2 ½ - Years      
  ODA 0.9841 0.0159 0.00184 74 4,571 
  ODAHRT 0.9900 0.0100 0.00150 44 4,347 
  ODHRT 0.9790 0.0210 0.00356 34 1,586 
  ODNOTX 0.9811 0.0189 0.00157 143 7,425 
  NOODTX 0.9980 0.00196 0.000249 62 31,565 
3 - Years      
  ODA 0.9774 0.0226 0.00218 105 4,540 
  ODAHRT 0.9870 0.0130 0.00171 57 4,334 
  ODHRT 0.9790 0.0210 0.00356 34 1,586 
  ODNOTX 0.9781 0.0219 0.00168 166 7,402 




Table 3.46 Non-ITT: Kaplan-Meier Life Table for wrist fracture 
Time Interval 
  Intervention Group 






6- Month      
   ODA 0.9955 0.00452 0.000984 21 4,624 
  ODAHRT 0.9973 0.00273 0.000788 12 4,379 
  ODHRT 0.9951 0.00494 0.00174 8 1,612 
  ODNOTX 0.9958 0.00423 0.000746 32 7,536 
  NOODTX 1.000 0.000032 0.000032 1 31,626 
1 - Year      
  ODA 0.9929 0.00710 0.00123 33 4,612 
  ODAHRT 0.9957 0.00433 0.000991 19 4,372 
  ODHRT 0.9938 0.00617 0.00195 10 1,610 
  ODNOTX 0.9911 0.00885 0.00108 67 7,501 
  NOODTX 0.9999 0.000095 0.000055 3 31,624 
1 ½ - Years      
  ODA 0.9884 0.0116 0.00157 54 4,591 
  ODAHRT 0.9927 0.00729 0.00128 32 4,359 
  ODHRT 0.9907 0.00926 0.00238 15 1,605 
  ODNOTX 0.9880 0.0120 0.00125 91 7,477 
  NOODTX 0.9998 0.000158 0.000071 5 31,622 
2 - Years      
  ODA 0.9826 0.0174 0.00192 81 4,564 
  ODAHRT 0.9891 0.0109 0.00157 48 4,343 
  ODHRT 0.9877 0.0123 0.00274 20 1,600 
  ODNOTX 0.9845 0.0155 0.00142 117 7,451 
  NOODTX 0.9998 0.000190 0.000077 6 31,621 
2 ½ - Years      
  ODA 0.9763 0.0237 0.00223 110 4,535 
  ODAHRT 0.9845 0.0155 0.00186 68 4,323 
  ODHRT 0.9846 0.0154 0.00306 25 1,595 
  ODNOTX 0.9818 0.0182 0.00154 138 7,430 
  NOODTX 0.9998 0.000221 0.000084 7 31,620 
3 - Years      
  ODA 0.9724 0.0276 0.00240 128 4,517 
  ODAHRT 0.9813 0.0187 0.00204 82 4,309 
  ODHRT 0.9821 0.0179 0.00329 29 1,591 
  ODNOTX 0.9781 0.0219 0.00168 166 7,402 




Cox Proportional-Hazards Model 
 A direct Cox proportional-hazards model was used to assess the relationship 
between survival time and the set of covariates.  The primary purpose of this analysis was 
to determine if there was a difference in time to fracture between intervention groups 
after adjusting for the effects of the other covariates.  As with the logistic regression 
analyses, two series of Cox regressions were performed.  The first series included all five 
intervention groups and covariates.  The second series included only the active 
intervention groups and examined age as a continuous variable and oral corticosteroid use 
with a duration > 1-year.   
 In both the first series and second series of Cox regression analyses, four separate 
Cox regressions were performed, one for each type of fracture (any fracture, hip fracture, 
vertebral fracture, and wrist fracture), to determine the risk of fracture (intervention 
effectiveness) for each intervention group.  For both the first and second series of Cox 
regressions analyses, the significance of the risk factors and other covariates in the 
prediction of osteoporotic fracture were determined from the output of the Cox regression 
analysis for any fracture.  While both the treatment categories and the covariates of 
interest were included in each regression analysis, the results of the treatment effects are 
described in separate tables from the covariate results. 
First Series of Cox Regressions   
Intervention Effectiveness (Intent-To-Treat Cohort) 
 The Cox regression model for the intent-to-treat cohort showed that patients in the 
ODAHRT and NOODTX intervention groups had a significantly longer survival time 
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for: any fracture (hazard ratio (HR) = 0.711, 95% hazard ratio confidence limits (CI) 
0.590 to 0.856, p = 0.0003;  HR = 0.68, 95% CI = 0.055 to 0.083, p < 0.0001, 
respectively); for hip fracture (HR = 0.673, 95% CI 0.476 to 0.950, p = 0.244;  HR = 
0.041, 95% CI = 0.026 to 0.064, p < 0.0001, respectively); and for vertebral fracture(HR 
= 0.578, 95% CI 0.420 to 0.796, p = 0.0008;  HR = 0.141, 95% CI = 0.109 to 0.183, p < 
0.0001, respectively) compared to those in the ODNOTX intervention group.  Only the 
NOODTX intervention group had statistically significant longer survival time for wrist 
fracture (HR = 0.013, 95% CI = 0.007 to 0.025, p < 0.0001).  Table 3.47 shows the Cox 















Table 3.47 FS ITT: Cox regression model for intervention effectiveness parameter 
estimates 
Fracture Type 
  Intervention Group 




95% Hazard Ratio 
Confidence Limits 
Any 
  ODA -0.09021 0.2815 0.914 0.775 1.077 
  ODAHRT -0.34159 0.0003 0.711 0.590 0.856 
  ODHRT -0.14307 0.2913 0.867 0.664 1.130 
  NOODTX -2.69278 < 0.0001 0.068 0.055 0.083 
Hip 
  ODA -0.23707 0.1216 0.789 0.584 1.065 
  ODAHRT -0.39659 0.0244 0.673 0.476 0.950 
  ODHRT -0.48994 0.1059 0.613 0.338 1.109 
  NOODTX -3.20020 < 0.0001 0.041 0.026 0.064 
Vertebral 
  ODA -0.14777 0.2767 0.863 0.661 1.126 
  ODAHRT -0.54746 0.0008 0.578 0.420 0.796 
  ODHRT 0.08402 0.6739 1.088 0.735 1.609 
  NOODTX -1.95883 < 0.0001 0.141 0.109 0.183 
Wrist 
  ODA 0.09725 0.4588 1.102 0.852 1.426 
  ODAHRT -0.19322 0.1862 0.824 0.619 1.098 
  ODHRT -0.15262 0.4786 0.858 0.563 1.309 
  NOODTX -4.34873 < 0.0001 0.013 0.007 0.025 
* Bolded = p < 0.05 
Risk Factor Significance (Intent-To-Treat Cohort) 
Risk factors age, previous osteoporotic fracture, and corticosteroid use were 
shown to significantly decrease survival time, whereas intervention compliance and statin 
use were shown to significantly increase survival time.  Using age-category 50-54 as the 
reference category, the survival time decreased significantly with each successive 
increase in age-category (age-category 55 to 59: HR = 1.406, 95% CI = 1.082 to 1.825, p 
= 0.0106; age-category 60 to 64: HR = 1.581, 95% CI = 1.242 to 2.012, p = 0.0002; age-
category 65 to 69: HR = 1.846, 95% CI = 1.403 to 2.429, p < 0.0001; age-category 70 to 
74: HR = 2.628, 95% CI = 1.994 to 3.465, p < 0.0001; age-category 75 to 79: HR = 
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2.961, 95% CI = 2.256 to 3.885, p < 0.0001; age-category 80 to 84: HR = 4.418, 95% CI 
= 3.274 to 5.961, p < 0.0001; age-category ≥ 85: HR = 5.555, 95% CI = 3.962 to 7.787, p 
< 0.0001).  Likewise, a previous osteoporotic fracture was shown to significantly 
decrease survival time (HR = 3.863, 95% CI = 3.150 to 4.737, p < 0.0001).   
Evidence supporting a decreased survival time relative to corticosteroid dose and 
duration use was not as conclusive.  Only corticosteroid dose/duration categories 
<5mg/>365 days and >10≤20mg/>365 days were found to significantly decrease survival 
time (corticosteroid dose/duration category <5mg/>365 days: HR = 1.640, 95% CI = 
1.124 to 2.393, p = 0.0103; corticosteroid dose/duration category: >10≤20mg/>365 days: 
HR = 2.054, 95% CI = 1.343 to 3.142, p = 0.0009).   
Intervention compliance was shown to have an additional protective effect when 
compared to non-compliance for the ODAHRT intervention group (HR = 0.622, 95% CI 
= 0.401 to 0.964, p = 0.0338).  Statin use was shown to have a statistically significant 
protective effective for osteoporotic fracture for low dose statin for each level of duration 
(statin dose/duration category: low/≤1 year: HR = 0.416, 95% CI = 0.313 to 0.552, p < 
0.0001; statin dose/duration category: low/>1≤2 years: HR = 0.631, 95% CI = 0.478 to 
0.834, p < 0.0012; statin dose/duration category: low/>2 years: HR = 0.659, 95% CI = 
0.535 to 0.813, p = 0.0001) and for high dose statin dose/duration category - high/≤ 1year 
(HR = 0.424, CI = 0.245 to 0.734, p = 0.0022).  Table 3.48 shows the Cox proportional 




Table 3.48 FS ITT: Cox regression model for risk factor parameter estimates 




95% Hazard Ratio 
Confidence Limits 
Age Category 
55 - 59 0.34047 0.0016 1.406 1.082 1.825 
60 – 64 0.45790 0.0002 1.581 1.242 2.012 
64 – 69 0.61312 < 0.0001 1.846 1.403 2.429 
70 – 74 0.96629 < 0.0001 2.628 1.994 3.465 
75 – 79 1.08540 < 0.0001 2.961 2.256 3.885 
80 – 84 1.48560 < 0.0001 4.418 3.274 5.961 
≥ 85 1.71462 < 0.0001 5.555 3.962 7.787 
Compliance 
ODA 80% MPR -0.29676 0.0579 0.743 0.547 1.010 
ODHRT 80% MPR -0.24019 0.5226 0.786 0.377 1.642 
ODAHRT 80% MPR -0.47452 0.0338 0.622 0.401 0.964 
Corticosteroid Use 
<5mg; ≤180 days -0.66644 0.1041 0.514 0.230 1.147 
<5mg; >180≤365 days -10.2942 0.9481 0.000 0.000 0.000 
<5mg; >365 days 0.49477 0.0103 1.640 1.124 2.393 
≥5≤10mg; ≤180 days -0.02246 0.8925 0.978 0.706 1.354 
≥5≤10mg; >180≤ 365 days -0.72854 0.2082 0.483 0.155 1.501 
≥5≤10mg; >365 days 0.30868 0.0676 1.362 0.978 1.896 
>10≤ 20mg; ≤180 days -0.10760 0.5020 0.898 0.656 1.229 
>10≤ 20mg; >180≤365 days 0.30769 0.3871 1.360 0.677 2.732 
>10≤ 20mg; >365 days 0.71975 0.0009 2.054 1.343 3.142 
>20mg; ≤180 days -0.03958 0.7404 0.961 0.761 1.215 
>20mg; >180≤365 days 0.77532 0.0589 2.171 0.971 4.854 
>20mg; >365 days 0.47317 0.5044 1.605 0.400 6.439 
Statin Use 
Low; ≤1 year -0.87712 < 0.0001 0.416 0.313 0.552 
Low; >1≤ 2 years -0.46032 0.0012 0.631 0.478 0.834 
Low; >2 years -0.41657 < 0.0001 0.659 0.535 0.813 
High; ≤1 year -0.85716 0.0022 0.424 0.245 0.734 
High; >1≤ 2 years -0.44218 0.0717 0.643 0.397 1.040 
High; >2 years -0.28294 0.1028 0.754 0.536 1.059 
Previous Fracture 
Previous Fracture 1.35140 < 0.0001 3.863 3.150 4.737 
* Bolded = p < 0.05 
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Intervention Effectiveness (Non Intent-To-Treat Cohort) 
Comparison of the intervention effectiveness results of obtained for the non 
intent-to-treat cohort to the intent-to-treat cohort revealed two significant differences.  
First, the ODAHRT intervention group was found to only have a statistically significant 
longer survival time for vertebral fracture.  Second,   the ODHRT intervention group was 
found to have a statistically significant longer survival time for hip fracture.  Table 3.49 
provides the Cox proportional hazard regression model for intervention effectiveness 
parameter estimates. 
Table 3.49 FS Non-ITT: Cox regression model for intervention effectiveness parameter 
estimates 
Fracture Type 
  Intervention Group 




95% Hazard Ratio 
Confidence Limits 
Any 
ODA -0.01264 0.9047 0.987 0.803 1.215 
ODAHRT -0.21111 0.0663 0.810 0.646 1.014 
ODHRT -0.18109 0.3503 0.834 0.571 1.220 
NOODTX -3.03966 < 0.0001 0.048 0.036 0.064 
Hip 
ODA -0.13077 0.4650 0.877 0.618 1.246 
ODAHRT -0.28813 0.1548 0.750 0.504 1.115 
ODHRT -1.28014 0.0304 0.278 0.087 0.886 
NOODTX -3.57540 < 0.0001 0.028 0.015 0.052 
Vertebral 
ODA 0.04783 0.7986 1.049 0.726 1.515 
ODAHRT -0.50976 0.0259 0.601 0.384 0.940 
ODHRT 0.23467 0.4308 1.264 0.705 2.267 
NOODTX -2.06741 < 0.0001 0.127 0.086 0.187 
Wrist 
ODA 0.07846 0.6337 1.082 0.783 1.494 
ODAHRT -0.03974 0.8158 0.961 0.688 1.343 
ODHRT -0.08358 0.7668 0.920 0.529 1.598 
NOODTX -5.13391 < 0.0001 0.006 0.002 0.019 
* Bolded = p < 0.05 
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Risk Factor Significance (Non Intent-To-Treat Cohort) 
Comparison of risk factor significance results of obtained for the non intent-to-
treat cohort to the intent-to-treat cohort also revealed two major differences.  First, the 
ODAHRT intervention compliance no longer afforded an additional statistically 
significant protective effect.  Second,   the corticosteroid dose/duration category 
≥5≤10mg/>365 days no longer had a statistically significant decreased survival time.  


















Table 3.50 FS Non-ITT: Cox regression model for risk factor parameter estimates 




95% Hazard Ratio 
Confidence Limits 
Age Category 
55 - 59 0.24534 0.1535 1.278 0.913 1.790 
60 – 64 0.36342 0.0219 1.438 1.054 1.962 
64 – 69 0.48761 0.0060 1.628 1.150 2.305 
70 – 74 0.83275 < 0.0001 2.300 1.622 3.261 
75 – 79 1.01626 < 0.0001 2.763 1.968 3.880 
80 – 84 1.27665 < 0.0001 3.585 2.433 5.282 
≥ 85 1.64897 < 0.0001 5.202 3.426 7.898 
Compliance 
ODA 80% MPR -0.30187 0.0945 0.739 0.519 1.053 
ODHRT 80% MPR -0.38346 0.4708 0.682 0.240 1.932 
ODAHRT 80% MPR -0.40512 0.0866 0.667 0.420 1.060 
Corticosteroid Use 
<5mg; ≤180 days -82806 0.1530 0.437 0.140 1.360 
<5mg; >180≤365 days -10.2410 0.9588 0.000 0.000 0.000 
<5mg; >365 days 0.51262 0.0386 1.670 1.027 2.714 
≥5≤10mg; ≤180 days 0.17960 0.3480 1.197 0.822 1.714 
≥5≤10mg; >180≤ 365 days -1.28922 0.1980 0.275 0.039 1.961 
≥5≤10mg; >365 days 0.09671 0.6881 1.102 0.687 1.766 
>10≤ 20mg; ≤180 days -0.08497 0.6791 0.919 0.614 1.374 
>10≤ 20mg; >180≤365 days 0.08473 0.8661 1.088 0.406 2.915 
>10≤ 20mg; >365 days 0.69705 0.0134 2.008 1.155 3.490 
>20mg; ≤180 days -0.07835 0.6120 0.925 0.683 1.252 
>20mg; >180≤365 days 0.23751 0.7377 1.268 0.316 5.091 
>20mg; >365 days 0.17110 0.8644 1.187 0.167 8.456 
Statin Use 
Low; ≤1 year -0.90012 < 0.0001 0.407 0.279 0.592 
Low; >1≤ 2 years -0.49964 0.0081 0.607 0.419 0.878 
Low; >2 years -0.40327 0.0027 0.668 0.513 0.869 
High; ≤1 year -0.79869 0.0252 0.450 0.224 0.905 
High; >1≤ 2 years -0.42491 0.2072 0.654 0.338 1.265 
High; >2 years -0.26639 0.2239 0.766 0.499 1.177 
Previous Fracture 
Previous Fracture 1.18617 < 0.0001 3.275 2.486 4.312 




Second Series of Cox Regressions   
As with the second series of logistic regression analyses, the second series of Cox 
regressions involved only those intervention groups with a diagnosis of osteoporosis.  
Similar to the logistic regression analyses, the first series of Cox regression analyses 
revealed that the risk of an osteoporotic fracture event increased with each successive 
increase in age-category.  Likewise, the first series of Cox regression analyses suggested 
that possibly only long-term use of oral corticosteroids was associated with a statistically 
significant increased risk of osteoporotic fracture.  Therefore, in the second series of Cox 
regression analyses, age was treated as a continuous variable and only long-term (length 
of oral corticosteroid use > 1-year) oral corticosteroid use was assessed as a risk factor. 
A comparison of the Cox regression intervention effectiveness parameter 
estimates of the second series of Cox regression analyses to the first series for the intent-
to-treat cohort revealed no differences as to which intervention groups had a statistically 
significant decreased risk of osteoporotic fracture among the active intervention groups.  
A comparison of the Cox regression intervention effectiveness parameter estimates of the 
second series of Cox regression analyses to the first series for the non intent-to-treat 
cohort revealed one major difference.  In the second series, the ODHRT group was found 
to have a statistically significant decreased risk of any osteoporotic fracture. 
Results from the second series of Cox regression risk factor parameter estimates 
for both the intent-to-treat and non intent-to-treat cohorts revealed that for each one-year 
increase in age there was a statistically significant increased risk of osteoporotic fracture 
(RH = 1.044, 95% CI = 1.037 to 1.051, p < 0.0001; RH = 1.045, 95% CI = 1.036 to 
1.053, p < 0.0001, respectively).  Results for both cohorts also showed that oral 
corticosteroid use for a duration of > 1-year was associated with a statistically significant 
increased risk of osteoporotic fracture (RH = 1.518, 95% CI = 1.210 to 1.905, p = 0.0003; 
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RH = 1.370, 95% CI = 1.010 to 1.859, p = 0.0429).  As for the other risk factors and 
covariates, the results obtained for the second series of Cox regression risk factor 
parameter estimates paralleled those obtained for their respective cohorts in the first 
series of Cox regression analyses.  Tables 3.51 to 3.54 show the results for the second 
series of Cox regressions. 
Table 3.51 SS ITT: Cox regression model intervention effectiveness parameter estimates 




95% Hazard Ratio 
Confidence Limits 
Any 
  ODA -0.07764 0.3480 0.925 0.787 1.088 
  ODAHRT -0.34515 0.0002 0.708 0.589 0.851 
  ODHRT -0.15433 0.2550 0.857 0.657 1.118 
Hip 
  ODA -0.24234 0.1074 0.785 0.584 1.054 
  ODAHRT -0.41928 0.0161 0.658 0.467 0.925 
  ODHRT -0.48873 0.1067 0.613 0.339 1.111 
Vertebral 
  ODA -0.12631 0.3470 0.881 0.677 1.147 
  ODAHRT -0.53868 0.0009 0.584 0.425 0.801 
  ODHRT 0.07433 0.7100 1.077 0.728 1.594 
Wrist 
  ODA 0.14091 0.2762 1.151 0.893 1.484 
  ODAHRT -0.16861 0.2436 0.845 0.636 1.122 
  ODHRT -0.16591 0.4410 0.847 0.555 1.292 








Table 3.52 SS ITT: Cox regression model risk factor parameter estimates 




95% Hazard Ratio 
Confidence Limits 
Age Category 
Age 0.04310 < 0.0001 1.044 1.037 1.051 
Compliance 
ODA 80% MPR -0.29163 0.0620 0.747 0.550 1.015 
ODHRT 80% MPR -0.22859 0.5427 0.796 0.381 1.661 
ODAHRT 80% MPR -0.48399 0.0303 0.616 0.398 0.955 
Corticosteroid Use 
≤ 1-year -0.10024 0.2540 0.905 0.761 1.075 
> 1-year 0.41753 0.0003 1.518 1.210 1.905 
Statin Use 
Low; ≤1 year -0.87735 < 0.0001 0.416 0.308 0.562 
Low; >1≤ 2 years -0.47557 0.0016 0.622 0.463 0.835 
Low; >2 years -0.42119 0.0001 0.656 0.528 0.815 
High; ≤1 year -0.73683 0.0085 0.479 0.276 0.829 
High; >1≤ 2 years -0.45919 0.0786 0.632 0.379 1.054 
High; >2 years -0.36333 0.0517 0.695 0.482 1.003 
Previous Fracture 
Previous Fracture 1.36320 < 0.0001 3.909 3.190 4.790 





















Table 3.53 SS Non-ITT: Cox regression model intervention effectiveness parameter 
estimates 
Fracture Type 
  Intervention Group 




95% Hazard Ratio 
Confidence Limits 
Any 
  ODA -0.01535 0.8829 0.985 0.803 1.208 
  ODAHRT -0.22386 0.0490 0.799 0.640 0.999 
  ODHRT -0.18162 0.3487 0.834 0.570 1.219 
Hip 
  ODA -0.12730 0.4691 0.880 0.624 1.243 
  ODAHRT -0.29280 0.1441 0.746 0.504 1.105 
  ODHRT -1.24407 0.0353 0.288 0.090 0.918 
Vertebral 
  ODA 0.04868 0.7927 1.050 0.730 1.509 
  ODAHRT -0.52196 0.0216 0.593 0.380 0.926 
  ODHRT 0.22988 0.4412 1.258 0.701 2.259 
Wrist 
  ODA 0.10572 0.5156 1.112 0.808 1.529 
  ODAHRT -0.02056 0.9029 0.980 0.704 1.363 
  ODHRT -0.10048 0.7211 0.904 0.521 1.570 













Table 3.54 SS Non-ITT: Cox regression model risk factor parameter estimates 




95% Hazard Ratio 
Confidence Limits 
Age Category 
Age 0.04357 < 0.0001 1.045 1.036 1.053 
Compliance 
ODA 80% MPR -0.30083 0.0951 0.740 0.520 1.054 
ODHRT 80% MPR -0.35696 0.5019 0.700 0.247 1.984 
ODAHRT 80% MPR -0.40919 0.0833 0.664 0.418 1.055 
Corticosteroid Use 
≤ 1-year -0.11126 0.3177 0.895 0.719 1.113 
> 1-year 0.31517 0.0429 1.370 1.010 1.859 
Statin Use 
Low; ≤1 year -0.91317 < 0.0001 0.401 0.270 0.596 
Low; >1≤ 2 years -0.45782 0.0170 0.633 0.434 0.921 
Low; >2 years -0.42493 0.0021 0.654 0.499 0.857 
High; ≤1 year -0.70478 0.0483 0.494 0.246 0.995 
High; >1≤ 2 years -0.58364 0.1257 0.558 0.264 1.177 
High; >2 years -0.26766 0.2319 0.765 0.493 1.187 
Previous Fracture 
Previous Fracture 1.19696 < 0.0001 3.310 2.516 4.356 










OBJECTIVES 5 AND 6 
The logistic regression and direct Cox proportional-hazards regression models 
employed in objectives 2 and 4, respectively, provided the ability to determine the 
effectiveness of the osteoporosis treatment interventions while statistically controlling for 
the presence of risk factors and other covariates.  In objective 5, the cost-effectiveness of 
the treatment interventions is determined while statistically controlling for the presence 
of risk factors and other covariates in the heterogeneous observational data set by 
employing the net-benefit regression method of cost-effectiveness analysis.  This same 
methodology is employed in objective 6, where the importance of covariates on the 
marginal cost-effectiveness of an intervention is determined by examining interaction 
effects between each intervention and important patient subgroups.  
In this analysis, the direct treatment costs (cost of osteoporosis medications and 
fracture treatment costs) for the three-year observation period were examined from the 
perspective of the DoD.  The change in quality-adjusted life-years over the observation 
period was the main effectiveness measure and was calculated as described in the 
methodology section.  The net monetary benefits were calculated by employing λ values 
of $0, $30,000, $60,000, and $100,000.  The work performed in objectives 2 through 4 
identified the following set of clinically significant covariates to be included in the 
model: age ≥ 65, oral corticosteroid use duration > 1-year, statin use, and prior 
osteoporotic fracture.  The covariate intervention compliance was dropped from these 
analyses because it afforded no statistically significant protective effect for intervention 
groups ODA and ODHRT and ODAHRT compliant patients did not achieve much better 
outcomes when compared to the ODAHRT intervention group. 
As in the previous analyses, two separate analyses were performed, one for the 
intent-to-treat cohort and the other for the non intent-to-treat cohort.  For each cohort, two 
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separate analyses were initially performed, one without treatment interaction and the 
other with treatment interaction.  Results from these primary analyses provided evidence 
of a statistically significant positive incremental net-benefit for interaction terms formed 
between the active intervention groups and covariates age ≥ 65 and prior fracture.  
Therefore, subsequent post-hoc analyses were performed to determine if any of the active 
interventions were cost-effective in these sub-groups. 
Presented first, for each of the cohorts, are the results of the net-benefit regression 
analysis without treatment interaction.  This analysis provides an estimate of the overall 
cost-effectiveness of the interventions.  The second analysis presented includes treatment 
interaction, which provides an estimate of how the covariates impact the estimate of the 
intervention’s incremental net-benefit.  Lastly, the post-hoc analyses examining the cost-
effectiveness of the active intervention groups in the specific sub-groups (patients with a 
prior fracture or age ≥ 65) are presented.   
Before the net-benefit regression results for the primary analyses are presented, 
the estimated mean total cost and mean change in QALYs is provided for each of the 
intervention groups for both the intent-to-treat and non intent-to-treat cohorts in Table 
3.55. The purpose of this table is to provide background information, which may 









Table 3.55 Primary Analyses: Mean total cost and mean total QALYs by intervention 
group for the intent-to-treat and non intent-to-treat cohorts 
Intervention 
Group 




ODA 4,645 Total Cost 996.84 1,723.07 9.03 67,635.80 
  Total QALYS -0.0062 0.0344 -0.5372 0 
ODAHRT 4,391 Total Cost 1,415.22 1,390.87 45.15 34,898.42 
  Total QALYS -0.0042 0.2790 -0.3791 0 
ODHRT 1,620 Total Cost 347.77 1,535.65 0 39,828.32 
  Total QALYS -0.0049 0.0323 -0.5307 0 
ODNOTX 7,568 Total Cost 183.68 2,012.09 0 82,598.00 
  Total QALYS -0.0076 0.0417 -0.7573 0 
Non Intent-to-Treat Cohort 
ODA 3,845 Total Cost 1,023.87 1,824.44 9.03 67,635.80 
  Total QALYS -0.0058 0.0334 -0.5307 0 
ODAHRT 3,797 Total Cost 1,448.71 1,343.43 45.15 25,734.06 
  Total QALYS -0.0038 0.0266 -0.3791 0 
ODHRT 1,054 Total Cost 319.96 1,473.09 0 39,828.32 
  Total QALYS -0.0032 0.0261 -0.5307 0 
ODNOTX 4,313 Total Cost 197.01 2,280.25 0 82,598.00 
  Total QALYS -0.0071 0.0412 -0.7572 0 
Primary Analyses 
Intent-To-Treat Cohort 
In the analysis without treatment interaction, the coefficients of primary 
importance are those on the treatment dummy, which correspond to the incremental net-
benefit.  The coefficients for the covariates describe the impact on average net-benefits 
and are not of direct interest.  In general, examination of the treatment dummy 
coefficients in comparison to the constant term (control group) coefficient reveals that the 
incremental net-benefit for all active treatment interventions were less than the 
incremental net-benefit for the control group (no treatment).  More specifically, the 
incremental net-benefit for treatment with alendronate and the combination of 
alendronate and HRT were statistically significantly less than no treatment for all values 
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of λ.  In contrast, examination of the coefficients for treatment with HRT reveals that the 
incremental net-benefit, although lower, was not statistically significantly lower than no 
treatment at λ values ≥ $30,000.  The net-benefit regression results for the intent-to-treat 
cohort are presented in Table 3.56. 
Table 3.56 ITT: Net-benefit regression estimates without treatment interaction  




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 








Covariates     
































Treatment dummy     
























R-squared (adjusted) 0.0849 0.0519 0.0353 0.0267 
F(7,1826) 242.43 143.54 96.32 72.31 
Prob > F < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
In the second analysis with treatment interaction, interaction terms were formed 
between each of the active intervention groups and covariates: age ≥ 65, steroid > 1-year, 
and prior fracture.  In this analysis, the coefficients of primary importance are those for 
the interaction terms.  In general, all of the treatment interactions achieved a positive 
incremental net-benefit.  In other words, it was more cost-effective to treat patients in the 
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covariate sub-group compared to patients not in the covariate subgroup.  More 
specifically, the net-benefit regression results show that for the ODA intervention group 
there was a statistically significant interaction with age; patients age ≥ 65 achieved higher 
net-benefits from treatment in comparison to patients < 65 for values of λ ≤ $30,000.  
There was also a statistically significant interaction between the ODA intervention group 
and prior fracture; patients with a prior fracture achieved higher net-benefits from 
treatment in comparison to patients without a prior fracture for values of λ ≥ $30,000.  
Similarly, the ODAHRT intervention group was found to have statistically significant 
interactions with age and prior fracture.  The regression results show that for the 
ODAHRT intervention group, patients ≥ age 65 achieved higher net-benefits from 
treatment in comparison to patients < 65 for all values of λ.  Likewise, patients in the 
ODAHRT intervention group with a prior fracture achieve higher net-benefits from 
treatment in comparison to patients without a prior fracture for all values of λ.  The only 
significant interaction term formed between the ODHRT intervention group and a 
covariate was with prior fracture and this interaction term only became statistically 
significant at λ ≥ $60,000.  Although higher net-benefits were observed for the interaction 
terms formed between intervention groups and the covariate corticosteroid use duration > 
1-year, none of these were found to be statistically significant.  The net-benefit regression 











Table 3.57 ITT: Net-benefit regression estimates with treatment interaction 




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 
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R-squared (adjusted)        0.0865 0.0537 0.0379 0.0290 
F(16,18,207)                    108.87 65.69 44.80 34.04 
Prob > F                         < 0.0001 < 0.0001 < 0.0001 < 0.0001 
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Non Intent-To-Treat Cohort 
 The results obtained for the non intent-to-treat cohort mirrored those obtained for 
the intent-to-treat cohort for the net-benefit regression without treatment interaction.  
Table 3.58 shows the results of the net-benefit regression without treatment interaction 
for the non intent-to-treat cohort. 
Table 3.58 Non-ITT: Net-benefit regression estimates without treatment interaction 




λ = $0 [se] 
(p-value) 
NMB with 








λ = $100,000 
[se] 
(p-value) 








Covariates     
































Treatment dummy     
























R-squared (adjusted) 0.0798 0.0502 0.0332 0.0234 
F(7,13001) 162.24 99.17 64.84 45.55 
Prob > F < 0.0001 < 0.0001 < 0.0001 <0.0001 
 
 
 In general, the results from the net-benefit regression with treatment interaction 
obtained for the non intent-to-treat cohort were similar to those obtained for the intent-to-
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treat cohort for intervention groups ODA and ODAHRT.  However, the results for the 
ODHRT intervention group differed as to which estimates obtained statistical 
significance.  The interaction term formed between the ODHRT intervention group and 
age ≥ 65 was found to be statistically significant at λ = $0 and the interaction terms 
formed with prior fracture were statistically significant at all values of λ.  Table 3.59 

















Table 3.59 Non-ITT: Net-benefit regression estimates with treatment interaction 




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 





























































































































































R-squared (adjusted)         0.0821 0.0530 0.0360 0.0260 
F(16,12992) 73.72 46.51 31.35 22.67 
Prob > F (< 0.0001) (< 0.0001) (< 0.0001) (< 0.0001) 
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Post-hoc Analyses 
Results from the net-benefit regression with treatment interaction from the 
primary analyses provided evidence of a statistically significant interaction between the 
active intervention groups and covariates age ≥ 65 and prior fracture, with both 
interaction terms suggesting a positive incremental net-benefit.  These results beg the 
question as to whether any of the active treatment interventions are more cost-effective 
than the comparator intervention group, no treatment.  To answer this question, post-hoc 
net-benefit regression analyses were performed for each of the specific sub-groups. 
Presented first are results from the net-benefit regression for the sub-group of 
patients with a prior fracture for both the intent-to-treat cohort and the non intent-to-treat 
cohort.  The results for the sub-group of patients ≥ age 65 are presented next.  Since, the 
primary interest is in the overall cost-effectiveness of the active intervention groups; 
treatment interaction terms are not included in any of the analyses. 
As with the net-benefit regression results for the primary analyses, before the net-
benefit regression results for the post-hoc analyses are presented, the estimated mean 
total cost and mean change in QALYs is provided for each of the intervention groups for 









Table 3.60 Post-hoc analyses: Mean total cost and mean total QALYs by intervention 
group for the intent-to-treat and non intent-to-treat cohorts 
Intervention 
Group 
N Variable Mean Standard 
Deviation 
Minimum Maximum
Prior Fracture: Intent-to-Treat Cohort 
ODA 157 Total Cost 1,488.88 5,446.30 25.60 67,635.80 
  Total QALYS -0.0253 0.0853 -0.5373 0 
ODAHRT 130 Total Cost 1,327.72 858.97 214.82 5,109.29 
  Total QALYS -0.0198 0.0616 -0.3366 0 
ODHRT 58 Total Cost 721.58 2,791.50 1.29 21,298.00 
  Total QALYS -0.0236 0.0685 -0.3431 0 
ODNOTX 194 Total Cost 909.27 4,152.90 0 39,155.00 
  Total QALYS -0.0397 0.0893 -0.5698 0 
Prior Fracture: Non Intent-to-Treat Cohort 
ODA 132 Total Cost 1,517.76 5,854.43 25.60 67,635.80 
  Total QALYS -0.0216 0.0773 -0.5307 0 
ODAHRT 105 Total Cost 1,361.03 857.97 214.82 5,109.29 
  Total QALYS -0.0155 0.0549 -0.3366 0 
ODHRT 34 Total Cost 240.94 178.79 1.29 740.43 
  Total QALYS -0.0083 0.0419 -0.2437 0 
ODNOTX 110 Total Cost 1,313.13 5,209.30 0 39,155.00 
  Total QALYS -0.0347 0.0945 -05698 0 
Age ≥ 65: Intent-to-Treat Cohort 
ODA 2,549 Total Cost 1,088.72 2,182.70 9.03 67,635.80 
  Total QALYS -0.0088 0.0408 -0.5373 0 
ODAHRT 1,775 Total Cost 1,466.19 1,640.66 45.15 34,898.42 
  Total QALYS -0.0056 0.0320 -0.3791 0 
ODHRT 222 Total Cost 520.73 2,648.68 .86 22,823.30 
  Total QALYS -0.0078 0.0481 -0.5307 0 
ODNOTX 1,894 Total Cost 500.45 3,3638.64 0 82,598.00 
  Total QALYS -0.0124 0.0514 -0.5782 0 
Age ≥ 65: Non Intent-to-Treat Cohort 
ODA 2,134 Total Cost 1,116.54 2,299.41 9.03 67,635.80 
  Total QALYS -0.0082 0.0399 -0.5307 0 
ODAHRT 1,527 Total Cost 1,504.21 1,516.82 45.15 23,577.27 
  Total QALYS -0.0048 0.0296 -0.3791 0 
ODHRT 119 Total Cost 335.64 1,894.81 1.29 20,732.09 
  Total QALYS -0.0058 0.0501 -0.5307 0 
ODNOTX 1,263 Total Cost 496.43 3,881.21 0 82,598.00 
  Total QALYS -0.0114 0.0517 -0.5782 0 
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Patients with a Prior Fracture (Intent-To-Treat) 
In general, the results from the net-benefit regression for the patients with a prior 
fracture sub-group suggests that as the value of λ increases the active interventions 
become more cost-effective than no treatment.  More specifically, the active intervention 
becomes more cost-effective when λ ≥ $60,000 for alendronate, λ ≥ $30,000 for the 
combination of alendronate and HRT, and λ ≥ $0 for HRT.  However, possibly due to the 
smaller sample size (n = 538) and large standard errors, none of the coefficients for the 
active interventions at the different values of λ approach the level of statistical 
significance.  Table 3.61 shows the results for the net-benefit regression without 
treatment interaction for the patients with prior fracture sub-group. 
Table 3.61 ITT: Net-benefit regression estimates without treatment interaction for the 
patients with a prior fracture sub-group 




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 








Covariates     
























Treatment dummy     
























R-squared (adjusted) 0.0117 0.0182 0.0238 0.0277 
F(6,532) 2.06 2.66 3.19 3.56 
Prob > F 0.0559 0.0559 0.0044 0.0018 
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Patients with a Prior Fracture (Non Intent-To-Treat) 
The overall results obtained for the non intent-to-treat cohort were similar to those 
obtained for the intent-to-treat cohort.  However, there were two differences.  First, the 
alendronate treatment became more cost-effective at λ = $30,000.  Second, the 
incremental net-benefit at each value of λ for the HRT treatment was considerably higher 
for the non intent-to-treat cohort compared to the intent-to-treat cohort.  Table 3.62 shows 
the results for the net-benefit regression without treatment interaction for the patients 
with prior fracture sub-group. 
 
Table 3.62 Non-ITT: Net-benefit regression estimates without treatment interaction for 
the patients with a prior fracture sub-group 




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 








Covariates     
























Treatment dummy     
























R-squared (adjusted) 0.0045 0.0132 0.0193 0.0234 
F(6,374) 1.29 1.85 2.25 2.52 
Prob > F 0.2657 0.0887 0.0381 0.0213 
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Patients Age ≥ 65 (Intent-To-Treat Cohort) 
Overall, the results from the net-benefit regression for the patients ≥ age 65 sub-
group provide evidence that treatment with alendronate and the combination of 
alendronate and HRT are not more cost-effective than no treatment at any value of  λ.  In 
contrast, treatment with HRT was found to be more cost-effective than no treatment at 
values of λ ≥ $30,000.  However, possibly due to large standard errors, none of the 
coefficients for the ODHRT intervention group approached the level of statistical 
significance.  Table 3.63 shows the results for the net-benefit regression without 














Table 3.63 ITT: Net-benefit regression estimates without treatment interaction for the 
patients age ≥ 65 sub-group  




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 








Covariates     
























Treatment dummy     
























R-squared (adjusted) 0.0242 0.0170 0.0148 0.0145 
F(6,6,433) 27.57 19.59 17.15 16.79 
Prob > F < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Patients Age ≥ 65 (Non Intent-To-Treat) 
The overall results obtained for the non intent-to-treat cohort were parallel to 
those obtained for the intent-to-treat cohort for intervention groups ODA and ODAHRT.  
The only observable difference between the two cohorts for the ODHRT intervention 
group was that treatment with HRT was more cost-effective than no treatment at all 
values of λ.  Table 3.64 shows the results for the net-benefit regression without treatment 
interaction for the patients age ≥ 65 sub-group. 
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Table 3.64 Non-ITT: Net-benefit regression estimates without treatment interaction for 
the patients age ≥ 65 sub-group    




λ = $0 [se] 
(p-value) 
NMB with 
λ = $30,000 [se] 
(p-value) 
NMB with 
λ = $60,000 [se] 
(p-value) 
NMB with 
λ = $100,000 [se] 
(p-value) 








Covariates     
























Treatment dummy     
























R-squared (adjusted) 0.0254 0.0171 0.0136 0.0134 
F(6,5036) 22.86 15.62 12.59 11.37 


















Results for Study Hypotheses 
 In conclusion of the results section, Table 3.65 show the results for study’s null 
hypotheses set forth in Chapter 1.  
Table 3.65 Results for the study’s null hypotheses   
HYPOTHESES Accept Reject 
OBJECTIVE 2   
HO(1)  The odds ratio (OR) of osteoporotic fracture for intervention group 
ODA = ODHRT = ODAHRT = ODNOTX = 1  X 
HO(2)  The odds ratio (OR) of osteoporotic hip fracture for intervention 
group ODA = ODHRT = ODAHRT = ODNOTX = 1  X 
HO(3)  The odds ratio (OR) of osteoporotic vertebral fracture for 
intervention group ODA = ODHRT = ODAHRT = ODNOTX = 1  X 
HO(4)  The odds ratio (OR) of osteoporotic wrist fracture for intervention 
group ODA = ODHRT = ODAHRT = ODNOTX = 1 X  
OBJECTIVE 4   
HO(5)  There is no difference in the proportion of cases free of a 
osteoporotic fracture event at various points in time between the four 
intervention groups (ODA, ODHRT, ODAHRT, ODNOTX) 
 X 
HO(6)  There is no difference in the proportion of cases free of a 
osteoporotic hip fracture event at various points in time between the four 
intervention groups (ODA, ODHRT, ODAHRT, ODNOTX) 
 X 
HO(7)  There is no difference in the proportion of cases free of a 
osteoporotic vertebral fracture event at various points in time between the 
four intervention groups (ODA, ODHRT, ODAHRT, ODNOTX) 
 X 
HO(8)  There is no difference in the proportion of cases free of a 
osteoporotic wrist fracture event at various points in time between the four 
intervention groups (ODA, ODHRT, ODAHRT, ODNOTX) 
 X 
HO(9)  There is no difference between treatments (ODA, ODHRT, 
ODAHRT, ODNOTX) in time to osteoporotic fracture after statistically 
controlling for other covariates (risk factors and statin use) 
 X 
HO(10)  There is no difference between treatments (ODA, ODHRT, 
ODAHRT, ODNOTX) in time to osteoporotic hip fracture after statistically 
controlling for other covariates (risk factors and statin use) 
 X 
HO(11)  There is no difference between treatments (ODA, ODHRT, 
ODAHRT, ODNOTX) in time to osteoporotic vertebral fracture after 
statistically controlling for other covariates (risk factors and statin use) 
 X 
HO(12) There is no difference between treatments (ODA, ODHRT, 
ODAHRT, ODNOTX) in time to osteoporotic wrist fracture after 




Discussion and Conclusions 
 This chapter discusses the results of objectives one through six, makes concluding 
remarks, and discusses the study’s limitations. 
OBJECTIVE 1 
The purpose of objective 1 was to assess the epidemiology of osteoporotic 
fracture in the study population.  In the first part, the simple (unadjusted for covariates) 
three-year cumulative incidence and relative risk of an osteoporotic fracture were 
determined for the cohort as a whole and by intervention group.  In the second part, the 
simple three-year cumulative incidence and relative risk of an osteoporotic fracture were 
determined for each risk factor.   
Incidence and Relative Risk of Osteoporotic Fracture for the Cohorts and 
Intervention Groups 
During the three-year observation period, a total of 1,238 osteoporotic fractures 
were reported in the intent-to-treat cohort (n = 49,851) and a total of 737 osteoporotic 
fractures were reported in the non intent-to-treat cohort (n = 38,283).   The three-year 
cumulative incidence of osteoporotic fracture ranged from 1.93% for the Non-ITT cohort 
(5.2% in patients with an osteoporosis diagnosis; 0.24% in patients without an 
osteoporosis diagnosis) to 2.48% for the ITT cohort (6.1% in patients with an 
osteoporosis diagnosis; 0.40% in patients without an osteoporosis diagnosis).  Table 4.1 
provides a comparison of the three-year cumulative incidence and relative risk of fracture 
for the intent-to-treat and non intent-to-treat cohorts.   
Overall the incidence rates and relative risks for osteoporotic fracture were higher 
in the intent-to-treat compared to the non intent-to-treat cohort.  Comparison of the cohort 
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size and number of fractures between the intent-to-treat and non intent-to-treat cohorts 
provided an explanation for the difference in osteoporotic fracture incidence rates and 
relative risks observed between the two cohorts. A total of 11,568 patients in the intent-
to-treat cohort deviated from the index-intervention and were subsequently removed, 
along with their 501 reported fractures.  The incidence of osteoporotic fracture in this 
population was 4.33%, which was over 1.7-fold higher than the incidence experienced in 
the intent-to-treat cohort.  This suggests that patients who experienced an osteoporotic 
fracture event during the observation period were more likely to have deviated from their 
index-intervention group.    
 Unfortunately, a meaningful comparison of the incidence of osteoporotic fracture 
experienced in the study population to that experienced in the U.S. population is not 
possible.  The National Osteoporosis Foundation (NOF) statistics report the overall total 
number of osteoporotic fractures and total number by type of osteoporotic fracture 
without reporting the key piece of information, the size of the population at risk.  Instead, 
to convey the risk of osteoporotic fracture, the NOF typically reports the lifetime risk of 
the various types of osteoporotic fractures. 
Examination of the relative risks of osteoporotic fracture among the active 
intervention groups compared to the ODNOTX intervention group revealed both 
expected and unexpected results.  As expected, in both the intent-to-treat and non intent-
to-treat cohorts the ODAHRT, ODHRT, and NOODTX intervention groups had a lower 
relative risk of osteoporotic fracture when compared to the ODNOTX intervention group.  
Unexpectedly, however, the ODA intervention group had the higher relative risk of 
osteoporotic fracture (except for hip fracture) when compared to the ODNOTX 
intervention group.  This unexpected preliminary result provides the first clue to the 
possibility of selection bias in the study sample, which will be discussed in greater detail 
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in objective 2.  Among the active intervention groups, the ODHRT intervention group 
had the lowest relative risk for hip and wrist fracture, whereas the ODAHRT intervention 
group had the lowest relative risk for vertebral fracture. 
Table 4.1 Comparison of three-year cumulative incidence and relative risk of fracture for 
intent-to-treat and non intent-to-treat cohorts 











Hip 1.77 0.91 1.77 0.90 
Vertebral 2.45 1.04 1.87 1.15 
Wrist 2.93 1.27 2.52 1.21 ODA 
Total 7.15 1.08 6.16 1.09 
Hip 1.16 0.60 1.19 0.60 
Vertebral 1.46 0.62 0.95 0.58 
Wrist 1.91 0.83 2.00 0.96 ODAHRT 
Total 4.53 0.69 4.13 0.73 
Hip 0.93 0.48 0.47 0.24 
Vertebral 2.28 0.97 1.42 0.88 
Wrist 1.79 0.78 1.71 0.82 ODHRT 
Total 5.00 0.76 3.61 0.63 
Hip 1.94  1.97  
Vertebral 2.37  1.62  
Wrist 2.30  2.09  ODNOTX 
Total 6.61  5.68  
Hip 0.07 0.04 0.05 0.02 
Vertebral 0.30 0.13 0.18 0.11 
Wrist 0.03 0.01 0.01 0.01 NOODTX 
Total 0.40 0.06 0.24 0.04 
Hip 0.64  0.56  
Vertebral 0.98  0.62  
Wrist 0.87  0.74  Cohort 
Total 2.48  1.93  
* Reference group: ODNOTX 
Cumulative Incidence and Relative Risk of Osteoporotic Fracture by Risk Factor 
 Literature reports of an increased risk of osteoporotic fracture were substantiated 
for risk factors: age, osteoporosis diagnosis, previous osteoporotic fracture, and oral 
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corticosteroid use in both the intent-to-treat and non intent-to-treat cohorts.  It is 
important for the reader to realize, however, that the following reported relative risks 
associated with the risk factors for objective 1 are not adjusted for the presence of other 
confounding risk factors.  For this reason, a discussion comparing the reported relative 
risk associated with the various risk factors found in this study to those reported in the 
literature will be reserved for objective 3. 
 The relative risk of osteoporotic fracture steadily increased with each successive 
increase in age-category in both the intent-to-treat and non intent-to-treat cohorts.  A 
diagnosis of osteoporosis was shown to substantially increase the risk of osteoporotic 
fracture (RR = 15.32 intent-to-treat; RR = 10.55 non intent-to-treat).  Similarly, a prior 
osteoporotic fracture dramatically increased the risk of a subsequent osteoporotic fracture 
(RR = 11.08 intent-to-treat; RR = 21.92 non intent-to-treat).   
 The relative risk of osteoporotic fracture associated with oral corticosteroid use 
and statin use was examined two different ways: the first examined the relative risk 
regardless of dose and duration of exposure; the second examined the relative risk by 
dose and duration.  Exposure to oral corticosteroids, regardless of dose and duration, 
increased the risk of osteoporotic fracture by 36% in the intent-to-treat cohort and by 
40% in the non intent-to-treat cohort.  Examination of corticosteroid dose and duration 
categories revealed that, in general, the relative risk of osteoporotic fracture substantially 
increased when the duration of exposure exceeded one-year at all doses.  However, 
evidence supporting a dose-response relationship was inconsistent.  Exposure to statins, 
regardless of dose and duration, decreased the risk of osteoporotic fracture by 34% in the 
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intent-to-treat cohort and by 29% in the non intent-to-treat cohort.  Interestingly statin use 
was found to have a greater protective effect at low and high doses when the duration of 
exposure was two-years or less.  Intervention compliance, as previously defined, was also 
shown to have a protective effect for all intervention groups.  Table 4.2 shows a 
comparison of the three-year cumulative incidence and relative risk of fracture for the 






















Table 4.2 Comparison of three-year cumulative incidence and relative risk of fracture for 
the intent-to-treat and non intent-to-treat cohorts by risk factor 










Age Category     
  50-54 1.03  0.82  
  55-59 1.94 1.89 1.41 1.71 
  60-64 2.53 2.47 1.79 2.18 
  65-69 2.27 2.21 1.78 2.16 
  70-74 3.32 3.23 2.70 3.27 
  75-79 4.04 3.93 3.35 4.07 
  80-84 5.72 5.57 3.95 4.80 
  85 Plus 8.39 8.18 6.32 7.68 
Osteoporosis Diagnosis     
  Exposed 6.10 15.32 18.51 10.55 
  Non-exposed 0.40  1.75  
Previous Fracture     
  Exposed 24.77 11.08 5.20 21.92 
  Non-exposed 2.24  0.24  
Corticosteroid Use     
  Exposed 3.15 1.36 2.50 1.40 
  Non-exposed 2.32  1.79  




  < 5mg; ≤ 180 days 1.21 0.52 0.83 0.46 
  < 5mg; > 180 ≤ 365 days 0.00 0.00 0.00 0.00 
  < 5mg; > 365 days 8.62 3.72 7.51 4.19 
  ≥ 5 ≤ 10mg; ≤ 180 days 2.62 1.13 2.65 1.48 
  ≥ 5 ≤ 10mg; > 180 ≤ 365 days 1.33 0.57 0.63 0.35 
  ≥ 5 ≤ 10mg; > 365 days 6.60 2.85 4.54 2.53 
  > 10 ≤ 20mg; ≤ 180 days 2.23 0.96 1.79 1.00 
  > 10 ≤ 20mg; > 180 ≤ 365 days 4.10 1.77 2.76 1.54 
  > 10 ≤ 20mg; > 365 days 9.00 3.88 6.57 3.67 
  > 20mg; ≤ 180 days 2.31 1.00 1.90 1.06 
  > 20mg; > 180 ≤ 365 days 7.02 3.03 3.80 2.12 
  > 20mg; > 365 days 4.26 1.83 2.86 1.59 
* Reference category for age was the 50-54 age-category 




Table 4.2 Comparison of three-year cumulative incidence and relative risk of fracture for 










Statin Use     
  Exposed 1.85 0.66 1.52 0.71 
  Not Exposed 2.80  2.12  
Statin Use (Dose; Duration)     
  Low; ≤ 1 year 1.24 0.44 0.99 0.47 
  Low; > 1 ≤  2 years 1.79 0.64 1.35 0.63 
  Low; > 2 years 2.48 0.88 2.06 0.97 
  High; ≤ 1 year 1.06 0.38 0.93 0.44 
  High; > 1 ≤  2 years 1.72 0.61 1.30 0.61 
  High; > 2 years 2.73 0.98 2.44 1.15 
Intervention Compliance     
  ODA     
    Exposed 5.83 0.78 4.90 0.75 
    Not Exposed 7.51  6.54  
  ODHRT     
    Exposed 3.16 0.65 3.09 0.70 
    Not Exposed 4.86  4.40  
  ODAHRT     
    Exposed 3.85 0.74 3.05 0.82 
    Not Exposed 5.20  3.71  












The purpose of objective 2 was to determine the effectiveness of the interventions 
in the prevention of osteoporotic fracture, while controlling for exposure to risk factors 
and other covariates.  A total of eight different logistic regressions were performed for 
each cohort.  The first series (FS) of four logistic regressions were performed to 
separately determine the intervention effectiveness or fracture risks for each of the 
intervention groups for any fracture, hip fracture, vertebral fracture, and wrist fracture.  
This first series of regressions included all five intervention groups, treated the covariate 
age as multi-categorical, and the covariate oral corticosteroid use as multi-categorical.  
The second series (SS) of logistic regression differed from the first series in that they: 
only included the intervention groups with a diagnosis of osteoporosis, treated the 
covariate age as a continuous variable, and only examined oral corticosteroid use with 
duration of exposure > 1-year. 
Overall, the results from the first series of logistic regression analyses are 
consistent with the results from the second series of logistic regression analyses.  For the  
intent-to-treat cohort, the ODAHRT intervention group had a statistically significant 
decreased risk of  any fracture (FS: OR = 0.702, 95% CI = 0.579 to 0.851, p = 0.0003; 
SS: OR = 0.698, 95% CI = 0.577 to 0.845, p = 0.0002), hip fracture (FS: OR = 0.657, 
95% CI =0.463 to 0.934, p = 0.0192; SS: OR = 0.640, 95% CI = 0.453 to 0.906, p = 
0.0117), and vertebral fracture (FS: OR = 0.576, 95% CI = 0.416 to 0.797, p =0.0009; 
SS: OR = 0.580, 95% CI = 0.421 to 0.800, p = 0.0009).  For the non intent-to-treat 
cohort, the ODAHRT intervention group only showed a decreased risk for vertebral 
fracture (FS: OR = 0.599, 95% CI =0.381 to 0.941, p = 0.0263; SS: OR = 0.592, 95% CI 
= 0.378 to 0.928) and the ODHRT intervention group showed a decreased risk of hip 
fracture (FS: OR = 0.271, 95% CI = 0.085 to 0.869, p = 0.0281; SS: OR = 0.282, 95% CI 
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= 0.088 to 0.905, p = 0.0333).  Table 4.3 provides a summary of the logistic regression 
analyses performed to determine intervention effectiveness. 
The difference in results obtained for the intent-to-treat and non intent-to-treat 
cohorts can at least be partially explained by further examination of the population that 
deviated from their index-intervention.  As previously discussed, a total of 11,568 
patients deviated from their index-intervention and this population accounted for 501 
fractures.  Of those 501 fractures, 95 came from the ODA intervention group, 42 from the 
ODAHRT intervention group, 43 from the ODHRT intervention group, 255 from the 
ODNOTX intervention group, and 66 from the NOODTX intervention group, 
representing 29%, 21%, 53%, 51%, and 52% of all reported fractures in the intent-to-treat 
cohort for each intervention group, respectively.  Therefore, the results obtained in the 
non intent-to-treat cohort are favorably biased for the ODHRT, ODNOTX, and 
NOODTX intervention groups (over 50% of patients with fractures were eliminated from 
the analysis).  The favorable bias for the ODHRT intervention group helps to explain the 
statistically significant decreased risk of hip fracture obtained in the non intent-to-treat 
cohort.  The favorable bias for the ODNOTX intervention group indirectly influenced 
failure of the ODAHRT intervention group not achieving statistical significance for any 
fracture and hip fracture in the non-intent-to-treat cohort. 
With the possible exception of the results obtained for the ODAHRT intervention 
group, the results obtained in this study do not support the clinical efficacy results 
reported in clinical trials or the effectiveness results obtained in population based studies.  
The intervention effectiveness results obtained for alendronate in this study did not 
approach the level of the statistical significance for a decreased risk of osteoporotic 
fracture reported in a meta-analysis performed by Kanis et al.1  In his meta-analysis, 
alendronate was associated with a statistically significant decreased risk of vertebral 
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fracture (RR = 0.544, 95% CI = 0.448 to 0.659) and hip fracture (RR = 0.611, 95% CI = 
0.392 to 0.951), but was not associated with a statistically significant decreased risk of 
wrist fracture (RR = 0.866, 95% CI = 0.672 to 1.115).  Likewise, the intervention 
effectiveness results obtained for HRT in this study did not approach those of the 
Women’s Health Initiative (WHI)2,  which reported that estrogen plus progestin 
significantly reduced clinical vertebral fractures by 34% and hip fractures by 33% (RH = 
0.67; 95% CI = 0.47 to 0.96) and total osteoporotic fractures by 24% (RH = 0.76; 95% CI 
= 0.69 to 0.83).  
As suggested in objective 1, one logical explanation for the failure of the active 
intervention groups to achieve a statistically significant decreased risk of osteoporotic 
fracture relative to the ODNOTX group is selection bias.  Even though the ODNOTX 
intervention group had a diagnosis of osteoporosis, this group may have been at a lower 
risk of fracture compared to the active intervention groups.  However, if selection bias is 
present in the study, then the 29.8% lower odds of any fracture, the 34.3% lower odds of 
a hip fracture, and the 42.4% lower odds of a vertebral fracture in the ODAHRT 
intervention group compared to the ODNOTX intervention group are even more 
impressive.    
One possible explanation for the statistically significant decreased risk of any 
fracture, hip fracture, and vertebral fracture in the ODAHRT group was that the inclusion 
criteria allowed for previous use of HRT.  If the women in the ODAHRT intervention 
group were initially started on HRT while peri-menopausal or immediately post 
menopause, they were probably protected from the rapid BMD loss typically experienced 
at menopause.  The validity of this explanation of course hinges on the assumption that 
members in the other intervention groups were not afforded the same protection of early 
HRT use. 
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Table 4.3 Summary of logistic regression analyses for intervention effectiveness 
  INTENT-TO-TREAT COHORT 
  1st Series of Regressions 2nd Series of Regressions 













Any 0.915 0.770 1.087 0.922 0.778 1.093 
Hip 0.763 0.560 1.039 0.750 0.554 1.016 
Vertebral 0.871 0.663 1.143 0.886 0.677 1.159 ODA 
Wrist 1.102 0.848 1.431 1.152 0.890 1.490 
Any 0.702 0.579 0.851 0.698 0.577 0.845 
Hip 0.657 0.463 0.934 0.640 0.453 0.906 
Vertebral 0.576 0.416 0.797 0.580 0.421 0.800 ODAHRT 
Wrist 0.823 0.616 1.100 0.847 0.552 1.297 
Any 0.869 0.659 1.145 0.859 0.652 1.132 
Hip 0.595 0.326 1.087 0.598 0.327 1.091 
Vertebral 1.101 0.739 1.642 1.093 0.733 1.630 ODHRT 
Wrist 0.859 0.560 1.317 0.847 0.552 1.297 
  NON INTENT-TO-TREAT COHORT 
Any 0.989 0.798 1.228 0.982 0.794 1.215 
Hip 0.852 0.594 1.221 0.844 0.593 1.202 
Vertebral 1.061 0.730 1.540 1.059 0.733 1.529 ODA 
Wrist 1.079 0.777 1.496 1.109 0.803 1.532 
Any 0.806 0.639 1.017 0.795 0.632 1.001 
Hip 0.740 0.494 1.107 0.731 0.491 1.089 
Vertebral 0.599 0.381 0.941 0.592 0.378 0.928 ODAHRT 
Wrist 0.961 0.685 1.348 0.980 0.702 1.369 
Any 0.834 0.565 1.232 0.835 0.565 1.233 
Hip 0.271 0.085 0.869 0.282 0.088 0.905 
Vertebral 1.275 0.706 2.302 1.270 0.703 2.296 ODHRT 
Wrist 0.920 0.527 1.608 0.904 0.518 1.579 
*Bolded = p < 0.05
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OBJECTIVE 3 
The purpose of objective 3 was to determine the significance of the risk factors 
and other covariates in the prediction of osteoporotic fracture, while controlling for 
exposure to other risk factors and covariates.  Two different logistic regressions were 
performed for each cohort.  The first series (FS) of logistic regressions performed 
included all five intervention groups, treated the covariate age as categorical, and the 
covariate oral corticosteroid use as multi-categorical.  The second series (SS) of logistic 
regression differed from the first series in that they: only included the intervention groups 
with a diagnosis of osteoporosis, treated the covariate age as a continuous variable, and 
only examined oral corticosteroid use with duration of exposure > 1-year.  Both the first 
series and the second series of logistic regressions examined the significance of the risk 
factors and other covariates for any fracture. 
 The results from the first series of logistic regression analyses suggested that age 
could be better treated as a continuous variable and that the focus of the risk associated 
with oral corticosteroid use should be limited to oral corticosteroid use with duration of > 
1-year.  Moreover, since the focus of this study is on the effectiveness of the active 
interventions, a decision was made to only include the intervention groups with a 
diagnosis of osteoporosis in the second series of logistic regression analyses.  Since the 
overall results from the first series and second series of logistic regression analyses for 
the intent-to-treat and non intent-to-treat cohorts are consistent, the following discussion 
focuses on the results obtained in the second series of logistic regression analyses.  For 
the sake of completeness, a summary table of risk factor and other covariate significance 
for the first series of regression results are presented in Table 4.4. 
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Risk factors age, prior fracture, and corticosteroid use were shown to significantly 
increase the risk of osteoporotic fracture.  Age was shown to be a strong predictor of 
osteoporotic fracture, with nearly identical results obtained for the intent-to-treat and non 
intent-to-treat cohorts (ITT: OR = 1.047, 95% CI = 1.039 to1.055; Non-ITT: OR = 1.047, 
95% CI = 1.037 to 1.056).  The strongest predictor of an osteoporotic fracture was prior 
fracture (ITT: OR = 4.279, 95% CI = 3.401 to 5.382; Non-ITT: OR = 3.446, 95% CI = 
2.548 to 4.66).   Oral corticosteroid use duration > 1-year was also shown to significantly 
increase the risk of osteoporotic fracture (ITT: OR = 1.553, 95% CI = 1.220 to 1.977; 
Non-ITT: OR = 1.379, 95% CI = 1.037 to 1.056).   
Intervention compliance in the ODAHRT intervention group and statin use were 
shown to decrease the risk of osteoporotic fracture.  Intervention compliance in the 
ODAHRT intervention group was shown to have a weak protective effect only in the 
intent-to-treat cohort (OR = 0.610, 95% CI = 0.390 to 0.953).  However, this protective 
effect is probably more a function of the overall treatment effectiveness exhibited in the 
ODAHRT intervention group.  Statin use was found to have a protective effect for statin 
categories: low dose ≤ 1-year (ITT: OR = 0.417, 95% CI = 0.307 to 0.566; Non-ITT: OR 
= 0.410, 95% CI = 0.276 to 0.609), low dose > 1-year ≤ 2-years (ITT: OR = 0.616, 95% 
CI = 0.454 to 0.834; Non-ITT: OR = .627, 95% CI = 0.427 to 0.921), low dose > 2-years 
(ITT: OR = 0.648, 95% CI = 0.518 to 0.811; Non-ITT: OR = 0.649, 95% CI = 0.492 to 
0.857), and high dose < 1-year (ITT: OR = 0.472, 95% CI = 0.269 to 0.827; Non-ITT: 
OR = 0.490, 95% CI = 0.240 to 1.000), but was not found to have a statistically 
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significant protective effect in the high dose > 1-year ≤ 2-years or the high dose > 2-years 
category. 
 The risk factors shown to be associated with a statistically significant risk of 
osteoporotic fracture in this study coincide with those reported in the literature.  This 
study provides evidence that the odds of women having an osteoporotic fracture 
increased over 4% for each year over the age of 50.  Although not directly comparable, 
these results show the same trend as the National Osteoporosis Foundation’s predicted 5-
year probabilities of various types of fractures at various ages for average-risk Caucasian 
women (Table 1.2).  This study found an approximate 4-fold increase in the odds of 
having an osteoporotic fracture in patients with a prior fracture.  The literature similarly 
reports that a past history of postmenopausal fracture confers a 4-fold increase in the risk 
of hip fracture relative to a negative fracture history3 and that vertebral fracture increases 
the risk of additional fractures by at least 4-fold (independent of BMD).4  The literature 
reports that corticosteroid therapy is the most common cause of drug-related 
osteoporosis, with an estimated 30-50% of patients receiving chronic corticosteroid 
therapy experiencing fractures.5  In this study, only 309 of the 9,797 (3.15%) oral 
corticosteroid users experienced a fracture during the 3-year observation period, however 
the odds of experiencing an osteoporotic fracture was 35 to 55% higher among chronic 
oral corticosteroid users whose exposure exceeded a 1-year duration.  
 Perhaps the most surprising result for objective 3 was the protective effect of 
statins on osteoporotic fracture.  Although the aim of this study was not to perform an 
epidemiological study to examine a causal relationship between statin exposure and 
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osteoporotic fracture, to my knowledge this was the first study to examine exposure of 
statins by dose and duration.  The results from this study suggest that statins may have a 
protective effect for osteoporotic fracture regardless of dose or duration.  Although the 
high dose > 1-year ≤ 2-years and high dose > 2-years category did not achieve statistical 
significance, examination of the confidence intervals for both dose and duration 
categories at least suggest a trend towards a protective effect.   Table 4.5 provides a 
summary of the second series of logistic regression analyses for risk factors and other 














Table 4.4 Summary of the first series of logistic regression analyses for risk factors and other covariates of significance 
 Intent-to-Treat Non Intent-to-Treat 
 Adjusted Odds Ratio Adjusted Odds Ratio 








Age Category       
55 - 59 1.412 1.082 1.843 1.280 0.909 1.804 
60 – 64 1.601 1.252 2.048 1.460 1.064 2.002 
65 – 69 1.898 1.435 2.512 1.650 1.158 2.352 
70 – 74 2.713 2.042 3.604 2.347 1.642 3.356 
75 – 79 3.108 2.349 4.112 2.863 2.021 4.055 
80 – 84 4.730 3.456 6.474 3.727 2.493 5.573 
≥ 85 6.194 4.307 8.910 5.665 3.633 8.832 
Corticosteroid Use       
<5mg; ≤180 days 0.505 0.223 1.144 0.428 0.135 1.351 
<5mg; >180≤365 days < 0.0001 < 0.0001 > 999.99 <0.001 <0.001 >999.999 
<5mg; >365 days 1.674 1.119 2.503 1.733 1.036 2.899 
≥5≤10mg; ≤180 days 0.984 0.702 1.380 1.221 0.827 1.802 
≥5≤10mg; >180≤ 365 days 0.479 0.151 1.517 0.271 0.037 1.961 
≥5≤10mg; >365 days 1.387 0.977 1.967 1.083 0.663 1.768 
>10≤ 20mg; ≤180 days 0.906 0.655 1.254 0.924 0.611 1.397 
>10≤ 20mg; >180≤365 days 1.404 0.673 2.930 1.107 0.399 3.076 
>10≤ 20mg; >365 days 2.153 1.359 3.413 2.096 1.163 3.776 
>20mg; ≤180 days 0.964 0.757 1.228 0.925 0.678 1.263 
>20mg; >180≤365 days 2.249 0.949 5.328 1.295 0.305 5.499 
>20mg; >365 days 1.705 0.399 7.293 1.233 0.162 9.389 
*Bolded = p < 0.05 
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Table 4.4 Summary the first series of logistic regression analyses for risk factors and other covariates significance (cont’d) 
 Intent-to-Treat Non Intent-to-Treat 
 Adjusted Odds Ratio Adjusted Odds Ratio 








Intervention Compliance       
ODA 80% MPR 0.739 0.537 1.017 0.741 0.514 1.069 
ODHRT 80% MPR 0.768 0.360 1.637 0.670 0.232 1.938 
ODAHRT 80% MPR 0.616 0.394 0.963 0.663 0.413 1.063 
Statin Use       
Low; ≤1 year 0.417 0.313 0.556 0.414 0.284 0.603 
Low; >1≤ 2 years 0.626 0.471 0.834 0.601 0.412 0.877 
Low; >2 years 0.653 0.526 0.811 0.666 0.508 0.872 
High; ≤1 year 0.418 0.239 0.731 0.445 0.219 0.907 
High; >1≤ 2 years 0.639 0.390 1.047 0.654 0.333 1.286 
High; >2 years 0.747 0.526 1.060 0.757 0.488 1.176 
Previous Fracture       
Previous Fracture 4.229 3.358 5.326 3.422 2.527 4.634 








Table 4.5 Summary the second series of logistic regression analyses for risk factors and other covariates significance   
 Intent-to-Treat Non Intent-to-Treat 
 Adjusted Odds Ratio Adjusted Odds Ratio 








Age        
Age 1.047 1.039 1.055 1.047 1.037 1.056 
Intervention Compliance       
ODA 80% MPR 0.743 0.540 1.022 0.744 0.516 1.071 
ODHRT 80% MPR 0.779 0.366 1.659 0.691 0.239 1.996 
ODAHRT 80% MPR 0.610 0.390 0.953 0.659 0.411 1.057 
Corticosteroid Use       
≤ 1-year 0.907 0.758 1.084 0.895 0.715 1.121 
≥ 1-year 1.553 1.220 1.977 1.379 1.002 1.898 
Statin Use       
Low; ≤1 year 0.417 0.307 0.566 0.410 0.276 0.609 
Low; >1≤ 2 years 0.616 0.454 0.834 0.627 0.427 0.921 
Low; >2 years 0.648 0.518 0.811 0.649 0.492 0.857 
High; ≤1 year 0.472 0.269 0.827 0.490 0.240 1.000 
High; >1≤ 2 years 0.626 0.369 1.060 0.554 0.258 1.189 
High; >2 years 0.686 0.471 1.001 0.756 0.482 1.187 
Previous Fracture       
Previous Fracture 4.279 3.401 5.382 3.446 2.548 4.660 





There were two general goals for objective 4: 1) to describe the proportion of 
cases free of a fracture event at various points in time, and 2) to assess the relationship 
between survival time and a set of covariates to determine whether treatment differences 
exist after statistically controlling for the other covariates. 
Kaplan-Meier Life Tables and Survival Plots 
The Kaplan-Meier method of life tables was used to describe the proportion of 
cases free of a fracture event at various points in time.  Life tables and survival plots were 
constructed to describe the proportion of cases free of any fracture event, hip fracture 
event, vertebral fracture event, and wrist fracture event at various points in time 
Results for the intent-to-treat cohort and non intent-to-treat cohorts revealed that 
there were statistically significant differences in survival functions between the 
intervention groups for: any fracture event, hip fracture event, vertebral fracture event, 
and wrist fracture event (p < 0.0001).  As expected, examination of the Kaplan-Meier 
estimates (survival) revealed that the NOODTX intervention group had the greatest 
probability that a patient would be fracture-free at each duration interval for any fracture 
and for each specific type of fracture.  In the intent-to-treat cohort, among intervention 
groups with an existing osteoporosis diagnosis, the ODAHRT intervention group had the 
greatest probability that a patient would be fracture-free at each duration interval for any 
fracture and for vertebral fracture.  For hip fracture, the ODAHRT intervention group had 
the greatest probability that a patient would be fracture-free for up to 1 ½ years.  At 1 ½ 
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years or more, the ODHRT intervention group had the highest probability that a patient 
would be fracture-free.  Similarly for wrist fracture, the ODAHRT intervention group had 
the greatest probability that a patient would be fracture-free up to two years.  At two 
years or more, the ODHRT intervention group had the highest probability that a patient 
would be fracture-free.  The Kaplan-Meier life tables and survival plots for the non 
intent-to-treat cohort mirrored those of the intent-to-treat cohort, with one notable 
exception in which the ODHRT intervention group had the greatest probability that a 
patient would be fracture-free for any fracture after approximately 2 ½ years.  The 
explanation for the difference in results obtained for the intent-to-treat and non intent-to-
treat cohorts are the same as described for objective 2. 
The Kaplan-Meier life tables and survival curves provide an unadjusted estimate 
of intervention effectiveness.   From these results, it appears that treatment with the 
combination of alendronate and HRT provide the highest probability of survival for any 
fracture and vertebral fracture and the highest probability of survival for hip and wrist 
fracture for the first half of the observation period, at which point treatment with HRT 
alone provides the highest probability of survival.  However, these results do not account 
the presence of confounding covariates.   
Cox Proportional-Hazards Model 
A direct Cox proportional-hazards model was used to assess the relationship 
between survival time and the set of covariates.  The primary purpose of this analysis was 
to determine if there was a difference in survival time between intervention groups after 
adjusting for the effects of the other covariates.  A total of eight different logistic 
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regressions were performed for each cohort.  The first series (FS) of four separate logistic 
regressions were performed to determine the hazard ratio for each of the intervention 
groups for any fracture, hip fracture, vertebral fracture, and wrist fracture.  This first 
series of regressions included all five intervention groups, treated the covariate age as 
multi-categorical, and the covariate oral corticosteroid use as multi-categorical.  The 
second series (SS) of logistic regression differed from the first series in that they: only 
included the intervention groups with a diagnosis of osteoporosis, treated the covariate 
age as a continuous variable, and only examined oral corticosteroid use with duration of 
exposure > 1-year. 
Overall, the results from the first series of logistic regression analyses are 
consistent with the results from the second series of logistic regression analyses.  For the  
intent-to-treat cohort, the ODAHRT intervention group had a statistically significant 
decreased risk of  any fracture (FS: HR = 0.711, 95% CI = 0.590 to 0.856; SS: HR = 
0.708, 95% CI = 0.589 to 0.851), hip fracture (FS: OR = 0.673, 95% CI =0.476 to 0.950; 
SS: HR = 0.658, 95% CI = 0.467 to 0.925), and vertebral fracture (FS: HR = 0.578, 95% 
CI = 0.420 to 0.796; SS: HR = 0.584, 95% CI = 0.425 to 0.801).  For the non intent-to-
treat cohort, the ODAHRT intervention group only showed a decreased risk for vertebral 
fracture (FS: HR = 0.601, 95% CI =0.384 to 0.940; SS: HR = 0.593, 95% CI = 0.380 to 
0.926) and for hip fracture (HR = 0.799, 95% CI = 0.640 to 0.999) in the second series of 
logistic regressions only.  The ODHRT intervention group showed a decreased risk of hip 
fracture (FS: HR = 0.278, 95% CI = 0.087 to 0.866); SS: HR = 0.288, 95% CI = 0.090 to 
0.918).  Table 4.6 provides a summary of the logistic regression analyses performed to 
determine intervention effectiveness. 
The results obtained for the logistic regression analyses are remarkably similar to 
those obtained in the Cox proportional-hazards regression, not only in the overall results 
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but also in the size of the coefficients.  This normally would suggest that time is not a 
significant factor in determining the effectiveness of the interventions.  However, the Cox 
proportional-hazards model used in this study violated the assumption of proportional 
hazards, which means one or more of the covariates interacted with time.  The 
consequence of violating the proportional hazards assumption is that the coefficient, for 
the variable which varied with time, represents more of an average effect for the variable 
over time, thus information is lost and results may be misleading.6  Although not 
presented in the results section, an attempt was made to analyze the data set using a non-
proportional hazards model.  Two covariates were identified as having a significant 
interaction with time, the intervention groups and age.  Unfortunately, the non-
proportional hazards model failed to provide an interpretable interaction effect for both 
age and the intervention group covariates, especially the ODHRT intervention group.  
The significance of the risk factors and other covariates in the direct Cox 
proportional hazards model were nearly identical to those obtained in the logistic 
regression analyses.  For this reason, a separate discussion of their significance is not 
provided.  
The results obtained from the direct Cox proportional-hazards model are 
disappointing in that they afforded no additional information than what was gained from 
the logistic regression analyses.  However, evidence of an interaction between the 







Table 4.6 Summary results of Cox regression analyses for intervention effectiveness 
  INTENT-TO-TREAT COHORT 
  1st Series of Regressions 2nd Series of Regressions 













Any 0.914 0.775 1.077 0.925 0.787 1.088 
Hip 0.789 0.584 1.065 0.785 0.584 1.054 
Vertebral 0.863 0.661 1.126 0.881 0.677 1.147 ODA 
Wrist 1.102 0.852 1.426 1.151 0.893 1.484 
Any 0.711 0.590 0.856 0.708 0.589 0.851 
Hip 0.673 0.476 0.950 0.658 0.467 0.925 
Vertebral 0.578 0.420 0.796 0.584 0.425 0.801 ODAHRT 
Wrist 0.824 0.619 1.098 0.845 0.636 1.122 
Any 0.867 0.664 1.130 0.857 0.657 1.118 
Hip 0.613 0.338 1.109 0.613 0.339 1.111 
Vertebral 1.088 0.735 1.609 1.077 0.728 1.594 ODHRT 
Wrist 0.858 0.563 1.309 0.847 0.555 1.292 
  NON INTENT-TO-TREAT COHORT 
Any 0.987 0.803 1.215 0.985 0.803 1.208 
Hip 0.877 0.618 1.246 0.880 0.624 1.243 
Vertebral 1.049 0.726 1.515 1.050 0.730 1.509 ODA 
Wrist 1.082 0.783 1.494 1.112 0.808 1.529 
Any 0.810 0.646 1.014 0.799 0.640 0.999 
Hip 0.750 0.504 1.115 0.746 0.504 1.105 
Vertebral 0.601 0.384 0.940 0.593 0.380 0.926 ODAHRT 
Wrist 0.961 0.688 1.343 0.980 0.704 1.363 
Any 0.834 0.571 1.220 0.834 0.570 1.219 
Hip 0.278 0.087 0.886 0.288 0.090 0.918 
Vertebral 1.264 0.705 2.267 1.258 0.701 2.259 ODHRT 








OBJECTIVES  5 & 6 
In objective 5, the incremental cost-effectiveness of the treatment interventions 
was determined while statistically controlling for the presence of risk factors and other 
covariates by employing the net-benefit regression method of cost-effectiveness analysis.  
The same methodology was employed in objective 6, where the importance of covariates 
on the marginal cost-effectiveness of an intervention was determined by examining 
interaction effects between each intervention and important patient subgroups.  
As in the previous analyses, two separate analyses were performed, one for the 
intent-to-treat cohort and the other for the non intent-to-treat cohort.  For each cohort, two 
separate analyses were initially performed, one without treatment interaction and the 
other with treatment interaction.  Results from the primary analyses provided evidence of 
a statistically significant positive incremental net-benefit for interaction terms formed 
between the active intervention groups and covariates age ≥ 65 and prior fracture.  
Therefore, subsequent post-hoc analyses were performed to determine if any of the active 
interventions were cost-effective in these sub-groups. 
Results from Primary Analyses 
 Results from the net-benefit regression without treatment interaction showed that 
the incremental net-benefits for all active treatment interventions were less than the 
incremental net-benefit for no treatment in both the intent-to-treat and non intent-to-treat 
cohorts.  The incremental net-benefit for treatment with alendronate and the combination 
of alendronate and HRT were statistically significantly less than no treatment for all 
values of λ.  In contrast, the incremental net-benefit for treatment with HRT, although 
lower, was not statistically significantly lower than no treatment at λ values ≥ $30,000.   
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In the second analysis with treatment interaction, interaction terms were formed 
between each active intervention group and covariates: age ≥ 65, oral corticosteroid use > 
1-year, and prior fracture. The results from the net-benefit regression with treatment 
interaction revealed that all of the treatment interactions achieved a positive incremental 
net-benefit.  For treatment with alendronate, the net-benefit regression with treatment 
interaction results showed a statistically significant positive incremental net-benefit with 
age ≥ 65 for values of λ ≤ 30,000 and prior fracture for values of λ ≥ $30,000.  Similarly, 
treatment with the combination of alendronate and HRT achieved a statistically 
significant positive incremental net-benefit with age ≥ 65 and prior fracture for all values 
of λ.  Likewise, patients in the ODAHRT intervention group with a prior fracture 
achieved higher net-benefits from treatment in comparison to patients without a prior 
fracture for all values of λ.  In the intent-to-treat cohort, the only significant interaction 
term formed between treatment with HRT and a covariate was with prior fracture and this 
interaction term only became statistically significant at λ ≥ $60,000.  In the non intent-to-
treat cohort, the interaction term formed between treatment with HRT and age ≥ 65 was 
found to be statistically significant at λ = $0 and the interaction terms formed with prior 
fracture were statistically significant at all values of λ.  Although higher net-benefits were 
observed for the interaction terms formed between intervention groups and the covariate 
corticosteroid use > 1-year, none of these were found to be statistically significant.   
Post-hoc Analyses 
In general, the results from the net-benefit regression for the sub-group of patients 
with a prior fracture sub-group suggests that as the value of λ increases, the active 
interventions become more cost-effective than no treatment.  More specifically, the active 
intervention becomes more cost-effective when λ ≥ $30,000 (non intent-to-treat cohort) 
or $60,000 (intent-to-treat cohort) for the alendronate, when λ ≥ $30,000 for the 
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combination of alendronate and HRT, and when λ ≥ $0 for HRT.  However, none of the 
coefficients for the active interventions at the different values of λ approach the level of 
statistical significance.   
Overall, the results from the net-benefit regression for the sub-group of patients ≥ 
age 65 provide evidence that treatment with alendronate and the combination of 
alendronate and HRT are not more cost-effective than no treatment at any value of  λ.  In 
contrast, treatment with HRT was found to be more cost-effective than no treatment at all 
values of λ (non intent-to-treat cohort) or at values of λ ≥ $30,000 (intent-to-treat cohort).  
However, none of the coefficients for the ODHRT intervention group approached the 
level of statistical significance.   
Summary of Results 
 Results from the net-benefit regression without treatment interaction suggest that 
there is not a statistically significant difference in the cost-effectiveness between 
treatment with HRT and no treatment at values of λ ≥ $30,000, which is the threshold of 
cost-effectiveness established by the NOF.  Results from the net-benefit regression with 
treatment interaction and post-hoc analyses provide evidence of a trend in which 
treatment with HRT in the high-risk subgroups (age ≥ 65 and prior fracture) becomes 
more cost-effective than no treatment. 
 Results from the net-benefit regression without treatment interaction reveal that 
treatment with alendronate and the combination of alendronate and HRT were 
statistically significantly less cost-effective than no treatment for all values of λ.  
However, the results from the net-benefit regression with treatment interaction and post-
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hoc analyses suggest a trend in which treatment with alendronate or the combination of 
alendronate and HRT become more cost-effective than no treatment for patients with a 
prior fracture  when λ ≤ $30,000 for alendronate and when λ ≥ $30,000 for the 
combination of alendronate and HRT. 
 The results from this study suggest that current treatment interventions employed 
by the DoD are not cost-effective in the prevention of osteoporotic fractures.  These 
results, to some extent, contradict the cost-effectiveness studies found in the literature for 
the various interventions.  There are four primary reasons or explanations as to why the 
current treatment interventions were not found to be cost-effective: 1) the interventions 
were expensive, 2) the value for the effect variable (quality-adjusted life-years (QALYs)) 
was small, 3) only direct medical costs were included in the model, and 4) the risk of 
fracture in the population was possibly low. 
 As with other published studies, the intervention costs were the primary driver of 
costs in this study.  The intervention costs used in this study reflected either the 
acquisition cost to the DoD or the “total submitted amount due” to the managed care 
contractor.  Unlike previous HRT cost-effectiveness studies which only used the average 
cost for oral HRT dosage forms, this study used the actual cost for each  HRT oral dosage 
form and used the actual cost of the more expensive transdermal preparations.  Therefore, 
the costs for HRT intervention and the combination of alendronate and HRT may have 
been somewhat higher in this study compared to those of previously published studies. 
 In this study, the effect on QALYs was probably lower than those reported in 
previous studies for primarily three reasons.  First, this study only examined the change 
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in QALYs over the three-year observation period, whereas other studies that 
predominantly employed long-term cost-effectiveness models examined the effect on 
QALYs over the life of the patient.  Second, this study employed age-adjusted 
empirically derived health state values (HSVs), which were substantially higher (less of a 
decrement to QALYs) than expert-opinion derived HSVs used in previously published 
studies.  Lastly other studies, particularly those involving HRT, included the non-skeletal 
impact on QALYs such as relief from menopausal symptoms and decreased risk of 
cardiovascular disease. 
 Many of the previously published long-term cost-effectiveness studies included 
direct non-medical costs, indirect costs, and mortality costs in addition to direct medical 
costs to justify the cost-effectiveness for a particular intervention.  In contrast, this study 
only included the direct medical cost associated with an osteoporotic fracture.  Failure to 
account for the costs associated with discharge to an orthopedic rehabilitation facility or 
long-term care in a nursing home resulting from a hip fracture and mortality associated 
with a hip fracture is a considerable limitation of this study.  
 This study reflects the actual use of osteoporotic fracture interventions in the DoD 
population.  The population used was arguably at a lower risk of fracture than the 
populations used to determine the clinical efficacy of a treatment intervention in 
randomized controlled trials or the hypothetical population used in many of the long-term 
cost-effectiveness models.  As demonstrated in this study, selected use of an osteoporotic 




The epidemiologic study results showed that in the study population of females 
age ≥ 50 DoD beneficiaries, an osteoporotic fracture was a relatively rare event, with a 
three-year cumulative incidence of an osteoporotic fracture ranging between 1.93 to 2.48 
% for the population.  The intent-to-treat analysis revealed that the three-year cumulative 
incidence of osteoporotic fracture in patients with an osteoporosis diagnosis (6.1%) was 
15-fold higher than in those without an osteoporosis diagnosis (0.4%).  
If the possible presence of selection bias is ignored, the intervention effectiveness 
results from both the logistic regression model and the direct Cox proportional-hazards 
model suggest that women treated with the combination of alendronate and HRT are at a 
lower risk for any fracture, hip fracture, and vertebral fracture when compared to no 
treatment, while statistically controlling for the presence of risk factors and other 
covariates.  In contrast, treatment with alendronate or HRT alone was not found to 
provide a statistically significant decreased risk of any fracture, hip fracture, vertebral 
fracture, or wrist fracture when compared to no treatment, while statistically controlling 
for the presence of risk factors and other covariates.  The effectiveness results for 
alendronate and HRT in the prevention of osteoporotic fracture from this study contradict 
the efficacy results obtained in the clinical trials for alendronate and the effectiveness 
results obtained for HRT in the WHI.  For this reason, the presence of selection bias 
cannot be ignored and it’s suggested that additional statistical measures need to be 
performed to diagnose the level of selection bias and attempt to correct for its presence. 
The results of this study support published reports of a statistically significant 
relationship between age, corticosteroid use, and prior osteoporotic fracture and an 
increased risk of osteoporotic fracture.  This study provides evidence that the risk of 
osteoporotic fracture increases: 4-fold with a prior fracture, 4% with each year over 50, 
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and between 38 and 55% with oral corticosteroid use > 1-year (in a three-year period).  
This study also provides evidence of not only a statistically significant relationship 
between statin use and a decreased risk of osteoporotic fracture, but also that such effect 
is independent of dose and duration. 
The primary focus of this research was the application of the net-benefit 
regression method of CEA to determine the cost-effectiveness of the DoD’s current anti-
osteoporotic fracture interventions.  The results from this study suggest that globally 
current use of the treatment interventions is not cost-effective in the short-term when 
compared to no treatment.  However, this study also provides evidence that the current 
treatment interventions become more cost-effective when targeted at high risk 
populations, such as patients with a prior osteoporotic fracture.  Here again, these results 
are potentially influenced by the presence of selection bias and also warrant that 
additional statistical measures be performed to diagnose the level of selection bias and if 













When interpreting the results of this study, it is important to consider the potential 
limitations which might affect the internal and construct validity of the study results. As 
previously discussed, the primary limitation and threat to the internal validity of this 
study was the possible presence of selection bias.  In general, selection bias may be 
present if knowledge of the disease affects selection or classification of exposed (active 
intervention group) and non-exposed (control group) individuals to be included in the 
study.  In this study, the concern is whether patients who received an active intervention 
(exposed) were at a greater risk of osteoporotic fracture compared to those in the control 
group (non-exposed).  More specifically, patients in the ODNOTX intervention group 
may have had a lower risk of osteoporotic fracture compared to those patients in the 
active intervention groups (ODA, ODAHRT, and ODHRT), thus biasing the results to the 
null hypothesis.  The results obtained in this study suggest that the intervention groups 
were not at equal risk, especially the ODA intervention group, and that selection bias may 
be present. 
Perhaps the second biggest limitation of this study and threat to internal validity is 
confounding by other risk factors not included in the model, which in this case is 
somewhat related to the potential presence of selection bias.  This study included all risk 
factors and potentially important covariates that were obtainable from the health care 
claims and prescription databases.  However, at least two important risk factors (BMD 
and race) were not available and were not included in the analyses, and thus may 
potentially confound the results. 
This study was limited in that it only examined of the short-term (three-year) cost-
effectiveness of the DoD’s current osteoporosis interventions, thus ignoring long-term 
costs and consequences associated with osteoporotic fracture.  Moreover, this study only 
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examined the direct medical costs associated with the prevention and treatment of 
osteoporotic fracture that were readily available from the health care and prescription 
claims databases.  Significant costs associated with discharge to rehabilitation centers and 
nursing homes was not included nor did this study account for mortality and its 
associated costs.  
Another potential limitation and threat to the internal validity of this study was the 
use of administrative health care and prescription claims data for an unintended use.  In 
this study, health care claims data provided the diagnostic information used to determine 
fracture events  These data were potentially subject to under- and over-coding and data 
entry errors for a variety of reasons to include, reimbursement systems, provider 
behavior, and/or documentation systems.  Furthermore, prescription claims data only 
indicates that a prescription was dispensed, thus requiring the assumption that the patient 
actually took the medication as prescribed using the proper technique, which is a big 
assumption with alendronate. 
A threat to construct validity and another potential limitation of this study were 
the operational definitions employed to diagnose a new osteoporotic fracture.  Initially, 
the intent was to adopt the same operational definitions employed by Westfall et al.  
However, since approximately 8% of the health care claims did not contain a primary 
procedure code, a more conservative operational definition of a new osteoporotic fracture 
event was employed.  This more conservative definition was not jointly exhaustive and 
mutually exclusive and could have potentially resulted in an under-representation of the 
actual number of fracture events. 
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